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Summary 
The term retinitis pigmentosa (RP) describes a group of retinal degenerations, in which 
inherited mutations lead to disturbed physiological functions of photoreceptors (PR) or 
retinal pigment epithelium (RPE) cells and progressive visual loss. Although gene 
therapy of RP can prevent loss of vision, the high heterogeneity of gene mutations 
restricts one gene therapy only to a subset of patients. In contrast, trophic factor delivery 
cannot be curative for RP, but protects PR irrespective of the underlying gene defect, 
leading to a significant delay in PR death and temporally maintaining residual vision. In 
experiments on rodent models of RP, subretinally injected glial cell line-derived 
neurotrophic factor (GDNF) significantly preserved morphology and function of rod 
cells. This neuroprotective effect is postulated to be indirect through retinal Müller glial 
(RMG) cells, which release a variety of factors upon GDNF stimulation. These factors in 
turn bind to receptors on the PR membrane to stimulate signal transduction pathways, 
which are crucial for their survival.  
Encouraged by very promising results of GDNF’s indirect prosurvival action in many 
studies of rodent retina, we focused on the investigation of the neuroprotective potential 
of RMG cells. To achieve this aim, primary mouse RMG cells were stimulated with 
GDNF and seven secreted factors were found to be highly upregulated. Out of this group, 
cysteine-rich heparin-binding protein 61 (Cyr61), a molecule with proved prosurvival 
activity in the context of cancer cells, was chosen for further investigation. As 
anticipated, Cy61 did indeed increase PR survival in ex vivo experiments on short-term 
and long-term rd1 mouse retinal explants, , confirming its neuroprotective activity.  
Subsequently, we focused on the mechanism of Cyr61’s prosurvival action on PR. 
Stimulation of the whole retinal tissue revealed activation of mitogen-activated protein 
kinase (MAPK)/Erk and janus kinase (JAK)/Stat pathways, but not phosphoinositide 3-
kinase (PI3K)/Akt. Furthermore, analysis of very pure PR cultures treated with Cyr61 
showed no activation of any of mentioned pathways, suggesting lack of a direct 
prosurvival effect of Cyr61. In contrast, stimulations of primary porcine RMG cells 
showed an increase in phosphorylation of all investigated proteins: Erk1/2, Stat3 and Akt. 
These results uncovered a positive feedback loop of Cyr61 action on RMG, implying at 
the same time an indirect mechanism for Cyr61 mediated neuroprotection. Investigation 
of Cyr61 treatment of primary porcine RPE cells demonstrated a very strong activation of 
MAPK/Erk and PI3K/Akt but not JAK/Stat3, suggesting indirect protection of PR also 
through RPE cells stimulation. Treatments of the human RMG and RPE cell lines      
MIO-M1 and ARPE19 with Cyr61 additionally revealed nuclear translocation of 
activated MAPK/Erk. 
To determine the consequences of MAPK/Erk, JAK/Stat and PI3K/Akt pathways 
stimulation in RMG cells, we focused on Cyr61 induced secretome changes. Secretome 
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analysis using LC-MS/MS based quantitative proteomics showed an increase in the 
secretion of several proteins involved in extracellular matrix organization. The 
upregulation of two of these proteins - collagen, type III alpha 1 (COL3A1) and family 
with sequence similarity 3, member C (FAM3C), at the transcriptional level was 
confirmed by qPCR. 
Finally, we investigated whether Cyr61 could protect PR in vivo in an RP rodent model. 
To this end we used the S334ter-3 rat model. Preliminary data form intravitreal injections 
of Cyr61 showed substantial changes in vascularization of the retina and lack of 
neuroprotective action on PR. Furthermore, Cyr61 significantly increased the percentage 
of TUNEL positive cells in the inner nuclear layer (INL). It remains to be determined 
whether alterations in the retinal vasculature may be a factor, which diminishes the 
neuroprotective potential of Cyr61  
Taken together, the presented results introduce Cyr61 as a novel neuroprotective agent 
prolonging PR survival in an indirect way through stimulation of RMG and RPE cells. 
Further investigations may confirm Cyr61’s neuroprotective effect in vivo and describe 
molecular basis of its indirect action in more detail. 
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Zusammenfassung  
Eine bestimmte Gruppe von erblichen Retinadegenerationen wird unter dem Begriff 
retinitis pigmentosa (RP) zusammengefasst. Dieser Gruppe ist gemein dass die 
unterschiedlichen Mutationen letztlich zu einer Störung der physiologischen Funktionen 
der Photorezeptoren (PR) oder retinalen Pigmentepithelzellen (RPE) führen und damit 
einem fortschreitenden Verlust des Sehvermögens verursachen. Obwohl dieser Verlust 
durch Gentherapie verhindert werden kann, beschränkt die große Heterogenität der 
Genmutationen einen Gentherapieansatz auf nur eine Untergruppe der Patienten. Im 
Gegensatz dazu kann die Behandlung mit einem trophischen Faktor unabhängig vom 
jeweiligen Gendefekt für die symptomatische Behandlung eingesetzt werden. Durch 
diesen Ansatz kann das Absterben der PR verlangsamt und das verbliebene Sehvermögen 
länger erhalten werden. 
Verschiedene Studien in Nagermodellen von RP haben bisher gezeigt, dass subretinale 
Injektion des neurotrophen Faktors glial cell line-derived neurotrophic factor (GDNF) die 
Morphologie und Funktion der PR erhält. Es wird postuliert daß dieser neuroprotektive 
Effekt indirekt durch eine Stimulation der retinalen Müller Gliazellen (RMG) bewirkt 
wird, welche nach GDNF Stimulation verschiedene andere neurotrophe Faktoren 
sekretieren. Diese Faktoren scheinen das Überleben der PR  durch Aktivierung mehrerer 
Signaltransduktionswege zu fördern.  
In Anbetracht der Wirksamkeit von GDNF, wurde in dieser Arbeit das neuroprotektive 
Potential von RMG untersucht. Zu diesem Zweck wurden primäre murine RMG mit 
GDNF stimuliert und es wurden sieben stark GDNF induzierte Faktoren identifiziert, von 
denen Cysteine-rich heparin-binding protein 61 (Cyr61) zur weiteren Untersuchung 
ausgewählt wurde, da für dieses Molekül bereits eine überlebensfördernde Wirkung aus 
der Krebsforschung bekannt war. 
Eine neuroprotektive Aktivität von Cyr61 ließ sich tatsächlich nachweisen, da Cyr61 in 
ex vivo Retinaexplantaten von rd1 Mäusen das Überleben der PR verlängern konnte.  
Daher wurde das Wirkungsspektrum von Cyr61 in der Retina auf Zelltyp- und 
Singaltransduktionsebene untersucht um den molekularen Mechanismus des 
neuroprotektiven Effektes genauer zu charakterisieren. Stimulation der intakten Retina 
zeigte Aktivierung der mitogen-activated protein kinase (MAPK)/Erk und janus kinase 
(JAK)/Stat Transduktionswege, allerdings keine Stimulation des phosphoinositide 3-
kinase (PI3K)/Akt Weges.  
Allerdings zeigte die Analyse von hochreinen PR Kulturen, dass Cyr61 keinen der obigen 
Transduktionswege in diesen Zellen aktivierte, was gegen einen direkten Einfluss von 
Cyr61 auf die PR sprach. Im Gegensatz dazu reagierten primäre Schweine-RMG auf 
Cyr61 Stimulation mit einer Aktivierung aller drei Transduktionwege - Erk1/2, Stat3 und 
Akt. Diese Ergebnisse zeigen einen positiven Rückkopplungsmechanismus von Cyr61 
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auf RMG und implizieren gleichzeitig einen indirekten Mechanismus des 
neuroprotektiven Effekts von Cyr61. 
Die Untersuchung des Einflusses von Cyr61 auf RPE zeigte außerdem eine sehr starke 
Aktivierung der MAPK/Erk und PI3K/Akt Signalwege, allerdings keine Aktivierung des 
JAK/Stat3 Weges. Daher ist ein indirekter Mechanismus des neuroprotektiven Effekts 
über RPE ebenfalls plausibel. Weiterhin konnte gezeigt werden dass Behandlung der 
humanen RMG und RPE Zelllinien MIO-M1 und ARPE19 mit Cyr61 zur Aktivierung 
und nukleären Translokation von Erk und Akt führte.  
Um die weiteren Folgen der Aktivierung der MARK/Erk, JAK/Stat und PI3K/Akt 
Transduktionswege in RMG zu bestimmen, wurden Cyr61 induzierte Änderungen im 
Sekretom dieser Zellen mittels LC-MS/MS basierter Proteomik untersucht Dies zeigte 
Sekretionsinduktion mehrerer Proteine die in der Organisation der Extrazellulären Matrix 
involviert sind. Diese Induktion wurde für zwei Proteine – Kollagen Typ III alpha 1 
(COL3A1) und family with sequence similarity 3, member C (FAM3C) auch auf der 
transkriptionellen Ebene mittels qPCR bestätigt. 
Schließlich wurde das therapeutische Potential von Cyr61 in dem Ratten RP Model 
S334ter-3 untersucht. Vorläufige Daten zeigten allerdings keinen neuroprotektiven Effekt 
nach intravitrealer Injektion von Cyr61. Paradoxerweise erhöhte Cyr61 Behandlung den 
Anteil TUNEL positiver Zellen in der inneren nukleären Schicht der Retina. Ungeklärt 
bleibt, ob Änderungen in der Vaskularisierung der Retina, die zusätzlich beobachtet 
wurde, dieses Ergebnis verursacht haben könnten.  
Insgesamt charakterisieren die Ergebnisse dieser Arbeit Cyr61 als einen neuen 
neuroprotektiven Faktor der das Überleben von PR durch einen indirekten Mechanismus 
über Aktivierung von RMG und RPE verlängern kann. Weitere Erforschung des 
neuroprotektiven Effekts von Cyr61 wird die Frage seiner Wirksamkeit in vivo klären und 
dessen molekulare Grundlage tiefergreifend aufklären. 
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I. INTRODUCTION 
Chapter One: The human retina and its physiology 
The visual perception is a fascinating sense giving us important information from the 
surrounding environment. Light that enters the cornea is focused by the lens and passes 
through the vitreous body to fall on the receptive tissue of the vision sense – the retina. 
Here, neuronal cells collect the light photons and pass the registered signal through optic 
nerve to the higher centres of the brain where it is further processed to eventually create 
an image of the surrounding scene. Retinal degenerations, attributable to genetic 
disturbances, may lead to the preliminary death of neuronal or supporting cells causing 
vision disorders leading even to total blindness. 
The introduction is divided into three parts. Chapter one describes retinal histological 
structure (1.1) with focus on the role of individual cell types - photoreceptors (PR, 1.1.1), 
retinal ganglion cells (GC, 1.1.2), retinal Müller glial (RMG, 1.1.3) cells and retinal 
pigment epithelium (RPE, 1.1.4) cells - in the process of vision. These types of cells will 
be the main focus of the research presented in this thesis. In addition, the development of 
a healthy retinal vasculature will be described, as some results are better appreciated with 
knowledge of the subtle structure of the retinal blood supply (1.2). 
1.1 Structure of the retina 
The retina is located at the back of an eye to process the image projected by the lens into 
electrical impulses and send them further to the visual cortex to create an image in our 
brain. Five types of neuronal cells are involved in this process: PRs detect signals from 
photons and pass them to horizontal and bipolar cells through synaptic connections. 
Horizontal cells probably feed the signal back to PR (to inhibit them) or pass the 
stimulation to bipolar cells. Bipolar cells send the signal to GC, in a direct way, or 
indirectly, through amacrine cells. Ganglion cells then further process the signals and 
send them to the brain through the optic nerve. 
The neuronal cells and RMG cells are anatomically organised into layers creating the 
retinal tissue (Fig. 1). The innermost layer is composed of GC and is followed by the 
inner plexiform layer (IPL) created from GC axons together with axons of amacrine and 
bipolar cells. The following inner nuclear layer (INL) consists of nuclei of neuronal cells: 
bipolar, amacrine and horizontal cells together with nuclei of RMG cells. The penultimate 
outer plexiform layer (OPL) is easy to distinguish histologically as it contains the 
processes of bipolar, horizontal and PR cells. The final, outermost, layer is composed of 
PR cells, whose nuclei are densely organized creating the outer nuclear layer (ONL). The 
sensory part of the retina is embedded in the retinal pigment epithelium, whose RPE cells 
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contact the PR on their apical side and are firmly attach to choroid layer of the eye 
through their basal side (Wright et al. 2010). 
Besides neuronal cells the human retina consists of three types of glial cells: RMG cells 
(described in 1.1.3), microglial cells and astrocytes. Microglial cells are immune cells, 
derived from blood and responsible for the initiation of inflammatory processes as well as 
defence against invading pathogens. Microglia activation in the retina can also be closely 
related to PR cell death and retinal degeneration (Karlstetter et al. 2010). Astrocytes 
influence the development of the superficial and deep layers of retinal vasculature by 
secretion of vascular endothelial growth factor (VEGF). Moreover, they accompany as 
well as stabilize the developing blood vessels, becoming a part of the blood-retinal 
barrier, and regulate blood flow within the retinal tissue (Gardner et al. 1997, Kur et al. 
2012). 
 
Figure 1. Histological structure of porcine retina. 
Retinal tissue consists of five different layers: ganglion cell layer (GCL), inner plexiform layer (IPL), inner 
nuclear layer (INL), outer plexiform layer (OPL) and outer nuclear layer (ONL). Blue – DAPI for nuclei, 
green - arrestin for cones, red – glutamine synthetase for RMG, inner segments (IS), outer segments (OS). 
1.1.1 Photoreceptors 
Photoreceptors are located in the outermost layer of the retinal tissue, in the longest 
distance from the lens, right before RPE cells. This requires the light to travel through all 
other retinal layers before reaching the PR outer segments. To facilitate the light to reach 
the PR without being highly scattered, the axons of neuronal cells in the plexiform layers 
of the retina are unmyelinated, making these layers relatively transparent (Kandel et al. 
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2000). Additionally, RMG possess features of optical fibres, allowing light to be 
transmitted to PR with only minimal loss (Franze et al. 2007). 
Photoreceptors respond to light with gradual changes in their membrane potential, where 
the amplitude of hyperpolarization increases monotonically as a function of decreasing 
light intensity till achieving saturation (Fu 2010). The vision system gains information 
from two types of photoreceptor cells with complementary specialization in order to 
collect more information from the surrounding environment.  
 
Figure 2. Photoreceptor inner and outer segments. 
Rods and cones were stained on mouse retina. Rods outer segments (OS) were stained with anti-rhodopsion 
(red). Cones were stained with peanut agglutinin (green). OS, inner segments (IS) and synaptic endings in 
outer plexiform layer (OPL) of cones are indincated on the right. Nuclei were stained with DAPI (blue) to 
show outer nuclear layer (ONL) and inner nuclear layer (INL). Scale bar – 50µm.  
Cones (Fig. 1, 2, 4) are specialized for vision in daylight and are characterised by a high 
acuity of vision (Kandel et al. 2000). They are concentrated in the fovea centralis and 
become less abundant toward the periphery of the retina. They have high temporal 
resolution (short integration time and fast response) and they are more sensitive to direct 
axial rays than rods. The cone system is chromatic, because there are three subgroups of 
these cells, which can detect light of a different wavelength, depending on the visual 
pigment they contain (Fu 2010). Cones expressing L–opsin are sensitive to the 
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electromagnetic spectrum in the red region, cones filled with M-opsin register light from 
green region and S-opsin cones detect parts of the blue spectrum of light. Each of these 
cones is connected to one bipolar cell. As a result, the brain obtains colour information 
from comparison of the responses from the three types of cones. On the other hand, lower 
signal amplification makes them less sensitive to photons than rods. Cone response to 
photons is much faster than that of rods and they can detect flickering light of frequencies 
higher than 55Hz (Kandel et al. 2000). Cones are the main receptive cells of the vision 
sense and people with cone dysfunction are legally blind. 
Rods are responsible for night and peripheral vision and their special distribution as well 
as physiological adaptations serves this function. They are located on the whole retinal 
tissue except for the fovea centralis (Curcio et al. 1990). Their light reception is 
achromatic, because they posses only one type of pigment activating phototransduction 
cascade - rhodopsin. Rhodopsin belongs to the super family of G-protein coupled 
receptors. It consists of the protein opsin with the reversibly covalently bound ligand, 11-
cis-retinal (Khorana 1992). Thanks to its stability rhodopsin can be densely packed in the 
rod discs. Additionally, many rods create synapses with the same target bipolar cell, 
strengthening the light signals initiated in any single cell and raising the retina’s ability to 
detect dim light (Kandel et al. 2000). These features give rods light sensitivity much 
greater compared to cones, allowing them to detect even single photons. The 
disadvantage of this is the rod’s slow response to light, with a 100ms interval, because the 
effects of the photons absorbed during this time need to be summed together (Kandel et 
al. 2000). As a result, their temporal resolution is low, leading to long integration times 
and slow responses. This also prevents them from resolving light in time laps shorter than 
12Hz (Kandel et al. 2000). Furthermore, since many rods connect to the same bipolar 
cell, they create a large unit of resolution, which decreases the acuity of vision in 
comparison to cones. Loss of rods results in tunnel vision and night blindness. 
Four major functional compartments in rods and cones can be distinguished (Wright et al. 
2010). From outside to inside, relative to the layers of the retina, the first compartment - 
outer segment (OS), is characterized by intracellular stacked membrane inclusions. Light 
sensitive visual pigment molecules are embedded in these stacks, making this region 
responsible for phototransduction. The second compartment is the inner segment (IS), 
which is densely packed with most of biosynthetic cell machinery, consisting of 
microtubules, mitochondria, endoplasmic reticulum and the Golgi complex. The third 
compartment contains the nucleus and is followed by the fourth one comprised of 
synaptic ending forming connections with interneurons - horizontal and bipolar cells 
(Kandel et al. 2000, Wright et al. 2010).  
1.1.1.1 Phototransduction in rod photoreceptors 
The light absorption by the visual pigments in photoreceptors stimulates a cascade of 
changes that leads to hyperpolarization of the PR membrane through reduced membrane 
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conductance for cations (Na+ and Ca2+) (Fu 2010). Phototransduction in rods is the best-
characterized sensory transduction pathway. The key molecule in their phototransduction 
cascade is the second messenger cyclic guanosine 3’-5’ monophosphate (cGMP). Cyclic 
GMP governs ionic fluxes by opening cGMP-gated ion channels, which leads to Na+ and 
Ca2+ ion inward currents.  
 
Figure 3. Rod visual phototransduction. 
Photons (hv) fall on a rhodopsin molecule R, embedded in the rod outer segment membrane, which induces 
isomerization of 11-cis retinal to all-trans retinal within the molecule, and activates rhodopsin (R*). Each 
excited R* contacts molecules of transducin (G), catalyzing the exchange of GDP for GTP on their α 
subunit (G*). Activated G*, dissociate from transducin and binds to the γ subunit of phosphodiesterase 
(PDE). When two G* molecules bind to the PDE holomer, PDE α and β subunits are released from 
inhibition of γ subunits and PDE is activated (PDE**). Next, PDE** reduces cytoplasmic cGMP 
concentration through hydrolysis. This causes closure of cGMP-gated channels in the membrane. The rate 
constant of PDE** hydrolysing cGMP is indicatd by β and the rate of guanyl cyclase (GC) synthetising 
cGMP is indicated by α. Reprinted by permission from Elsevier (Leskov et al. 2000) 
In darkness, cytoplasmic concentrations of cGMP are elevated, keeping cGMP-gated ion 
channels open. The resulting inward current of Na+ ions through open cGMP-gated 
channels exceeds an outward current of K+ through non-gated K+ selective channels. This 
net inward current, also called dark current, keeps PRs in a partly depolarized state (-
35mV), in the absence of light (Moriondo et al. 2001). In darkness, rhodopsin is in an 
inactive state, because of 11-cis retinal that blocks free opsin from activating the 
transduction cascade. When photons fall on the OS discs of rod PR (Fig. 3), it is absorbed 
by 11-cis retinal. This causes retinal isomeration from the 11-cis to all-trans 
configuration. As a result, the interaction of the all-trans retinal molecule with the amino 
acid side chains in the opsin-binding site forces a conformational change of rhodopsin 
into the unstable metarhodopsin II (Khorana 1992). Next, metarhodopsin II activates 
transducin, by catalyzing the exchange of GDP for GTP in its α subunit. This exchange 
enables the transducin α subunit to dissociate from the β and γ subunits and to bind to the 
γ subunit of phosphodiesterase (PDE6) (Norton et al. 2000). This sterically displaces the 
subunit and releases the PDE α and β subunits from inhibition. Subsequently, activated 
PDE6 lowers cGMP concentration through its hydrolysis to GMP, which leads to closure 
of Na+/ Ca2+ selective cGMP-gated ion channels. The persisting K+ outward current 
	  	  14 
causes PR hyperpolarization, increasing the membrane potential to 30mV, followed by 
closure of voltage-gated Ca2+ channels (Moriondo et al. 2001). Since calcium is essential 
for the fusion of neurotransmitter vesicles with their presynaptic membranes, this results 
in decreased release of the excitatory neurotransmitter glutamate from PR. Subsequently, 
decreased glutamate release from PR causes activation (depolarization) of rod On bipolar 
cell or inhibition (hyperpolarization) if it is an OFF bipolar cell. Bipolar cells then 
transmit the signal directly or indirectly (through amacrine cels) to the GC, which then 
passes the information to the neurons in the brain (Kandel et al. 2000, Nelson 2007). 
Recovery of the rod is essential after light activation and requires inactivation of the 
phototransduction cascade components: metharhodopsin II, transducin and PDE6. 
Recoverin, a calcium-binding protein, is activated by the decrease in intracellular calcium 
concentration and dissociates from rhodopsin kinase. Activated rhodopsin kinase 
phosphorylates metarhodopsin II thus decreasing its affinity for transducin. The 
phosphorylated metarhodopsin II is then bound by arrestin, which completely deactivates 
it (Fu 2010). Eventual all-trans retinal disconnect from the unstable metarhodopsin II and 
is transported to RPE cells, where it is converted back to 11-cis retinal and is send back to 
the PR to regenerate light receptive rhodopsin (Sakamoto & Khorana 1995, McBee et al. 
2001).  
Inactivation of transducin proceeds by hydrolysis of bound GTP through its intrinsic 
GTPase activity. This process is accelerated by the interaction with the GTPase activation 
protein, GTPase- activating proteins (GAP) complex: R9AP-RGS9-1-Gβ5L. The RGS9-1 
subunit of this complex facilitates the hydrolysis of GTP to GDP. Dissociation of the α 
subunit of GDP leads to inactivation of PDE6 (Fu 2010). 
In addition to the inactivation of the main signalling pathways proteins, there is a second 
very important event that must occur – cGMP restoration. The concentration of a free 
cGMP is dependent not only on the hydrolysing activity of PDE6 but also on guanylate 
cyclase (GC), which can synthetise cGMP. Activity of GC is dependent on guanylate-
cyclase-activating proteins (GCAPs) and the Ca2+ concentration. In darkness, GCAPs are 
bound to Ca2+, but after activation of phototransduction, Ca2+ concentration is low, which 
causes the ions to dissociate from GCAPs. GCAPs released from Ca2+ can bind to GC, 
activating it, returning the cGMP basal concentration within a short time. Finally, the 
dark current is restored and PR again release neurotransmitters (Fu 2010). 
1.1.2 Retinal ganglion cells 
Ganglion cells constitute the innermost layer of the retina (Fig. 1) and their axons form 
the optic nerve, which then projects to the thalamus and other targets in the brain. 
Ganglion cells transmit information as a series of action potentials and they report 
contrast in light, rather than the absolute light intensity (Nelson 2007). The reason for this 
property lies in the receptive field organization of GCs, which is the area of PR that is 
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monitored by one GC. Receptive fields are characterised by two important features: they 
are circular and in most cases divided into two parts: a circular centre zone (receptive 
field centre) and the surrounding area of the field. The main classes of ganglion cells can 
be distinguished based on this organization. On-center gangion cells are stimulated when 
light falls on the centre of their receptive field. Light that falls on the surrounding area 
inhibits the GC. In contrast, off-center ganglion cells are inhibited by light in the central 
zone of the receptive field and excited when light falls on the area surrounding the 
receptive field. Both type of GC are equal in abundance and the size of the receptive 
fields is dependent on their localization in different areas of the retina (Kandel et al. 
2000). In the fovea centralis region, where the acuity of vision is the greatest, the 
receptive fields are small while in the periphery the fields are larger. Parallel functioning 
of on-center and off-center ganglion cells also improves the visual system’s sensitivity to 
rapid changes in light intensity (Nelson 2007). On-center ganglion cells perceive rapid 
increase in light intensity while off bipolar cells signal rapid decrease in light. Moreover, 
the centre-surrounding structure of GC receptive fields gives more information about 
brightness and colour of objects since this react mainly to changes in contrast, rather than 
on the absolute amount of light, giving more information about brightness and colour of 
objects (Nelson 2007). In general, gangion cells can be divided into two functional groups 
(each containing on- and off-center GC): the M (magni or large) type and the more 
abundant P (parvi or small) type (Kolb 2011). M cells have large dendritic arbors, 
reflective of their large receptive fields, and respond temporally to sustained illumination. 
They detect big features of objects and can follow fast changes in the light stimulus – its 
movement (Kandel et al. 2000). On the other hand, P cells have small receptive fields and 
respond to particular wavelengths, making them more perceive for form and colour 
(Kandel et al. 2000, Nelson 2007).  
1.1.3 Retinal Müller glial cells 
Retinal Müller glial cells stretch through all layers of the retina and enclose all retinal 
neuronal cells (Fig. 1 and 4). RMG introduce a great functional support and their proper 
activity is essential for the normal functioning of the tissue and correct vision. As their 
physical structure is similar to that of optical fibers, they can participate in low-loss light 
transfer through the whole retinal tissue to the PR (Franze et al. 2007). RMG cells greatly 
support the histological structure of the retina (Willbold et al. 1997) and constitute an 
anatomical link for retinal neurons to exchange molecules with the vitreous body and 
blood vessels (Reichenbach et al. 1993, Newman & Reichenbach 1996). They maintain 
pH, ion and water homeostasis within the retinal tissue (Newman & Reichenbach 1996, 
Bringmann et al. 2006), control the retinal blood flow (Paulson & Newman 1987) and 
take part in formation and maintenance of the blood-retinal barrier (Tout et al. 1993). 
Furthermore, RMG are involved in glucose tissue homeostasis, and provide neurons with 
nutrients (eg. lactate/puryvate) essential for neuronal oxidative metabolism (Poitry-
Yamate et al. 1995, Tsacopoulos & Magistretti 1996). Moreover, they provide precursors 
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of neurotransmitters, which they also take up and recycle later on. This role in 
neurotransmitter recycling makes them important regulators of the physiological 
processes in neuronal signalling (Bringmann et al. 2006). In addition, RMG secrete 
vasoactive factors like VEGF (Eichler et al. 2000), pigment epithelium-derived factor 
(PEDF) (Eichler et al. 2004), transforming growth factor-β (TGF-β) (Ikeda et al. 1998), 
as well as neurotrophic factors like ciliary neurotrophic factor (CNTF), brain-derived 
neurotrophic factor (BDNF), lens epithelium-derived growth factor (LEDGF) (Seitz et al. 
2010), leukemia inhibitory factor (LIF) (Agca et al. 2013), fibroblast growth factor 2 
(FGF-2, bFGF) (Hauck et al. 2006b) and glial cell-derived neurotrophic factor (GDNF) 
(Zhu et al. 2012). Finally, RMG have been found to influence neuronal excitability 
(Newman & Zahs 1998, Stevens et al. 2003).  
In contrary to retinal neuronal cells, which are susceptible to injury by different 
perturbations, RMG cells are highly resistant to hypoglycemia or disturbed blood supply 
leading to ischemia or anoxia within the tissue (Bringmann et al. 2006). This difference in 
robustness can induce a disproportional RMG proliferation leading to gliosis, which 
exacerbates retinal degeneration and PR death (Bringmann et al. 2009). RMGs display a 
stereotypic response to injury independent of different noxious conditions, which includes 
upregulation of glial fibrillary acidic protein (GFAP) (Bringmann & Reichenbach 2001) 
and activation of extracellular signal-regulated kinases (ERKs) (Geller et al. 2001). 
However, specific responses have also been described. One example for a specific 
response is the regulation of glutamine synthetase (GS) expression. While it decreases 
after PR degeneration caused by light damage (Grosche et al. 1995), it increase after 
hepatic retionopathy, when it is necessary to detoxify the tissue from elevated levels of 
ammonia (Reichenbach et al. 1995). Similarly, neurotrophic factors like LIF are secreted 
by RMG after light injury to protect PR from premature death (Agca et al. 2013). 
The wide range of RMG functions within the retina and their resistance to different injury 
conditions make RMG an important therapeutic target. Many investigations in the last 20 
years have focused on the influence of Müller glial-derived prosurvival factors as a 
potential therapy for retinal degenerations, including retinitis pigmentosa. Neurotrophic 
factors like BDNF, CNTF, GDNF or LIF whose receptors are present on RMG but not on 
PR were shown to prolong PR survival in different animal models of retinal 
degenerations (Faktorovich et al. 1990, Di Polo et al. 1998, LaVail et al. 1998, Frasson et 
al. 1999a, Kirsch et al. 2010). 
1.1.4 Retinal pigment epithelium cells 
Retinal pigment epithelium cells form a single epithelial layer on the inside of the 
choroid. They contact PR outer segments on their apical side. Interactions between PR 
and RPE cells play an important role in retinal metabolism and recycling (Wright et al. 
2010). Since PR do not have the necessary enzymes, all-trans retinol is transported from 
PR to RPE cells and re-isomerised to 11-cis retinal, essential for the light reactions in 
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phototransduction (see 1.1.1.1), and send back to PR (Wright et al. 2010). In addition, 
RPE cells contain melanosomes - the pigment granules that absorb stray light falling into 
the eye, which improves the quality of the PR light perception (Kandel et al. 2000).  
 
Figure 4. Retinal Müller glial cells surround neuronal retinal cells. 
Retinal Müller glial cells were visualized by immunohistochemistry on mouse retina with glutamine 
synthetase (red). Cone axons and synaptic endfeet were stained with peanut agglutinin (green). DAPI was 
used to visualise nuclei (blue) Scale bar 10µm. 
Furthermore, studies on genetically inherited retinal degenerations reveal a strong 
dependence of PR and RPE from each other. On one hand PR degeneration is followed 
by RPE cell atrophy in some patients with RP as well as in the rd1 and rd10 mouse model 
of RP (Mitamura et al. 2012, Pennesi et al. 2012, Samardzija et al. 2012). On the other 
hand, RPE cells secrete many factors like CNTF, BDNF, FGF-2, VEGF, GDNF, LIF, 
PEDF, TGF-β2, beta-nerve growth factor (BNGF), insulin-like growth factor-binding 
protein 1 (IGFBP-1) (Li et al. 2011), LEDGF (Matsui et al. 2001), insulin-like growth 
factor-1 (IGF-1) (Savchenko et al. 2001), platelet-derived growth factor (PDGF) 
(Campochiaro et al. 1994) and tissue inhibitor of matrix metalloprotease 1 (TIMP1) 
(Padgett et al. 1997). These molecules influence not only PR survival (Ahuja et al. 2001), 
PR outer segment regeneration and the phototransduction machinery (Wen et al. 2012) 
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but also the endothelium of blood vessels in the eye (Lambooij et al. 2003). The 
basolateral side of the RPE, together with Bruch’s membrane and choriocapilars, forms 
an outer part of blood-retina barrier (Hamilton & Leach 2011). Therefore, RPE cells have 
the additional function of controlling ion homeostasis as well as the epithelial transport 
into the eye. Specifically, they supply PR with nutrients (e.g. glucose and ω-3 fatty acids), 
and mediate the retrograde transport of metabolic end-products back to the circulation 
(Kandel et al. 2000). 
RPE cells are constantly at risk of very intense oxidative stress, since they have the task 
of clearing PR outer segments damaged by excessive photo oxidation through 
phagocytosis. On the basal side RPE adjoin choroid tissue characterised by a strong 
oxygen blood perfusion (Shadrach et al. 2013). To survive in such a highly photo-
oxidative environment with a high amount of free radicals, RPE cells possess the ability 
to detoxify peroxidized lipids, proteins and DNA through high concentrations of 
enzymatic and non-enzymatic anti-oxidant systems (Kandel et al. 2000). 
Finally, RPE cells are a part of the immunological defence system of the eye. The RPE 
contributes to these defences through formation of a physical barrier that separates the 
blood stream from the inner space of the eye. Additionally, they secrete immune 
modulatory factors like interleukin-8 (IL-8) and IL-6 (Li et al. 2011), cyclin A (Kaestel et 
al. 2005) and complement factor H (CFH) (Mandal & Ayyagari 2006). Interestingly, RPE 
express toll-like receptors (Kumar et al. 2004), and under certain circumstances even 
MHC class II receptors (Makhoul et al. 2012), which are thought to enable them to 
participate in pathogen recognition.  
1.2 Vasculature of the retina 
Development of the retinal blood vessels is similar in rat and mouse (Cairns 1959, Ritter 
et al. 2005). During fetal development blood vessels sprout at the head of optic nerve and 
spread radially from the centre of the retina to the peripheral parts. At birth the retina of a 
rat is avascular and the hyaloid system of vessels nourishes the lens and the retina. 
Hyaloid vessels originate from the optic disc, cross the vitreous body and pass close to 
the surface of the retina. This arrangement persists between postnatal day (PN) PN0-PN5. 
At around PN6, the hyaloid vessels start to regress, and at PN9 only a small residue of the 
vessels, crossing the vitreous body, is left. The eventual atrophy of the hyaloid vessels is 
observed between PN15-PN22 (Cairns 1959). 
The development of the main retinal vessels starts after birth at the innermost side of the 
retina and progress outward in the direction of the choroid (Fig. 5). Four to eight 
arterioles spring from the central retinal artery and symmetrically radiate out in the optic 
nerve fiber layer. First capillaries bud from these radiating arterioles between PN1 and 
PN2 and form the superficial plexus. These capillaries avoid the immediate proximity of 
the artery, but not the vein. Its development is almost complete by PN8-PN10, except for 
	  	   19 
minor maturation of the retina in the periphery until PN16 (Cairns 1959, Engerman & 
Meyer 1965). The deep capillary plexus, which will supply the inner retina, springs from 
the superficial plexus between PN6-PN8 (Cairns 1959, Engerman & Meyer 1965). The 
capillary network penetrates deeply into the inner nuclear layer but not further than the 
outer plexiform layer. Large collecting veins that arise from the plexus perforate the inner 
nuclear layer. The deep capillary plexus fully develops, draining the peripheral area, by 
PN15-PN16, at which time the hyaloid vessels are basically gone (Cairns 1959).  
 
 
Figure 5. Vasculature of an adult human eye. 
The picture presents the retinal vasculature, penetrating the retina from the inner side as well as the 
choroidal vasculature surrounding the RPE (subretinal vasculature). Reprinted by permission from Elsevier 
(Anand-Apte & Hollyfield 2010). 
In human retina hyaloid vessels are present in the embryonic and fetal stages of 
development. It is fully developed at the ninth week and starts to regress right afterwards. 
By the sixth month of gestation, hyaloid vessels are gone and only the Cloquet canal, 
spreading from the optic disk to the posterior surface of the lens, remains. The retinal 
vascular network starts to develop during the fourth month of gestation, when first vessels 
form a first primitive central retinal arterial system. The vessels then extend from the 
optic nerve to the periphery of the retina, so by the time of delivery the whole retina is 
surrounded. Human retina achieves the vasculature pattern of an adult by the fifth month 
after birth (Anand-Apte & Hollyfield 2010). 
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Chapter Two: Retinal pathology 
Chapter two focuses on retinal pathology caused by genetic mutations. It shortly presents 
inherited retinal degenerations (2.1), focusing on symptoms and retinal changes in 
patients with retinitis pigmentosa (RP, 2.1.1), the disease that is the focus of the 
experimental part of the thesis. The chapter is closed by the descriptions of retinitis 
pigmentosa animal models (2.2) – Pde6brd1 (rd1) mouse (2.2.1) and S334-ter-line 3 
(S334ter-3) rat (2.2.2), which were used in this study. 
2.1 Inherited retinal degenerations 
Genetically inherited mutations leading to disorders of photoreceptor or supporting cells 
are a common reason for impaired vision. Some of them, like Leber congenital amaurosis 
(Perusek & Maeda 2013), or Batten disease (Rakheja et al. 2007) affect vision from early 
childhood. Others like Stargardt disease starts in patients before they are 20 years old 
(Nentwich & Rudolph 2013). Similarly, the age of onset for the disease investigated in 
this study, retinitis pigmentosa, ranges from childhood to early adulthood (Hartong et al. 
2006).  
2.1.1 Retinitis pigmentosa 
Retinitis pigmentosa is a collective term for a group of hereditary retinal progressive 
diseases, in which the genes affected by mutations lead to rod, cone or RPE cell 
degeneration (van Soest et al. 1999). Around 1 in 4000 individuals is affected by this 
disease worldwide (Hartong et al. 2006). This translates to around one million patients in 
total. Due to a severely constricted visual field most RP patients are legally blind by the 
age of 40 (Hartong et al. 2006).  
Retinitis pigmentosa can be inherited in an autosomal dominant, autosomal recessive or 
X-linked way. Today, 57 genes and loci responsible for the disease have been identified 
(RetNet: https://sph.uth.edu/RetNet/sum-dis.htm). Autosomal recessive RP accounts for 
50 – 60% of cases, out of which mutations in α or β subunits of rod phosphodiesterase are 
one of the most common with 9% of total cases. Mutations in both subunits of PDE6 are 
found at about equal proportions in patients. Autosomal dominant RP accounts for 30-
40% of cases and within this group, mutations of rhodopsin make up the lion’s share with 
25% of cases. X-linked mutations are responsible for only a minor fraction (5-15%) of RP 
cases. Interestingly, – only one gene accounts for 70 -80% of X-linked RP cases - GTPase 
regulator (RPGR) (Hartong et al. 2006). Retinitis pigmentosa occurs in patients from 
childhood to adulthood and is usually limited to the eyes. Nevertheless, around 20-30% of 
patients are afflicted by additional non-ocular manifestation caused by their respective 
gene defects. Examples of these cases are Usher’s syndrome or α-tocopherol transport 
protein deficiency, although more than 30 other forms have been described (Hartong et al. 
2006).  
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The symptoms and disease progression of retinitis pigmentosa are highly variable. Some 
patients lose sight in childhood, while others in mid-adulthood. In most of the patients, 
the rods are the first cells to be affected, which causes night blindness followed by loss of 
peripheral vision and finally tunnel vision. Patients with end-stage retinits pigmentosa 
often present with an almost complete loss of central vision by the age of 60 (Hartong et 
al. 2006). However, retinitis pigmentosa can start with cone rather than rod degeneration 
in a subgroup of patients, leading to impaired central vision, impaired visual acuity and 
defective colour vision (Birch et al. 1999). Symptoms may also include refractive error in 
the eye and patients may develop myopia (mostly X-linked RP, (Fishman et al. 1988)) or 
hyperopia (mostly dominant RP, (Hartong et al. 2006)). RP can remain undiagnosed for 
long periods of time, if patients live in environments that are electrically illuminated 
during the night. Moreover, during daily tasks no subjective difficulties will arise even if 
the visual field is reduced to around 50 degrees in diameter (compared to 180 degrees for 
a healthy person). Even more striking is the fact that patients can lose 90% of cones in the 
fovea centralis before realising a reduction in visual acuity (Geller & Sieving 1993). 
Furthermore, patients with electroretinogram amplitude 50 times smaller than normal can 
still have ambulatory vision (defined as an ability to move around using only visual 
information) and read newspapers (Andreasson et al. 1988). Taken together, by the time 
patients notice visual disturbances the disease may already be in very advanced stages.  
The disease is diagnosed by measurements of colour vision, dark adaptation and contrast 
sensitivity as well as fundus observations. In addition, the electrical responses of the 
photoreceptors to the flashes of light are measured using electroretinography (ERG). 
Patients affected by RP have delayed rod and cone response with reduced amplitude 
during ERG measurements (Hartong et al. 2006). Similarly, atrophy of retinal vessels 
together with intraretinal pigmentation in the periphery of the tissue is found in almost all 
cases (Fig. 6). For some patients, images of the fundus autofluorescence reveal increased 
concentrations of the age-related pigment lipofuscin in the RPE. These regions also have 
decreased ERG amplitudes (Popovic et al. 2005, Robson et al. 2006). Around 50% of 
patients develop posterior subscapular cataracts (Heckenlively 1982, Fishman et al. 
1985). Additionally, the head of the optic nerve can have a pale colour (optic-disc pallor) 
(Fig. 6). Furthermore, changes in the retinal morphology, like thickness, structure of the 
PR layer and presence of macular oedema, have been described using non-invasive optic 
coherence tomography (Jacobson et al. 2000, Ko et al. 2005, Sandberg et al. 2005). 
2.2 Animal models of retinitis pigmentosa 
RP research currently utilizes a large number of different animal models to investigate 
different therapeutic approaches. The rd1 mouse and S334ter line 3 (S334ter-3) rat animal 
models of RP, used in this study, will be described below, together with a short 
description on validated therapies. 
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Figure 6. Morphological alterations in the fundus of a retinitis pigmentosa patient. 
Healthy retinal vasculature (on the left side) versus vasculature of an RP patient (on the right side) was 
assessed by funduscopy. RP retina shows vascular atrophy, peripheral pigment deposits as well as a pale 
optic disc. Reprinted by permission from Elsevier (Hartong et al. 2006). 
2.2.1 rd1 mouse 
The retinal degeneration (Pde6brd1, rd1, C3H/HeJ) mouse, firstly described as the 
“rodless retina” (r) (Keeler 1924), is currently the best characterized animal model for 
RP. In these animals degeneration of the retina is caused by a mutation on chromosome 4 
and in exon 7 of the β-subunit of PDE6 (Fig. 3), which leads to production of a non-
functional protein (Bowes et al. 1990, Pittler & Baehr 1991). This mutation has been also 
found in human patients affected with autosomal recessive RP (see 2.1.1). The retina of 
rd1 mice shows first signs of PR abnormality already from the day of birth - increased 
activity of anaerobic glycolysis and increased production of lactate (Acosta et al. 2005). 
In the next stage (PN4) retarded growth of photoreceptor inner segments can be observed 
(Caley et al. 1972, Sanyal & Bal 1973), followed by swollen mitochondria of the rod 
inner segments at PN8 (Farber & Lolley 1974). Subsequently, increased uptake of 
oxygen, utilization of higher amounts of glucose as well as lactic acid production 
followed by the rapid decrease of these parameters at PN12 takes place for the whole rd1 
retinal tissue (Bowes et al. 1990). Moreover, although cellular integrity and thickness of 
ONL in PN10 rd1 retina is comparable to the wild type retina, outer segment disks show 
signs of disruption (Carter-Dawson et al. 1978). This phenomenon is accompanied by 
pyknotic nuclei and the beginning of rods degeneration (Sanyal & Bal 1973). At PN11, 
the rate of rod degeneration starts to increase progressively, but the rods are still present 
and the general number of PR is not yet significantly decreased in comparison to wild 
type (Portera-Cailliau et al. 1994, Hauck et al. 2006a). The peak of degeneration is 
around PN12-PN14 (Fig. 7) (Sanyal & Bal 1973, Carter-Dawson et al. 1978) and no rods 
are left in the central retina by PN36 and in the periphery by PN65 (Carter-Dawson et al. 
1978). Cones, although not affected by the mutation, degenerate secondarily within the 
first six postnatal months although residual nuclei can occasionally be found at the age of 
18 months (Carter-Dawson et al. 1978).  
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Figure 7. The peak of rd1 retinal degeneration occurs between PN12 and PN14. 
Ultrastructural comparison between wild type (Balb/c) and rd1 mice. Wildtype control retinas at PN14 (A) 
and PN26 (C) are shown for comparison. Photoreceptor loss is observable at PN14 (B) and pronounced at 
PN26 (D) in rd1 mice. On the pictures are indicated: retinal pigment epithelium (PE), outer segments (OS), 
inner segments (IS), outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), 
inner plexiform layer (IPL). Magnification 500x Reprinted by permission from Springer (Sanyal & Bal 
1973). 
On the cellular level, the PR degeneration process in the rd1 mouse retina is difficult to 
classify since it does not conform to the characteristics of either classical apoptosis or 
necrosis (Leist & Jaattela 2001, Edinger & Thompson 2004). On one hand, Apoptosis 
inducing factor (AIF) and caspase-12 - two markers of apoptosis – were shown to 
translocate to the nucleus of degenerating PR (Sanges et al. 2006). Similarly, elevated 
Ca2+ level and swollen mitochondria indicate induction of PR death through apoptosis 
(Lipton & Nicotera 1998). On the other hand, the degeneration happens without 
activation of initiator caspases (-8, -9) or downstream effector caspases (-2, -3, -7) and 
without release of cytochrome c (Holcik & Korneluk 2001, Doonan et al. 2003, Zeiss et 
al. 2004). Moreover, although there is massive death of PR cells within a short 
timeframe, there is no evidence for necrosis or an inflammatory reaction (Portera-Cailliau 
et al. 1994). The fact that between PN10 and PN14 activated microglia cells migrate to 
the degenerating PR is another mosaic piece in the degeneration of the rd1 retina (Zeiss & 
Johnson 2004, Zeng et al. 2005). Taken together, the rd1 PR degeneration appears to be 
caused by a type of apoptosis, which deviates from the textbook definition in some 
regards, the missing cytochrome c release, for instance.  
Many therapeutic strategies were already applied in the rd1 RP animal model. Impairment 
of the β-subunit of PDE6 leads to accumulation of cGMP (Farber & Lolley 1974), which 
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causes an constant influx and eventual overload of calcium and sodium through cGMP-
gated sodium channels. The excessive Ca2+ influx into PR cell together with upregulation 
of CaM kinase II is visible between PN5 - PN10 (Fox et al. 1999, Doonan et al. 2005, 
Hauck et al. 2006a, Sanges et al. 2006) and causes mitochondria depolarization and 
energy collapse (Doonan et al. 2005) as well as endoplasmic reticulum (ER) stress (Yang 
et al. 2007). As this mechanism is reminiscent of the induction of neuronal death through 
overstimulation with excitatory neurotransmitters and resulting calcium overload 
(excitotoxicity) (Lipton & Nicotera 1998), many experiments applying calcium channel 
inhibitors were performed. D-cis diltiazem is a competitive antagonist of L-type calcium 
and cyclic nucleotide-reglated channels, clinically used in cardiology (Koch & Kaupp 
1985, Haynes 1992). In one in vivo study on rd1 mice it partially rescued PR from 
preliminary death (Frasson et al. 1999b). On the other hand, other studies on D-cis 
diltiazem could not confirm its neuroprotective effect (Tawara et al. 1989, Pawlyk et al. 
2002, Fox et al. 2003, Takano et al. 2004). Another L-type antagonist of calcium 
channels, nivadipine, was effective in preserving PR morphology, but not function, in in 
vivo studies on rd1 mice (Takano et al. 2004). Application of pharmacological inhibitors 
of cGMP-dependent protein kinase (PKG) into rd1 mouse eye resulted in a strong 
decrease in PR death (Paquet-Durand et al. 2009). 
Interestingly, increased activity of the Ca2+ dependent protease - calpain has been found 
in TUNEL positive rd1 PR after PN11. This increase has been linked to phosphorylated 
cAMP responsive element-binding protein (CREB-1) dependent downregulation of 
calpastatin, an endogenous inhibitor of calpain (Paquet-Durand et al. 2006). Since calpain 
activation can be connected to neuronal degeneration (Sakamoto et al. 2000, Arataki et 
al. 2005), different calpain inhibitors were tested. Intravitreal injections of a calpastatin 
peptide resulted in decreased PR cell death (Paquet-Durand et al. 2010). Furthermore, 
intravitreal injections with calpain inhibitor I and II inhibited activation of two markers of 
apoptosis - AIF and caspase-12 and decreased PR cell death (Sanges et al. 2006). On the 
other hand, in vivo experiments performed only with calpain inhibitor I failed to show 
reduction of PR cell death in rd1 mouse retina (Doonan et al. 2005).  
Calcium overload in neuronal cells also results in mitochondrial depolarization and 
subsequent reactive oxygen species production (Lipton & Nicotera 1998). Severe 
mitochondrial oxidative stress is already observable after the first week of life in rd1 mice 
(Farber & Lolley 1974, Vlachantoni et al. 2011). Consistent with a role of oxidative stress 
in rd1 PR cell death, seven days of hypoxia could prolong PR survival in rd1 retinal 
explants. However, treatment of rd1 mice with the antioxidant MSO10 (MitoQ) failed to 
increase PR survival (Vlachantoni et al. 2011). Another strategy, injections of different 
antioxidants between PN18 and PN35, resulted in the reduction of cone oxidative 
damage, increased survival rate and partially preserved cone function (Carter-Dawson et 
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al. 1978). This last result is in line with the hypothesis that cone death is caused by 
oxidative stress arising after rod cell death (Carter-Dawson et al. 1978). 
2.2.2 S334ter line 3 pigmented rat 
Multiple missense mutations at the C-terminus (Pro347Ser, Pro347Leu, Pro437Gln, 
Val345Leu, Val345Met and Q344ter) (Sung et al. 1991, Sung et al. 1993, Jacobson et al. 
1994, Sandberg et al. 1995) were found in human cases of RP (Fig. 8). The C-terminus 
contains the rhodopsin-sorting signal, responsible for targeting the protein to the PR outer 
segments. Mutations in this region cause the most severe symptoms in RP patients 
(Sandberg et al. 1995). 
Mutant rhodopsin transgenic S334ter rats were developed in the laboratories of the 
University of California in San Francisco in 1996 
(http://www.ucsfeye.net/mlavailRDratmodels.shtml). The S334ter mutation causes 
premature termination of rhodopsin translation resulting in a C-terminally truncated 
rhodopsin protein lacking the last 15 amino acid residues. As a consequence, almost all of 
the phosphorylation sites of the molecule are missing (Mendez et al. 2000, Concepcion et 
al. 2002). Five lines (line  -3, -4, -5, -7, - 9) of S334ter rats with the same mutation but 
different rates of PR degeneration were obtained. The S334ter-3 line shows, after S334-
ter-7 rats, the second most severe phenotype (Pennesi et al. 2008, Martinez-Navarrete et 
al. 2011). 
In the S334ter-3 retina, the first pycnotic nuclei can be found in the proximal half of the 
ONL at PN4 and PN6 followed by occasional degenerating PR observed from PN8 until 
PN11 (Liu et al. 1999, Pennesi et al. 2008, Martinez-Navarrete et al. 2011). Next, 
between PN11 and PN12, caspase-3 activation increases and rods undergo rapid 
degeneration, causing more than 50% of them to die (Liu et al. 1999, Martinez-Navarrete 
et al. 2011). At PN15, 65% of PRs are lost (Pennesi et al. 2008). This is accompanied by 
a significant increase of endoplasmic reticulum stress markers (Kroeger et al. 2012). The 
next day, the PR layer declines to two or three rows. At PN20 – PN30 only one or two 
rows remain with residual inner segments (Liu et al. 1999, Martinez-Navarrete et al. 
2011) and at PN60 only cones are left (Martinez-Navarrete et al. 2011). Increased 
expression of GFAP by RMG as a reaction to PR degeneration begins around PN21. The 
RMG cells form a seal between PR and RPE starting at PN60 (Ray et al. 2010). Rod 
outer segments never develop in the heterozygous S334ter-3 rats (Liu et al. 1999, 
Martinez-Navarrete et al. 2011) while cone outer segments are shorter and distorted in 
comparison to normal rats (Martinez-Navarrete et al. 2011, Ji et al. 2012). After rod 
degeneration, cones start to lose their outer segments, and within two months start to die 
(Li et al. 2010) Nevertheless, cone degeneration does not lead to complete cone loss even 
at PN600 (Ji et al. 2012). In the early stages of the degeneration cones without outer 
segments are viable and capable to regenerate the outer segments. (Li et al. 2010). 
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Figure 8. Mutations in the rhodopsin C-terminus lead to retinitis pigmentosa. 
A mutation on the cytoplasmatic C-terminus of rhodopsin causes the most severe symptoms in patients with 
retinitis pigmentosa. The S334ter mutation (red) shortens the C-terminus by 15 amino acids, which deprive 
the protein of most of its phosphorylation sites (blue). Reprinted by permission from Elsevier (Mendes et 
al. 2005) 
In contrast to the rd1 mouse model, apoptosis of rods is accompanied by activation of the 
canonical pathway with increased activity of caspase-9, caspase-3 and cytochrome c 
release (Kaur et al. 2011). Moreover, the irreversible caspase-3 inhibitor z-DEVD-fmk 
inhibits PR degeneration (Liu et al. 1999). Calpastatin downregulation, strong activation 
of calpain and poly ADP-ribose polymerase (PARP) together with increased oxidative 
DNA damage and poly ADP-ribose (PAR) polymer accumulation heavily imply the 
canonical apoptosis pathway in the death of PR in the S334ter model (Kaur et al. 2011). 
S334ter-3 retinas undergo an interesting secondary modification concomitant with PR 
degeneration. Both PR types form circular structures around dying cells as rods start to 
degenerate at PN10-PN15 (Fig. 9). These structures are spread throughout the whole 
retina by PN90 (Ji et al. 2012, Zhu et al. 2013). They are very regular and consistent 
structures, with respect to cone spatial arrangement as well as orientation. Their 
formation is probably modulated by RMG (Lee et al. 2011, Zhu et al. 2013). At PN180, 
the circular structures start to loose their form, the cones lose their specific orientation 
and start to die (Ji et al. 2012). Activated microglia invade the space left by dead PR and 
are replaced later by remodelled RMG processes (Zhu et al. 2013).  
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Rapid rod death forces changes in other neurons. The first cells undergoing cellular 
modifications are rod bipolar and horizontal cells, followed by amacrine cells (Ray et al. 
2010, Martinez-Navarrete et al. 2011). Bipolar cells show retraction of dendrites, form 
clusters along the outer plexiform layer at PN11-13 and by PN60 their number deteriorate 
to half their original number in the central retina (Ray et al. 2010, Martinez-Navarrete et 
al. 2011). The decrease continues afterwards, affecting about one-third of the bipolar cells 
in the healthy retina (Ray et al. 2010). Horizontal cell processes appear thinner and less 
complex around PN11-PN21 (Ray et al. 2010, Martinez-Navarrete et al. 2011), leading to 
gaps in the outer plexiform layer. Between PN60 and PN90 around half of the horizontal 
cells are lost and almost no terminal tips can be observed in the remaining horizontal cells 
(Ray et al. 2010, Martinez-Navarrete et al. 2011). Additionally, the density of horizontal 
cells in whole mount retina at PN60 and PN90 is significantly reduced in the central, but 
not the peripheral retina (Ray et al. 2010). Amacrine cells are affected as well and their 
mislocalization toward the INL at PN180 and PN600 has been reported (Ray et al. 2010). 
One study showed indications for apoptosis in inner retinal neurons and within ganglion 
cells after PR degeneration (Martinez-Navarrete et al. 2011), which had not been 
observed in an earlier study (Ray et al. 2010). Surprisingly, ganglion cells ON and OFF 
responses were recordable even from three-month-old homozygous S334ter-3 rats (An et 
al. 2002). 
 
Figure 9. Photoreceptors form circular structures around dying cells in the degenerating 
S334ter-3 rat retina. 
Confocal images of the whole-mount retina prepared from PN15 rats. During rod degeneration around 
cones (M-opsin, violet) and rods (rhodopsin, green) arrange themselves in circular structures around 
TUNEL positive cells (green). Scale bar 100µm Reprinted by permission from John Wiley and Sons (Ji et 
al. 2012). 
Early rod degeneration also negatively influences retinal blood vessel development. The 
deep capillary plexus in rat retina is mature by PN15, but in S334ter-3 65% of PRs are 
gone by this time. As a consequence, capillaries do not develop properly and their 
number reaches only 6-7% relative to wild type retinas at this time point. This effect is 
permanent and even after one year no increase in vascularization of the deep capillary 
plexus could be found (Pennesi et al. 2008). 
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Chapter three: Therapeutic strategies against retinitis pigmentosa 
Chapter three briefly summarizes novel therapeutic strategies against RP (3.1) and 
reviews neuroprotective factors that are currently under investigation (3.2). Additionally, 
it provides the rationale for more detailed studies on GDNF neuroprotective action 
(3.2.1), presenting a wide spectrum of successful research conducted on different animal 
models of RP. Eventually, cysteine rich protein 61 (Cyr61/CCN1), the molecule whose 
neuroprotective potential was chosen for investigation in the presented thesis, is described 
in detail (3.2.2). 
3.1 Experimental therapies for retinitis pigmenotsa 
Many different treatment strategies are investigated to treat RP. These include gene 
therapies, transplantation of whole retinas or stem cell therapy, implantation of electrical 
devices, pharmacological treatment with vitamin supplementation, or factor application. 
Each of them has advantages as well as disadvantages. 
Gene therapy, so far the most successful, is dependent on the type of mutation and aims 
to induce the local production of the missing or mutated protein. This therapy must be 
tailored specifically to each individual patient (Jacobson et al. 2000, Acland et al. 2005, 
Bi et al. 2006). Transplantation of fetal retinal sheets has proven a rescue in cases where 
PR and RPE cells had already degenerated, but because of difficulties with tissue supply 
and ethical issues, it cannot be assumed as a universal therapy (Seiler et al. 2008, Seiler & 
Aramant 2012). Stem cell therapy using pluripotent or multipotent adult stem cells are 
already under investigation and could be an alternative to transplantation of retinas from 
fetuses (Borooah et al. 2013, Bharti et al. 2014, Kamao et al. 2014). A different approach 
originates from the developing field of electrical devices that are able to stimulate the 
optic nerve, retina or visual cortex and may also be an option for patients with already 
degenerated PR (Chow et al. 2004, Brelen et al. 2005, Pezaris & Eskandar 2009, Zrenner 
et al. 2011). Another therapeutic strategy employs vitamin A supplementation which was 
shown to be beneficial in patients with mutations of genes responsible for retinoid 
recycling in the visual cycle (Perusek & Maeda 2013). Finally, the application of a 
neuroprotective factor has never been shown to be fully curative, but has the advantage of 
being more universal, as this strategy is focused on intervening at the level of cellular 
pathways leading to PR death (Van Hooser et al. 2000) which in many cases proceeds 
independently of a specific mutation (Kaur et al. 2011). Neurotrophic factors may have 
the potential to slow down PR death in retinal degenerations of various origins and 
preserving the patient’s residual vision for an extended period. While not curative in 
nature, this approach could offer a significant reduction in suffering and increase life 
quality for patients. 
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3.2 Neuroprotective factors 
In 1990 Faktorovich and co-workers published their pioneering work showing prolonged 
PR survival in the PR degeneration model Royal College of Surgeons (RCS) rat, after 
FGF-2 injection (Faktorovich et al. 1990). Since that time, many other successful studies 
on a variety of neurotrophic factors have been conducted in several animal models of RP 
(Thanos & Emerich 2005). These include BDNF (Zhang et al. 2009), CNTF (Li et al. 
2010, Lipinski et al. 2011), LEDGF (Baid et al. 2013), PEDF (Cayouette et al. 1999), 
granulocyte–macrophage colony-stimulating factor (GM-CSF) (Schallenberg et al. 2012) 
and rod-derived cone viability factor (RdCVF) (Yang et al. 2009). Since GDNF is one of 
the subjects of this thesis, its neuroprotective function in different models of retinal 
degeneration are reviewed in more detail in the following.  
3.2.1 GDNF in retinitis pigmentosa research 
GDNF, together with neurturin, artemin and persephin, is a member of the transforming 
growth factor-β-related neurotrophic factor family. It was first purified and described in 
1993, and was shown to promote neuronal survival from the embryonic stage in the 
central and peripheral nervous system (Lin et al. 1993, Homma et al. 2000, Sariola & 
Saarma 2003). Two of its receptors, GDNF receptor α-1 (GFRα1) and GFRα2, were 
shown to be present in the central nervous system as well as in spinal cord neurons (Jing 
et al. 1996, Yu et al. 1998, Liu & Rask-Andersen 2014). Furthermore, GFRα1 was found 
on neurons of the olfactory system (Marks et al. 2012). 
In the retina, GDNF is expressed already from the first weeks of embryonic life 
(Hellmich et al. 1996, Nosrat et al. 1996). Postnatal, GDNF is synthetized by RMG 
(Harada et al. 2003) and by RPE cells (Ming et al. 2009) and its receptors are expressed 
on RMG (Harada et al. 2003, Hauck et al. 2006b), ganglion cells and PR (Jomary et al. 
2004, Rothermel et al. 2004), although some available data contradict the presence of 
GDNF receptors on PR (Harada et al. 2003, Hauck et al. 2006b). 
For the first time, Frasson and coauthors validated GDNF’s neuroprotective effect in vivo 
in animal model of RP in 1999. Subretinal injection of GDNF into eyes of rd1 mice 
achieved spectacular effects in regard to prolonged survival but also function of PR. 
Moreover, no angiogenic activity or macrophages migration was diagnosed (Frasson et al. 
1999a). Since that time many investigations on GDNF’s neuroprotection were conducted, 
investigating different animal models of RP as well as different ways of trophic factor 
delivery. Overexpression of GDNF in PR or RPE of transgenic rd10 mice, showed 
significant increase in PR survival as well as function for up to 40 days (Ohnaka et al. 
2012). First attempts to use adeno-associated virus (AAV) gene transfer to deliver GDNF 
to the retina were conducted on the S334-ter-4 rat. Subretinal injections of AAV delayed 
PR cell death for at least 45 day and increased ERG amplitudes (McGee Sanftner et al. 
2001). A prolonged effect of GDNF rescue on the same rat model was achieved in 
following studies, injecting a special variant of AAV, capable of efficiently and 
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selectively transducing RMG. This therapy led to sustained functional PR rescue for more 
than five months (Dalkara et al. 2011). Moreover, combination of AAV neurotrophic 
factor delivery with gene replacement therapy brought further interesting results 
suggesting that the combination of both therapies may yield better results than gene 
therapy of factor application alone. AAV-mediated delivery of GDNF in addition to the 
X-chromosome linked inhibitor of apoptosis gene delivered to eyes of Prph2Rd2/Rd2 
mice and RCS rats prolonged PR survival and preserved their function for up to three and 
two months, respectively (Buch et al. 2006). Non-viral GDNF gene delivery was 
performed using GDNF-encoding plasmids transferred with electrical devices through 
ciliary muscles into the eyes of RCS rats. Its expression was confirmed for at least seven 
months, but PR survival as well as function was preserved for around 50 days (Touchard 
et al. 2012). Another GDNF based approach was intravitreal delivery of embryonic stem 
cells engineered to secrete GDNF. Tests on S334-ter-4 rats significantly prolonged PR 
survival for at least three months. Although no immunosuppression was required, several 
adverse effects, like lens opacities and total retinal detachment, were reported. At the 
same time, GDNF was increased 10-12 fold in serum samples, raising the danger of 
systemic negative effects, attributable to long-term exposure to GDNF (Gregory-Evans et 
al. 2009).  
Taken together, GDNF seems to be a powerful neurotrophic factor and investigation of its 
mode of action can shed more light on the molecular pathways leading to PR survival. 
3.2.2 Cyr61 
Cysteine-rich heparin-binding protein 61 (Cyr61, CCN1, IGF-binding protein 10) is a 
member of the CCN extracellular matrix protein family and was first investigated in 
studies on a mouse fibroblast cell line. The Cyr61 gene encodes a 379-amino-acid protein 
containing 38 cysteine residues (O'Brien et al. 1990). Cyr61 is classified as an 
immediate-early gene, as its mRNA is synthesized within minutes after serum or growth 
factor (PDGF, FGF2, TGF-β1) stimulation and peaks at 60 - 90 minutes, after which the 
level of mRNA decreases by transcriptional repression and rapid degradation (Lau & 
Nathans 1987, O'Brien et al. 1990, Jun & Lau 2011). The protein is synthetized within 
one to two hours after stimulation and is associated after secretion with the cell surface as 
well as the extracellular matrix, but it is not detectable in the conditioned medium of 
stimulated cells (O'Brien et al. 1990, Yang & Lau 1991). Intracellular and cell surface 
associated Cyr61 has a half-life of around 30 minutes (Lau & Nathans 1987, O'Brien et 
al. 1990, Yang & Lau 1991) while it has a half-life longer than 24 hours when associated 
with the extracellular matrix (Yang & Lau 1991). 
Cyr61 consists of four domains (Fig. 10). The first domain starts from an N-terminal 
secretory peptide and shares sequence homology with the N-terminal region of the insulin 
like growth factor-binding protein (IGFBP) domain. The second domain, von Willebrand 
factor type C (vWC), is followed by a variable or hinge region, which is highly charged 
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and does not contain any cysteines. The third domain is designated trombospondin type I 
repeat (TSR), based on homology. The fourth domain, containing a cysteine knot motif 
carboxyl-terminal (CT), resembles the CT domains of some other extracellular proteins 
and is believed to mediate protein-protein interaction. The first three domains are well 
preserved within the CCN family, while the CT domain varies between the family 
members (Lau & Lam 1999, Lau 2011).  
 
Figure 10. Schematic structure of Cyr61. 
Cyr61 consists of four domains: insulin like growth factor-binding protein (IGFBP), von Willebrand factor 
type C (vWC), trombospondin type I repeat (TSR) and carboxyl-terminal (CT). Binding sides for integrins 
have been localized on three of the domains. After (Lau 2011). 
Expression of cyr61 is induced as a result of a wide range of different stimuli like serum 
growth factors (O'Brien et al. 1990), PDGF and FGF-2 (Lau & Nathans 1987), TGF-β1 
(Brunner et al. 1991), estrogen (Csoregh et al. 2009), hypoxia (Shun et al. 2011), VEGF 
(Athanasopoulos et al. 2007), UV light (Quan et al. 2006), mechanical stretch (Chaqour 
& Goppelt-Struebe 2006) and inflammatory cytokines such as IL-1 and tumor necrosis 
factor α (TNF-α) (Gashaw et al. 2008). 
Cyr61 mediates different cellular responses by binding to a wide range of integrins and 
heparin sulfate proteoglycans (HSPGs) (Yang & Lau 1991, Lau 2011). Possible binding 
regions for some of the different Cyr61 integrin receptors have been identified in three of 
its domains (Fig. 10). Depending on a specific receptor type, Cyr61 promotes different 
cellular responses. For instance, binding of Cyr61 to αvβ3 integrin on endothelial cells 
(Leu et al. 2002) and breast cancer cells (Menendez et al. 2005) increases their survival, 
while binding of Cyr61 to α6β1 and syndecan4 on fibroblasts can initiate apoptosis 
(Todorovic et al. 2005). By virtue of it’s binding to other integrins, Cyr61 can also 
influence cell adhesion (α6β1 and HSPGs, αvβ3), migration (αvβ5), differentiation (αvβ3), 
invasiveness (αvβ3, αvβ5) and senescence (α6β1 and HSPGs) (Leask & Abraham 2006, Lau 
2011). Interestingly, Cyr61 was also shown to induce MMP13 expression in 
chondrosarcoma cells, implying possible effects on extracellular matrix organization (Tan 
et al. 2009). 
Cyr61 is highly upregulated during mouse embryogenesis and is associated with 
neuronal, skeletal and cardiovascular development (O'Brien & Lau 1992). It is also 
essential for proper placental development as well as vascular integrity (Mo et al. 2002). 
Consequently, disruption of Cyr61 gene is embryonically lethal (Mo et al. 2002). Cyr61 
can exert strong angiogenic properties (Brigstock 2002, Harris et al. 2012) and elevated 
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Cyr61 levels are associated with retinal vascular alterations in diabetic retinopathy (You 
et al. 2009, You et al. 2010, You et al. 2012). On the other hand, in an animal model of 
retinopathy of prematurity, overexpression of Cyr61 improved retinal vascularization and 
was suggested as a potential therapeutic factor (Hasan et al. 2011). Moreover, Cyr61 
supported proper perfusion of the vasculature in peripheral ischemic disease, making it a 
possible option for ischemia therapy development (Fataccioli et al. 2002, Rayssac et al. 
2009).  
In the prosurvival context, Cyr61 strong antiapoptotic capacities were shown on a variety 
of tumour cells (Menendez et al. 2005, Yoshida et al. 2007, Sabile et al. 2012, Zhang et 
al. 2012c), but at this point Cyr61 had not been investigated as a potential neuroprotective 
factor. Sparse information in the neuronal context reveals that cyr61 is expressed in 
primary neurons and glial cells in response to estrogen treatment (Csoregh et al. 2009) as 
well as in a hippocampal cell line in response to FGF-2 (Chung & Ahn 1998). On the 
other hand, downregulation of Cyr61 was observed during infantile Batten disease, 
characterised by neuronal cell degeneration including retinal degeneration (Haltia 2006, 
Qiao et al. 2007). Cyr61 was also shown to have an influence on the development of the 
proper dendritic branching pattern of neuronal cells (Malik et al. 2013). 
Taken together, not much is known about Cyr61 a possible player in neuroprotection, 
which made it a fascinating factor to study in this context. 
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II. MATERIALS AND METHODS 
A. Materials 
A.1 Chemicals, reagents, commercial kits, factors and enzymes 
In this study dH2O is referred to deionized water, ddH2O is referred to ultra-pure water 
(Milli-Q Biocel, Millipore, Billerica, MA, USA). The chemicals were bought from 
Sigma, Steinheim, Germany, if not stated otherwise. 
Name Manufacturer 
2-Iodacetamid (IAA) Merc, Darmstad, Germany 
Acrilamide Serva, Heidelberg, Germany 
Agaroze Biozym, Olderdorf, Germany 
BCA protein Assay Thermo Scientific, Waltham, USA 
Blotting grade milk powder BioRad, Munich , Germany 
Bovine serum albumin (BSA, lyophilized) Sigma, Steinheim, Germany 
Bradford Reagent Bio-Rad, Munich , Germany 
Calcein Invitrogen, Carlsbad, USA 
Complete protease inhibitor cocktail Roche, Mannheim, Germany 
1,4-Dithiothreit (DTT) Merc, Darmstad, Germany 
4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) 
Life Technologies, Carlsbad, USA 
DNase Sigma, Steinheim, Germany 
Endoproteinase Lys-C Sigma, Steinheim, Germany 
Glycerol Merc, Darmstad, Germany 
Hoechst 33342 Life Technologies, Carlsbad, USA 
High-performance liquid chromatography 
(HPLC) water 
Merc, Darmstad, Germany 
Hydroxypropyl methylcellulose 
(Methocel™ 2%) 
OmniVision, Puchheim, Germany 
NaCl Merc, Darmnstad, Germany 
NE-PER Nuclear and Cytoplasmic 
Extraction Reagents Kit 
Thermo Scientific, Waltham, USA 
Nonidet-P40 (NP-40) Roche, Mannheim, Germany 
Normal goat serum (NGS) Invitrogen, Carlsbad, USA 
Orange G Sigma, Steinheim, Germany 
Papain Worthington, Lakewood, USA 
Paraformaldehyde (PFA) Sigma, Steinheim, Germany 
Peanut agglutinin Vector Laboratiories, Peterborough, UK 
Phosphatase inhibitor cocktail P2, P3 Sigma, Steinheim, Germany 
Propidium iodide Life Technologies, Carlsbad, USA 
Proteinase K MP Biomedicals, Santa Ana, California, 
USA 
Recombinant Human Cysteine-rich 
angiogenic inducer 61 (Cyr61/CCN1) 
R&D Systems, Minneapolis, MN USA 
Recombinant Human Glial-Derived Peprotech, Princeton, USA 
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Neurotrophic Factor, ATF-1 (GDNF) 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific, Waltham, USA 
RNaseZap® RNase decontamination 
solution 
Life Technologies, Carlsbad, USA 
Serva Clear Stain Serva, Heidelberg, Germany 
Sodium dodecyl sulfate (SDS) Serva, Heidelberg, Germany 
Sucrose Merc, Darmstad, Germany 
Trypsin Sigma, Steinheim, Germany 
Tris-(hydroxymethyl)-aminomethan (Tris) Serva, Heidelberg, Germany 
Triton X-100 Merck, Darmnstad, Germany 
tropicamide eye drops (Mydriaticum 
Stulln™) 
Pharma Stulln, Germany 
TRIzol® Life Technologies, Carlsbad, USA 
Urea Merc, Darmstad, Germany 
Purisept PuriCore Labcaire Systems, Clevedon, UK 
A.2 Consumables 
Name Manufacturer 
96 well plates BD Bioscience, San Jose, USA 
96 well plates 4titued®  4titued®, Berlin, Germany 
Cell culture plates 6cm Ø Thermo Scientific, Waltham, USA 
Cell culture plates 6-well, 12-well and 3cm 
Ø 
BD Bioscience, Heidelberg, Germany 
Cell scraper 25 cm Sarstedt, Nümbrecht, Germany 
Cover glass 24 x 50mm; No. 1.5 VWR Interrnational, Darmstadt, Germany 
Disposal bags (sterile) Carl Roth, Karlsruhe, Germany 
ECL+ enhanced chemiluminescence films GE Healthcare, Buckinghamshire, UK 
Falcon conical tubes BD Bioscience, Heidelberg, Germany 
Flasks T-25, T-75, T-175 Greiner, Frickenhausen, Germany 
Fluoro Save Reagent Calbiochem, Merc, Darmstad, Germany 
Microscope slides Super Frost Plus® Menzel, Braunschweig, Germany 
Nanosep® Centifugal Devices Pall Life Sciences, New York, USA 
Needels, sterile, Sterican®  Braun, Melsungen, Germany  
Neubauer Chamber Cell Counting Celeromics, Grenoble, France 
Nitril gloves, powder-free Exceed, The Hauge, The Netherlands 
PVDV membrane GE Healthcare, Buckinghamshire, UK 
Petri dishes Greiner, Frickenhausen, Germany 
Pipetboy Eppendorf, Hamburg, Germany 
Pipetman 2µl 10µl, 20µl, 100µl, 200µl, 
1000µl 
Eppendorf, Hamburg, Germany 
Pipette tipps 10µl, 20µl, 200µl, 1000µl StarLab, Hamburg, Germany 
Plastic pipettes, Cellstar® 2ml, 5ml, 10ml, 
25ml, 50ml 
Greiner bio-one, Kremsmünster, Austria 
Polycarbonate membranes Costar Corning Incorporated, Corning, NY, USA 
Polypropylene conical tube, Falcon 15ml, 
50ml 
BD Bioscience, Heidelberg, Germany 
Protein LoBind Tubes Eppendorf, Hamburg, Germany 
Proteome ProfilerTM Mouse Angiogenesis 
Array 
R&D Systems, Minneapolis, MN USA 
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Tissue-Tek Sakura, staufen, Germany 
A.3 Laboratory equipment 
Instrument Manufacturer 
78 diopter double aspheric lens (Volk 
Optical™) 
Mentor, Ohio, USA 
Agfa Curix 60 Developer Agfa, Mortsel, Belgium 
Autoclave Tuttnauer Systec 5075 ELV Systec, Wettenberg, Germany 
Camera Easy 400K  Herolab, Wiesloch, Germany 
Cell incubator Sanyo Scientific, San Diego, USA 
Centrifuge 3-18K Sigma Laborzentrifugen, Osterode, 
Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5430R Eppendorf, Hamburg, Germany 
Cryotome CM 180 Leica Microsystems, Wetzlar, Germany 
Dissection microscope Leica Microsystems, Wetzlar, Germany 
Fluorescent microscope DM IRE2 Leica Microsystems, Wetzlar, Germany 
Laminar flow hood BDK, Sonnenbühl-Genkingen, Germany 
LightCycler© 480 System Roche, Mannheim, Germany 
Liquid Nitrogen Tank Chronos Messer, Sulzbach, Germany 
Inlab micro pH Electrode  Mettler-Toledo, Greifensee, Switzerland 
Inverse fluorescence microscope DMIRE2 Leica Microsystems, Wetzlar, Germany 
Magnetic stirrer RH basic IKA Labortechnik, Staufen, Germany 
Mass spectrometer Orbitrap XL Thermo Fisher Scientific, Waltham, USA 
Milli-Q Biocell Millipore, Billerica, USA 
Mini Trans Blot Electrophoretic Transfer 
Cell 
BioRad, Munich , Germany 
Mr. Frosty Freezing Container, Nalgene™ Thermo Scientific, Waltham, USA 
NanoDropTM Thermo Fisher Scientific, Waltham, USA 
PCR machine Peqstar Peqlab, Erlangen, Germany 
Power supply PowerPac 300  Bio-Rad, Freiburg, Germany 
Power supply PowerPac HC  Bio-Rad, Freiburg, Germany 
Scanner Epson Perfection 1240V Epson, Suwa, Japan 
Shaker Duomax 1030 HeidolphInstruments, Schwabach, Germany 
Shaker KS260 basic IKA Labortechnik, Staufen, Germany 
Synergy HT microplate reader Biotek, Bad Friedrichshall, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Ultra-low temperature freezer (-80°C) Sanyo Scientific, San Diego, USA 
Ultrasonic bath Transsonic 310/H ElmaUltrasonic, Singen, Germany 
Ultraspec 3300 pro UV/Vis photometer GE Healthcare, Buckinghamshire, UK 
UV transilluminator UVT-40M Herolab, Wiesloch, Germany 
Vortex Genius 3 IKALabortechnik, Staufen, Germany 
Spectralis HRA+OCT™, scanning-laser 
ophthalmoscope 
Heidelberg Engineering, Heidelberg, 
Germany 
A.4 qPCR Primers 
Name Sequence (5’-3’) Tm* 
Collagen type III, alpha I 
(COL3A1)_Forward 
AATGATGGTGCCCGAGGAAG 60°C 
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Collagen type III, alpha I 
(COL3A1)_Reversed 
AGCAGGACCCATTTCACCTT 60°C 








vascular endothelial growth 
factor (VEGF)_Forward 
CCACCATGCCAAGTGGTCC 60°C 
vascular endothelial growth 
factor (VEGF)_Reversed 
CACTCCAGACCTTCGTCGTT 60°C 
* Tm – melting temperature 
A.5 Antibodies for immunofluorescence and for western blotting 
Antibody Species Dilution Number Supplier 
pStat3 rabbit 1:2000 9145 Cell Signaling, Massachusetts, 
USA 
pStat3 rabbit 1:1000 9131 Cell Signaling, Massachusetts, 
USA 
Stat3 rabbit 1:2000 4904 Cell Signaling, Massachusetts, 
USA 
pAkt rabbit 1:2000 4060 Cell Signaling, Massachusetts, 
USA 
Akt rabbit 1:2000 4691 Cell Signaling, Massachusetts, 
USA 
pErk1/2 rabbit 1:2000 4370 Cell Signaling, Massachusetts, 
USA 
Erk1/2 rabbit 1:1000 9102 Cell Signaling, Massachusetts, 
USA 
α-tubulin rat 1:10000 T6074 Abcam, Cambridge, England 
b-Actin mouse 1:10000 A-5441 Sigma, Steinheim, Germany 
PARP mouse 1:2500 NB100-
64828 









rabbit 1:10000 AB15282 Millipore, Billerica, USA 
Recoverin rabbit 1:3000 AB5585 Millipore, Billerica, USA 
Alexa fluor 
488 
rabbit 1:1000 A12379 Life Technologies, Carlsbad, USA 
Alexa fluor 
568 
mouse 1:1000 F24630 Life Technologies, Carlsbad, USA 
A.6 Animals, primary cell cultures and cell lines used in the study 
The day of birth was defined as postnatal day (PN) 0. Animals were maintained with free 
access to water and food in an air-conditioned room on a 12-h light–dark cycle.  
	  	   37 
All experiments were carried out in accordance with applicable German laws, with the 
European Council Directive 86/609/EEC, and with ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. 
Cell/tissue type Culture type Species Supplier 






MIO-M1 Cell line Human Retinal 
Müller glial cell line 
kindly provided by 
Astrid Limb  
(Moorfields Hospital, 
London) 
Mouse retinal Müller 




transgenic mice on 
C57BL6 
background 
kindly provided by 
Magdalena Götz 




Photoreceptors (PR) Primary cell 
culture 
Pig local slaughterhouse 
Retinal pigment 
epithelial cells (RPE) 
Primary cell 
culture 
Pig local slaughterhouse 




Pig local slaughterhouse 





Bar Harbor, USA 
Eyes  In vivo studies S334ter rats Xenogen Biosciences, 
San Francisco, USA 
A.7 Media, buffers and standard solutions 
A.7.1 Media and antibiotics for cell and tissue culture 
Medium Components 
Medium for cell lines: ARPE19 and MIO-
M1 
Medium for primary mRMG, porcine 
RMG and porcine RPE cells 
Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Paisley, UK) 
10 % Fetal bovine serum (FBS) (Gibco, 
Paisley, UK) 
1% penicillin/streptomycin (Pen Strep) 
(Gibco, Paisley, UK) 
Medium for porcine RMG for analysis on 
Orbitrap XL 
Dulbecco’s modified Eagle’s medium 
(DMEM) without phenol red (Gibco, 
Paisley, UK) 
Medium for primary PR Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) 
(Gibco, Paisley, UK) 
10% FBS 
1% penicillin/streptomycin 
Medium for retinal explant culture (R-16 
serum-free medium) 
R-16 medium (Gibco, Paisley, UK) 
0.1µg/ml Biotin 
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1µg/ml Ethanolamine 
40nM NaSeO3 x 5H20 
5nM MnCl2 x 4H20 
20nM CuSO4 x 5H20 
32.5mM NaHCO3 
List of supplements to R-16 serum-free 





0.002µg/ml thyroid hormone T3 
0.02µg/ml corticosterone 
2.77µg/ml thiaminHCl (vitamin B1) 
0.31µg/ml vitamin B12 
0.045µg/ml α-LipoicAcid =Thiotic Acid 
0.1µg/ml retinol 
0.1µg/ml retinyl acetate 
1µg/ml DL-tocopherol 
1µg/ml tocopherylacetat 
1µg/ml linoleic acid 





100µg/ml vitamin C 
Serum-free medium for RMG and RPE DMEM 
1% penicillin/streptomycin 
Serum-free medium for PR DMEM/F-12 
1% penicillin/streptomycin 
Trypsinization Tripsin (Gibco, Paisley, UK) 
Washing Dulbecco's Phosphate-Buffered Saline 
(DPBS) (Gibco, Paisley, UK) 
ddH20 autoclaved 
A.7.2 Buffers and reagents for primary cell isolation 
Name Components 
Dissociation buffer for porcine RPE 1mM Ethylenediaminetetraacetic acid 
(EDTA) in DPBS 
260 mM L-Cys 
100 µg/ml BSA 
2.86 units of activated papain 
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pH 7.4 




A.7.3 Solutions for histology and immunofluorescence methods 
Solution Components 
4% paraformaldehyde (PFA) 4g of PFA 
50ml ddH2O 
50ml 0.2 PB 




up to 2 litters (L) of dH2O 
10M HCl to acquire pH7.4 
Blocking solution for ICC 10% NGS 
0.5% Triton X 
DPBS 
Blocking solution for IHC 10% NGS 
1% BSA 
0.5% Triton X 
0.1M PB (pH7.4) 
ICC primary antibody buffer 10% NGS 
0.5% Triton X 
DPBS 
ICC secondary antibody buffer  3% NGS 
0.5% Triton X 
DPBS 
IHC antibody buffer  3% NGS 
1% BSA 
0.5% Triton X 
0.1M PB (pH7.4) 
Permeabilization solution for TUNEL 0.1% Trition X 
0.1% sodium citrate, 
DPBS-Triton X 0-5% Triton X 
DPBS 
A.7.4 Buffers and standard solutions for protein biochemistry 
Lysis buffers 
Name Components 
Lysis buffer I 1% DM in 1% TBST 





Radioimmunoprecipitation assay buffer 
(RIPA) buffer 
50mM Tris-Hcl pH 7.4 
150mM NaCl 
0.1% SDS 
	  	  40 
0.5% Sodium Deoxycholate 
1% NP-40 
Solutions for SDS gels 
Gel solution for SDS separating gel (10 
ml) 
10% 
ddH2O 4 ml 
Acrylamide:bisacrylamide (37.5%:1%) 3.3 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml 
10% SDS 100 µl 
10% APS 50 µl 
TEMED 20 µl 
Gel solution for SDS stacking gels (5 ml) 4% 
ddH2O 3.5 ml 
Acrylamide:bisacrylamide (37.5%:1%) 700 µl 
1.5 M Tris-HCl pH 6.8 700 µl 
10% SDS 50 µl 
10% APS 50 µl 
TEMED 20 µl 
Buffers for SDS-Page and Western Blotting 
5x SDS sample buffer 5 % SDS 
250 mM Tris-HCl pH 6.8 
500 mM β-Mercaptoethanol 
50 % Glycerol 
0.4 % Bromphenol blue 
Blocking soultuion for 
immunoblotting 
TBST 
5 % Milk powder 
Blotting buffer 12 mM Tris base 
96 mM Glycine 
20 % Methanol 
SDS Electrophoresis buffer 50 mM Tris base 
384 mM Glycine 
0.2 % SDS 
Stripping buffer 100mM 2-Mercaptoethanol 
2% SDS 
62.5mM Tris-HCl pH6.7 
Tris-buffered saline (TBS) 6.05g Tris 
8.76g NaCl 
fill up to 1L with dH2O  
Tris buffer saline Tween (TBST) 1% 50 mM Tris-HCl pH7.5 
150 mM NaCl 
5% of Tween-20  
Buffers for FASP digestion 
Urea (UA) buffer 8M urea in 0.1M Tris/HCl pH 8.5 
Ammoniumbicarbonat (ABC) buffer 50mM ABC in HPLC water 
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A.7.5 Buffers and solutions for molecular biology 
TBE 89mM Tris 
89mM boric acid 
2mM EDTA 
1% agarose gel 3g agarose 
300ml TBE buffer 
9µl Serva Clean Stain 
6x loading buffer 0 mM Tris-HCl 
0.15% Orange G 
60% Glycerol 
60mM EDTA 
A.8 Software and databases 
Software Supplier 
Adobe Illustrator CS Adobe Systems, San Jose, USA 
Adobe Photoshop CS5 Adobe Systems, San Jose, USA 
EndNote Thomson Reuters 
GraphPad Software Statcon 
ImageJ (Fiji) W. Rasband 
LightCycler© 480 software Roche 
Mascot 2.4 Matrix Science, Boston, USA 
MS Office 2003 (Word, Excel, Powerpoint) Microsoft 
Progenesis LC-MS Non-Linear Dynamics, Newcastle, UK 




NCBI Blast http://blast.ncbi.nlm.nih.gov/Blast.cgi 
NCBI Nucleotide http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=nucleotide 
NCBI Protein http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=protein 
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B. Methods 
B.1 Preparation and maintenance of primary retinal cell cultures 
B.1.1 Mouse retinal Müller glial cells 
Mouse RMG (mRMG) cells were isolated from GFAP-eGFP/C57BL6 eyes, as described 
before (Hauck et al. 2008) with modifications. The mice were sacrificed and their eyes 
were enucleated shortly after the animals’ death. Eyeballs were disinfected with 80% 
ethanol and replaced into DPBS for dissection. Next, retinas were placed in an eppendorf 
tube washed two times with Ringer’s solution and treated with 2.2 units of activated 
papain (30min at 37˚C in activation solution) for 45min at 37˚C. Thereafter, the papain 
was stopped with DMEM medium containing 10% FBS and 150 units of DNAse and the 
tissue was carefully triturated into single cells. Then, cells were centrifuged (150 x g for 
5min), resuspended in fresh medium DMEM containing 10% FBS and 1% 
penicillin/streptomycin, plated on 12 well plates and cultured for 7 days (d7) in 5% CO2 
at 37°C. 
Before stimulation, cells were washed and starved in the serum-free medium for 24h. 
Next, new medium containing 0,1µg/ml GDNF, or medium without supplementation (for 
control cells) was applied for an additional 24h. Following stimulation, supernatants were 
collected and filtered (cut-off 0.2µm) to remove large cellular debris and residual cells 
(supernatant samples). Cells were lysed in 100µl of lysis buffer, including complete 
protease inhibitor cocktail and phosphatase inhibitor cocktails 2 and 3 (cell lysates 
samples). Supernatants and cell lysates were stored at -80°C until further analyses. 
B.1.2 Porcine retinal cells 
The porcine eyes were enucleated within 5min after death of the animals and kept on ice 
in CO2-independent medium until further use. The eyeballs were disinfected in 80% 
ethanol followed by Purisept, by immersion in each of them for 5min, than the eyeballs 
were placed in a fresh, sterile CO2-independent medium. Subsequently, the eyeballs were 
cut around the iris and the vitreous body was discarded. The retina was dissected for 
further isolation of photoreceptors (PR) and retinal Müller glial cells (RMG) while 
obtained eyecup served to isolate retinal pigment epithelium (RPE) cells. 
To control purity of each type of cell culture, representative samples from PR, RMG and 
RPE isolation were analysed by western blot. Marker proteins for each cell type were 
assessed by immuodetection: recoverin for PR, vimentin for RMG and RPE65 for RPE 
(Fig. 11). Given that different cultivation periods were used for each cell type (PR – 2 
days in culture, RMG – 8-11 days in culture, RPE – up to 5 days in culture) vimentin was 
chosen over glutamine synthetase (GS) for RMG identification. This stems from the fact 
that RMG in culture drastically decrease GS expression, while vimentin stays at around 
the same level (Hauck et al. 2003). On the presented picture (Fig. 11), RPE fraction 1 did 
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not achieve purity demands (too high RMG input in relation to RPE cells) and was 
excluded from further analysis. 
	  
Figure 11. Three retinal primary cell types: RMG, PR and RPE, could be prepared in high 
purity. 
Representative aliquots (10µg) from each primary cells isolation were blotted using wet transfer onto one 
membrane and protein markers for retinal Müller glial cells (RMG; vimentin), photoreceptors (PR; 
recoverin) and retinal pigment epithelium (RPE; RPE65) were visualized by immunodetection. α-tubulin 
serves as a loading control.  
B.1.2.1 Photoreceptors 
Primary porcine photoreceptor cultures were prepared according to two protocols. The 
first protocol (protocol I) was following protocol published before (Hauck et al. 2008). 
The second protocol (protocol II) was a modification of protocol I with the objective of 
increasing purity of PR preparations, as published recently (Kucharska et al. 2014). 
The major blood vessels were dissected from obtained retinal tissue, and the remaining 
tissue was cut into small pieces and distributed into 15ml falcon tubes (1,5 eyeball per 
falcon tube). Than retina was washed two times with 1ml of Ringer’s solution. For retinal 
dissociation, the tissue was incubated with 250µl Ringer’s solution containing 2.86 units 
of activated papain for 12min at 37˚C. Next, the digestion was stopped with 1ml of 
DMEM Nut MixF12 containing 10% FCS. Subsequently, 150 units of DNAse in 
activation solution were applied to the tissue and the whole falcon tube was shaken 20 
times to release PR. Then, the falcon tubes were left for 5min to sediment only partly 
dissociated tissue and eventually the supernatant containing the floating PR was collected 
into a new 50ml falcon tube. Only this first fraction was used for protocol II. In contrast, 
protocol I included a second isolation step to increase the yield of PR isolation at the cost 
of purity. Specifically, 1ml of medium enriched in serum was added to the partly 
dissociated tissue in falcon tubes and the tissue was mechanically dispersed, by aspirating 
it once through a fire-polished glass Pasteur pipette. The resulting second supernatant 
with floating PR was collected as a second fraction and added to the first PR fraction.  
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The PR cells collected into 50ml falcon tube (following protocol I or II), were pelleted by 
centrifugation (150 x g for 5min), resuspended in fresh DMEM/F-12 medium containing 
1% penicillin/streptomycin and 2% FCS (according to the protocol I) or 10% FCS 
(according to the protocol II), counted and between 16*105 and 22.4*105 cells were 
plated onto coated 6cm dishes (see B.1.2.1.1). Additionally, 6cm dishes were prepared, to 
control viability as well as purity of PR fractions. The remaining tissue in 15ml falcons 
was used to obtain RMG (see B.1.2.2). 
	  
Figure 12. Specificity of recoverin to stain photoreceptors in porcine retinal tissue. 
Porcine cryosections were stained with recoverin to visualize PR (green, panel A). Panel B shows overlay 
of panel A and nuclei visualized with Hoechst 33342 (red). Scale bars 100µm 
Isolated PRs were serum starved for 2h or 24h, for protocols II and I, respectively. 
Afterwards, cells were stimulated with 1µg/ml Cyr61 for the indicated time points. 
Subsequently, the medium was discarded and cells were lysed with RIPA buffer 
supplemented with complete protease inhibitor cocktail and phosphatase inhibitor 
cocktails 2 and 3. The samples were kept on ice with occasional vortexing. Lysates were 
centrifuged at 16000 x g for 30min and supernatants transferred to fresh eppendorf tubes. 
Total protein content was determined using the BCA protein assay before samples were 
stored at -80˚C until further use. 
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The viability of PR, obtained with protocol II, was controlled two times: the first time 
right after the isolation (using a cell counting chamber) and the second time at the day of 
the experiment (staining of the cells on 6cm dishes). To observe the amount of living and 
dead cells, PR were incubated with calcein, which stains living cells, or propidium iodide 
(PI), which stains dead cells. These two probes can be distinguished based on their 
different excitation/emission characteristics. In this way, high viability of PR preparation 
could be shown (Fig. 19). 
In addition, the purity of PR fraction obtained with protocol II was controlled in two 
ways: by western blotting (see Fig. 11) and by immunocytochemistry (ICC) using the 
marker proteins recoverin (for PR) and GS or vimentin (for RMG). Recoverin was used 
as a PR maker, as in porcine retina it is only present in PR (Fig. 12) (Guduric-Fuchs et al. 
2009, Ghosh & Arner 2010, Johansson et al. 2010). For ICC, at the day of the 
experiment, the cells were fixed with 4% PFA for 15min in RT, washed 3 times with 
DPBS and blocked for 1h at room temperature (RT) with blocking solution for ICC. 
Primary and secondary antibodies were diluted in ICC primary antibody buffer and ICC 
secondary antibody buffer, respectively, to visualize RMG cells and with Hoechst 33342 
(to stain nuclei). Images were required at 100 or 200-fold magnification with a Leica DM 
IRE2 fluorescent microscope (Fig. 22). 
Coating of 6 cm dishes for PR culture 
For culturing PR it is crucial to prepare an appropriate coating of the culture dishes, 
otherwise the cells will not attach properly and will be washed with first changing of the 
medium. For effective coating, firstly, dishes were incubated with 2µg/cm2 of p-Lysin for 
3h at 37°C. Next, dishes were washed with 2ml of autoclaved ddH2O and coated with 
1µg/cm p-Laminin at 37°C overnight. Finally, the dishes were washed 3 times with 3ml 
of ddH2O and left under UV light to dry out. Ready dishes were closed in sterile disposal 
bags and stored at 4°C for up to 2 weeks.  
B.1.2.2 Retinal Müller glial cells 
The remaining retina in 15ml falcon tubes after PR isolation (see B.1.2.1) was 
resuspended with DMEM containing 10% FCS and 1% penicillin/streptomycin and 
plated onto 10cm petri dishes. The next four days, non-attached cells were removed by 
agitation and changing the medium. Cells were cultured for up to 11 days to achieve 
confluence higher than 75%. 
At the day of the experiment, cells were washed and starved for 2h in the serum-free 
medium. Next, cells were stimulated with medium supplemented with 1µg/ml Cyr61 for 
indicated periods of time. Afterwards, supernatant was discarded and cells were lysed 
with RIPA buffer supplemented with complete protease inhibitor cocktail and 
phosphatase inhibitor cocktails 2 and 3. Next, lysates were kept on ice for 30min with 
occasional vortexing. Eventually, lysates were cleared by centrifugation (16000 x g for 
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30min) and the protein content was measured using bicinchoninic acid (BCA) protein 
assay. The samples were stored at -80˚C for further analysis. 
B.1.2.3 Retinal pigment epithelium cells 
The obtained eyecups (see B.1.2), with RPE still attached to the inner surface, were 
incubated with 1mM EDTA in DPBS for 15min at RT to discard residues of RMG and 
PR outer segments. Then, the eyecups were incubated with dissociation buffer for 25min 
in 37˚C. RPE cells were dissociated by gentle buffer agitation, collected, centrifuged (150 
x g for 5min), resuspended and plated on 6-well dishes. Every day the non-attached cells 
were removed by mild agitation and medium changes. Cells were incubated up to 5 days 
to achieve >75% confluence. 
Prior to experiments, cells were washed and starved in the serum-free medium for 2h 
followed by 1µg/ml Cyr61 medium supplementation for the indicated time periods. Next, 
the medium was discarded and cells were lysed with RIPA buffer supplemented with 
complete protease inhibitor cocktail and phosphatase inhibitor cocktails 2 and 3. 
Following, cells were incubated on ice for 30min with occasional vortexing. Finally 
lysates were cleared by centrifugation (16000 x g for 30 min) and stored at -80˚C for 
future analysis. The protein content was evaluated using BCA protein assay. 
B.2 Maintenance and growth of retinal cell line cultures 
The human RPE cell line - ARPE19 (Dunn et al. 1996) and the human RMG cell line -
 MIO-M1 (Limb et al. 2002) were grown in DMEM containing 10% FCS and 1% 
penicillin/streptomycin in 37˚C and 5% CO2. Cells were split 1:5 upon reaching 80% or 
100% confluence, for MIO-M1 or ARPE19, respectively First the old medium was 
removed and cells were washed with pre-warmed DPBS (at 37˚C). Then, 2ml of 
trypsin/EDTA (for a 10cm dish) were applied and cells were incubated at 37˚C for 5min. 
Finally, the trypsin activity was stopped by addition of 10ml DMEM containing 10% 
FCS and cells were collected by centrifugation at 150 x g for 3min at RT. The pellet 
containing cells was resuspended in 5ml of fresh medium and transferred into new culture 
dishes with fresh medium. 
For the generation of cryo-stocks cells were harvested using trypsin/EDTA and 
centrifuged as described above. The pelleted cells were resuspended in FCS 
supplemented with 10% DMSO and 1ml of the suspension was distributed into cryo-
tubes. Cryo-tubes were placed in Nalgene™ frosty freezing holder filled with isopropanol 
and left at -80˚C overnight. For long-term storage, cryo stocks were placed in a cryo tank 
filled with liquid nitrogen. To thaw the cells, cryo stocks were kept in a water bath (37˚C) 
with mild agitation. Shortly after thawing, a fresh medium containing serum and 
antibiotic was added and cells were plated onto a new culture dish. 
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B.2.1 Cell line stimulations 
ARPE19 and MIO-M1 cells were seeded in 6 well plates (for experiments in which the 
whole cell lysate was analysed) or in 6cm dishes (for experiments in which nuclear and 
cytosolic fractions were analysed separately) und cultivated until confluence >75% was 
reached. Before each experiment, cells were washed and starved for 3h in the serum-free 
medium. Thereafter, cells were stimulated with 1µg/ml of Cyr61 for indicated periods of 
time. For preparation of whole cell lysates, supernatants were discarded and cells were 
lysed by adding 60-100µl of lysis buffer (1% DM in 1% TBS-T,) including complete 
protease inhibitor cocktail and phosphatase inhibitor cocktails 2 and 3. For separation into 
nuclear and cytosolic fractions, supernatant was discarded and cellular fractions were 
prepared with NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit as described in 
the manufacturer’s protocol. First, cells were trypsinized, resuspended in ice cold DPBS, 
transferred to 1.5ml eppendorf tubes and pelleted via centrifugation at 800 x g for 3min. 
Next, supernatant was discarded and 200µl cytoplasmic extraction reagent I 
supplemented with complete protease inhibitor cocktail and phosphatase inhibitor 
cocktails 2 and 3 was added to the pelleted cells. After vigorous vortexing, samples were 
incubated on ice for 10min. Subsequently, 11µl of cytoplasmic extraction reagent II was 
added to the samples and after 1min incubation on ice samples were centrifuged for 5min 
at 16000 x g. Cytoplasmic fractions (supernatant) were transferred to fresh eppendorf 
tubes and stored in -80°C until further analysis. The insoluble fraction was resuspended in 
100µl ice-cold nuclear extraction reagent supplemented with complete protease inhibitor 
cocktail and phosphatase inhibitor cocktails 2 and 3 and kept on ice for 40min with very 
intense vortexing every 10min. Finally, samples were centrifuged (16000 x g for 10min) 
and the nuclear fraction (supernatant) was collected in fresh eppendorf tubes. Protein 
content of the lysates was determined using the Bradford assay. Samples were stored in -
80°C until further analysis. 
B.3 Organotypic retinal explant cultures 
B.3.1 Organotypic retinal explant cultures preparation 
Organotypic retinal explant cultures were performed as described before (Caffe et al. 
2001, Del Rio et al. 2011) with slight modifications. Pde6brd1 (rd1) mice at postnatal day 
5 (PN5, assuming the day of birth as PN0) were sacrificed and eyes enucleated. After 
disinfection in 80% ethanol, eyes were washed and incubated in R16 serum-free medium 
containing 36 units of proteinase K for 15min at 37°C. Afterwards, to stop proteinase K 
activity, the eyes were transferred to R16 medium containing 20% of FBS for 5min. Next, 
the anterior segment, sclera, choroids, lens and vitreous body were removed under a 
magnifying glass. The dissected retina, with attached RPE layer was cut at four edges and 
explanted on a polycarbonate membrane. Explants were incubated on polycarbonate 
membranes placed in R16 supplemented medium in the way, that the tissue was in a 
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separate compartment, over the medium in the culture well, in 5% CO2 at 37°C (see 
Materials: A.7.1). The medium was exchanged every second day. 
B.3.1.1 Short term and long term retinal explants  
Short-term retinal explants were prepared by Patricia del Rio from Research Unit Protein 
Science, in Helmholtz Zentrum München, Germany. Prepared explants from five days old 
rd1 mice (PN5) were cultured for 6 days (DIV6). At the second day of culture (PN5 
DIV2) medium was changed for R16 supplemented medium with addition of 0.5µg/ml 
Cyr61 (treated explants) or for only R16 supplemented medium (control explants). After 
6 days in culture explants were fixed in 4% paraformaldehyde for 15 minutes and washed 
in 0.1 PB (Fig. 13). The tissue was cryoprotected with an increasing gradient of sucrose 
diluted in 0.1M PB with pH 7.4. Explants were incubated for one hour in 10% sucrose 
and for one hour in 20% sucrose at RT and in 30% sucrose overnight at 4°C. At the end, 
samples were embedded in Tissue Tek and cryosectioned using a Leica cryotome and 
collected on Super Frost Plus® slides. Sections were stored in -20°C for TUNEL analysis. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 13. Mouse retinal explants PN5 DIV6 in 4% PFA on polycarbonate culture 
membranes. 
Retinal explants were fixed in 4% PFA after 6 days in culture, followed by washing and cryopreservation. 
Sliced retina was stained according to the TUNEL assay protocol (see B.5). 
Long-term retinal explants were prepared by Blanca Arango-Gonzalez from Institute of 
Ophthalmic Research, at University of Tübingen, Germany. Explants from PN5 rd1 mice 
were cultured in vitro for 12 days (DIV12). The R16 supplemented medium was 
exchanged for R16 supplemented medium with 1µg/ml Cyr61 (treated samples) at the 
second day of culture (PN7 DIV2). Explants serving as a control were supplied only with 
R16 supplemented medium. After 12 days in culture explants were fixed in 4% PFA, 
washed with 0.1M PB. For cryoprotection of the tissue, explants were incubated for one 
hour in 10% followed by one hour in 20% sucrose. Finally, explants were left in 30% 
sucrose at 4°C overnight. Thereafter, explants were embedded in Tissue Tek, sectioned 
on Super Frost Plus® slides using a cryotome and stored at -20°C for TUNEL analysis. 
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B.3.1.2 Stimulation of retinal explant cultures for Western blot analysis 
The eyes of PN6 mice were enucleated and retinal explant culture was prepared as 
described above (see B.3.1). After placing dissected retinal explants on a polycarbonate 
membrane in R16 serum-free medium, tissue was left for 6h in 5% CO2 at 37°C to 
recover. Afterwards, the membranes with retinas were transferred to R16 serum-free 
medium containing 1µg/ml Cyr61 for indicated periods of time. The tissue left in pure 
R16 serum-free medium served as a control. Next, explants were collected, put on ice, 
lysed in lysis buffer II, homogenized with sonification and centrifuged (16000 x g for 
30min). Cleared lysates were stored in -80°C for further analysis. 
B.4 Intraocular injection of Cyr61 into rat eyes 
The in vivo validation of Cyr61 was conducted in cooperation with Blanca Arango-
Gonzalez from Institute of Ophthalmic Research, at University of Tübingen, Germany. 
All experiments were carried out in accordance with applicable German laws, with the 
European Council Directive 86/609/EEC, with ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research and conformed to German law. 
Intravitreal injections were performed as described elsewhere (Arango-Gonzalez et al. 
2009). S334ter line 3 (S334ter-3) transgenic rats were anesthetized with ether and 
received a total of two intraocular injections at PN7 and PN10. Recombinant human 
Cyr61 (0.25 µg), dissolved in 1µl sterile phosphate-buffered saline (PBS; 0.05M, pH7.4), 
was injected with a fine glass microelectrode through the sclera into the vitreous body of 
the right eye at the level of the temporal peripheral retina. The contralateral eye received 
1µl of vehicle solution and served as a control.  
At PN12, after decapitation of the rats, the eyes were enucleated and the cornea and lens 
were removed. For radial sections, the remaining eye cup was immersed in 4% PFA in 
0.1 M PB (pH 7.4) for 1h at 4°C. After fixation, the eye cups were washed several times 
in 0.1 M PB, cryoprotected for one hour in 10% as well as in 20% sucrose in 0.1M PB 
and in 30% sucrose eyes were incubated at 4°C overnight. Next, the tissue was embedded 
in Tissuetek and frozen in liquid nitrogen. 
B.4.1 Visualization of rat retina vasculature 
Retinal vasculature analyses were done in collaboration with Vinícius Monteiro de Castro 
from University of São Paulo, São Paulo, Brazil and Blanca Arango-Gonzalez from 
Institute of Ophthalmic Research, at University of Tübingen, Germany. Blood vessels in 
the eyes of Cyr61 or DPBS injected S334ter-3 rats were evaluated by in vivo angiography 
using confocal scanning laser ophthalmoscopy (cSLO) combined with detection 
algorithms. This method allows for observation of vasculature originating from inner 
limiting membrane and deeper layers within the retina as well as visualization of 
pathological intraretinal structures like macular cysts (Bartsch & Freeman 1994, Elsner et 
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al. 1996). All experiments were performed in accordance with the Association for 
Research in Vision and Ophthalmology statements on the care and use of animals in 
ophthalmic research. Throughout the examination process, a calm, quiet ambiance with 
dim illumination was maintained. Immediately after sacrifice, pupils were dilated with 
tropicamide eye drops before image acquisition. Hydroxypropyl methylcellulose and a 
custom-made contact lens were applied on the eye. The animals and device were 
manually held and aligned closely together. 
The Spectralis HRA+OCT™ device is a digital cSLO equipped with three laser 
wavelengths (488, 785 and 815nm) with barriers filters for fluorescein (500nm) and 
indocyanine green (830nm) angiography. Appropriate barrier filters at 500nm and 830nm 
remove the reflected light with unchanged wavelength while allowing only the light 
emitted by the dye upon stimulation to pass through. To adapt the commercial system to 
the optics of the rat eye, a 78-dioptre double aspheric lens was added at the 40mm focal 
lens of the front objective and fixed directly to the outlet of the device. A custom-made 
contact lens with a focal length of 7mm was applied to the eye of the mouse with a drop 
of methylcellulose.  
For the images, optic disc was placed in a centre of each picture. For each animal infrared 
reflectance (IR) imaging (excitation laser of 815nm) and red-free reflectance imaging 
(RF) (excitation laser of 488nm) was obtained with two angles of view, 30º and for a 
detailed view 20º. The focus was adjustable over a +40/-10 diopters range. The built in 
software was used for post-processing the images, including alignment, adjustment of 
contrast, construction of a mean image and/or of a composite image. 
B.5 TUNEL staining 
Sections from mouse retinal explant cultures (see B.3) and from rat eyes (see B.4) were 
evaluated for detection of cell death with the terminal deoxynucleotidyl transferase dUTP 
nick end-labeling (TUNEL) assay according to the manufacturer’s instructions. First, 
slides were washed for 30min with DPBS followed by incubation with permeabilization 
solution for 2min on ice. Next, slides were washed with DPBS and TUNEL mixture 
reaction was applied on each slide (50µl enzyme solution mixed with 450µl of label 
solution). The slides were incubated in a humidified chamber for 60min in 37°C, in the 
dark. To ensure that the TUNEL mixture reaction spread homogeneously across the tissue 
and to avoid evaporation, the sections were covered with parafilm. Next, the slides were 
washed once with DPBS and incubated with Hoechst 33342 or DAPI diluted in DPBS 
(1:5000) for 8min. Finally, slides were washed 3 times with DPBS, dried out, embedded 
with antifade reagent and closed with cover glasses. For negative control, slides were 
incubated only with labeling solution, without terminal transferase. For positive control, 
prior to labeling procedures, sections were incubated for 30min with 100 units DNase I in 
50mM Tris-HCl, pH 7.5, 1mg/ml BSA, to induce DNA double strand breaks. No labeling 
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was observed in the negative control sections while for the positive control sections, all 
retinal layers were stained (data not shown). To visualize TUNEL positive cells beam 
pass (BP) filter with excitation BP450/490 wavelengths and emission BP515/565 
wavelengths was applied. The pictures of the retina were acquired at 200-fold 
magnification using fluorescent Axio Imager Z1 Zeiss microscope. 
B.5.1 Image analysis and statistics for TUNEL staining 
Subsets from each retinal section were defined and analysed with the Definiens 2 
software (Definiens Enterprise Image Intelligence™ Suite, Definiens AG, Munich). To 
determine the total cell number in outer nuclear layer (ONL), the area of ONL was 
measured and then divided through the average cell size. To calculate the percentage of 
TUNEL positive cells the number of TUNEL positive cells was divided by the total cell 
number in ONL. Statistical comparisons among different groups were made with 
GraphPad Prism, using the one-tailed Mann Witney U test. 
B.6 Immunofluorescence methods 
B.6.1 Preparation of porcine tissue for immunohistochemistry 
Porcine retina, dissected from an eyeball, or the mouse eyecup was fixed in 4% PFA for 
30min. Next the tissue was washed three times with DPBS and cryoprotected by 
incubation for one hour in 10% and 20% sucrose in 0.1M PB – one hour in each of the 
solution at RT followed by overnight incubation in 30% sucrose in 0.1M PB at 4°C. 
Finally, the tissue was embedded in Tissue Teck and stored in -80°C. Ready cryoblocks 
of the tissue were cut on microscope slides using a Leica cryotome. 
B.6.2 Immunohistochemistry 
Slides with fixed sections of retinal tissue were 3 times washed with DPBS followed by 
incubation with blocking buffer for one hour at RT. Next, samples were incubated with 
primary antibody diluted in IHC antibody buffer (for dilutions see A.5) for overnight at 
4°C. To avoid evaporation of the antibody solution, the slides were covered with 
parafilm. The next day the slides were washed three times for 5min with DPBS and 
incubated with secondary antibody diluted in IHC antibody buffer (for dilutions see A.5) 
for one hour at RT. Further, slides were incubated in Hoechst 33342 or DAPI diluted in 
DPBS (1:5000) for 8min. Finally, samples were washed three times for 5min with DPBS, 
dried out, embedded with antifade reagent and closed with cover glasses. 
B.6.3 Immunocytochemistry 
Dishes with fixed cells (see PR preparation B.1.2.1) were washed three times in DPBS 
and incubated with blocking solution for one hour at RT. Next, primary antibody diluted 
in ICC primary antibody buffer  (for dilutions see A.5) was applied and kept for overnight 
at 4°C. Then, dishes were washed 3 times for 5min with DPBS and the cells were 
incubated with secondary antibody diluted in ICC secondary antibody buffer (for 
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dilutions see A.5) for one hour at RT. Next, the cells were washed once with DPBS and 
Hoechst 33342 diluted in DPBS (1:5000) was applied for additional 8min. At the end, the 
cells were washed three times for 5min and were stored in DPBS at 4°C. 
B.7 Protein biochemistry 
B.7.1 Protein concentration measurements 
B.7.1.1 Bradford assay 
For evaluations of the protein concentration in cell lysates based on the Bradford assay, 
Bio-Rad Protein Assay Kit was used, following the manufacturer’s instructions. Dye 
reagent concentrate was diluted 1:5 in ddH2O. Cell samples (1-2µl) were pipetted to 
separate cuvettes followed by 1ml of diluted reagent. For standard curve, five cuvettes 
with BSA concentration raging from 0.5-6µg/µl were prepared. Absorption was measured 
at 595nm with an Ultraspec 3300 photometer and protein content was calculated based on 
the linear regression of the standard curve. 
B.7.1.2 BCA assay 
The bicinchoninic acid (BCA) assay was applied for samples containing high amounts of 
detergent (RIPA buffer), which interfere with the Bradford assay. Measurements were 
conducted using 96-well microtiter plates filled with 200µl final volume in each well. 
Eight points were measured in duplicates, to established standard curves – with final BSA 
concentrations rom 0.001 to 0.05µg/µl. Samples were measured in duplicates, applying 1-
2µl per well. Absorption was measured at 562nm was determined with a Synergy HT 
plate reader. The initial protein concentration in samples was calculated using Excel 
2010. 
B.7.2 SDS-PAGE  
One-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted 
to separate mixtures of proteins in cell lysates. Gels were prepared using casting 
chambers for mini gels with 1 or 1.5 mm spacers (for gels see A.7.4). First, separating gel 
solutions (10% acrylamide) was poured into the casting chambers, followed by covering 
with isopropanol, to prevent drying of the gel while polymerization. Following 
polymerization of the resolving gel, the isopropanol was removed and the stacking gel 
was overlaid. Finally, 10-well combs were placed on the upper rim of the glass plates. 
After polymerization, gels were placed in a Mini Protean Tetra Cell electrophoresis 
chamber, filled with SDS electrophoresis buffer (for buffers see Materials A.7.4). In order 
to prepare protein samples for loading, they were denatured by incubation with 5x SDS 
sample buffer at 94°C for 4min. Afterwards samples (10-20µg of protein) or a pre-stained 
protein marker were loaded onto the gel and electrophoresis was started at 70V until the 
bromophenol blue reached the end of stacking gel. Then, the voltage was changed to 
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110V till the end of the electrophoresis. Electrophoresis was stopped when bromophenol 
blue reached the end of the separating gel.  
B.7.3 Western blotting and immunodetection  
Western blotting was performed using the wet blotting technique. Proteins from the 
samples separated with SDS-PAGE were blotted onto polyvinylidene fluorie (PVDF) 
membranes according to manufacturer’s instructions. SDS gels with separated proteins 
were incubated in blotting buffer for 5min. Next PVDF membranes were activated in 
methanol for 15 seconds followed by hydration in blotting buffer. Subsequently, the 
proteins from the gel were transferred with electrotransfer, in a cold cabinet (4°C) with a 
constant voltage of 100V for 90 minutes. After the wet transfer, membranes were blocked 
with 5% milk in TBS-T for one hour on a roller at RT to prevent unspecific binding. 
Blocked membranes were incubated overnight at 4°C with primary antibodies (for 
dilutions see A.5) diluted in 5% milk in TBS-T. The next day, the membranes were 
washed three times with TBS-T, and incubated with horseradish peroxidase-coupled 
secondary antibodies diluted 1:11000 in 5% milk in TBS-T for one hour at RT. After 
washing the membranes three times in TBS-T, they were incubated with signal ECL+ 
enhanced chemiluminescence kit for 4min and transferred to a hypercassette. 
Chemiluminescence signal was detected using Hyperfilm ECL and an Agfa Curix 60 
developer. The films were digitalized using an Epson perfection scanner. To verify equal 
protein loading, membranes were stripped in a buffer for 30min at 50°C and reprobed, as 
described before, with appropriate primary and secondary antibodies. Quantifications of 
the blots were done using the ImageJ freeware.  
B.7.4 Mouse cytokine membrane array 
Nitrocellulose Proteome ProfilerTM Mouse Angiogenesis Arrays were blocked for one 
hour on a rocking platform shaker with blocking buffer supplied by manufacturer. Next, 
supernatants and lysates from control and experimental mRMG were combined with a 
cocktail of biotinylated detection antibodies and incubated for an hour at RT. Following, 
prepared sample and antibody mixtures were put on the membranes and incubated 
overnight at 4°C on a rocking platform shaker. Next, the membranes were washed with 
the washing buffer supplied by the manufacturer and incubated for 30min with 
horseradish peroxidase labelled streptavidin (streptavidin-HRP) on a rocking platform 
shaker at RT. Afterwards the membranes were washed with washing buffer and incubated 
with chemiluminescent detection reagents (Chemi Reagent Mix, supplied by the 
manufacturer) for one minute. Next, the membranes were placed in an autoradiography 
film cassette, exposed to X-ray film and developed with the Agfa Curix 60 developer. 
The Proteome arrays contain antibodies that are spotted in duplicates for each protein. 
Intensity of the signal at each antibody spot relates to the amount of captured protein. 
Array image scans were analysed using Image J (NIH Image) as indicated by 
manufacturer.  
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B.7.5 Mass spectrometry based proteomics 
B.7.5.1 Preparation of RMG cells secretome 
Porcine RMG cells were plated onto 10cm dishes and cultured until their confluence 
exceeded 75%. Then, the cells were washed and starved in DMEM without phenol red 
serum-free for 2h. Next the medium was exchanged for DMEM without phenol red 
serum-free medium supplemented with 0.5µg/ml Cyr61 (for treatment samples) or 
medium without supplementation (serving as controls). Cells were stimulated for 24h 
after which supernatants, containing RMG secretome proteins, were collected and 
centrifuged at 150 x g for 3min, to remove detached cells from the suspension.  
B.7.5.2 Filter aided sample preparation (FASP) digestion of secretome proteins 
Next, the secretome proteins from the medium were digested according to the filter aided 
sample preparation (FASP) protocol. 5µg of protein from supernatant was mixed with 
100mM DTT in HPLC water and incubated with shaking for 30min at 60°C. After 
cooling down to RT, 100µl of UA buffer followed by 10µl of 300mM IAA in HPLC 
water were added and the samples were incubated in the dark for 30min at RT. Next, 
samples were transferred to a 30kDa cut-off ultrafiltration filter (pre-washed with 50mM 
ABC) and centrifuged at 14000 x g for 15min at RT. Afterwards, the flow-through was 
discarded and the column was washed three times with 200µl of UA buffer (each time the 
flow through was discarded) followed by two times washing with 100µl of 50mM ABC 
(the flow through was discarded after each centrifugation). Next, the columns were 
transferred to fresh Protein LoBind tubes. and 40µl of 50mM ABC supplemented with 
1µg of endoproteinase Lys-C was applied on the filters and incubated for 2h in RT. Then, 
2µg of trypsin in 10µl of 50mM ABC was added onto each filter and tubes were closed 
with parafilm. Samples were digested overnight at 37°C. The next day, to elute the 
peptides from the filter, tubes were centrifuged at 16000 x g for 5min. In a second elution 
step, 20µl of 50mM ABC containing 2% acetonitrile (ACN) were added to the filters and 
the tubes were additionally centrifuged at 16000 x g for 15min at RT. Before loading onto 
the liquid chromatography – tandem mass spectrometry (LC-MS/MS) system, samples 
were acidified with trifluoroacetic acid (TFA) to yield pH 2. 
B.7.5.3 LC-MS/MS analysis of FASP digests and label-free quantification 
For each experiment four control and four treatment replicates (stimulated with 0.5µg/ml 
Cyr61 for 24h) were prepared. The samples were analysed in cooperation with the 
Helmholtz Core Facility Proteomics and Alexander Schäfer. Proteins were identified and 
quantified by LC-MS/MS. Peptides from FASP tryptic digests were loaded onto an LC-
MS/MS system composed of a nano-HPLC coupled online to an Orbitrap XL mass 
spectrometer. Peptides were separated by reverse-phase chromatogry on C18 analytical 
columns using a water/acetonitrile gradient of 170min length. Simultaneously, peptides 
were detected by the OrbitrapXL mass spectrometer. Full scan MS1 data for intact 
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peptides was acquired to determine mass and charge of peptides for identification and to 
enable label-free quantification later. During each cycle the ten most intense multiply 
charged ions were selected for collision induced dissociation (CID) based fragment 
spectrum (MS/MS) generation.  
Resulting raw files were imported into Progenesis LC-MS Version 3.1 for label free 
quantification. MS/MS spectra were exported and used for identification of proteins using 
Mascot Version 2.3.0.2. Mascot results were processed with Percolator to yield peptide 
false discovery rates of 1%, before they were reimported into Progenesis LC-MS. 
Proteins were quantified by the sum of their peptide MS1 intensities. Statistical 
evaluation was performed using a two-tailed Student’s t-test.  
B.8 Quantitative real-time PCR 
B.8.1 Isolation of mRNA 
Primary porcine RMG cells were prepared as described in the section B.1.2.2. Isolated 
cells were cultured on 6cm dishes till confluence exceeded 75%. Before the stimulation, 
cells were washed and starved in serum-free medium for 2h followed by medium 
exchange onto new serum-free medium supplemented with 0.5µg Cyr61 (for treatment 
samples) or without supplementation (for control samples). Cells were stimulated for 24h 
or 48h, after which RNA was isolated as described before (Chomczynski 1993). During 
RNA isolation, gloves, pipettes and work place were wiped with RNase decontamination 
solution. The RMG supernatant was discarded, cells were washed with DPBS and 
harvested in 750µl of TRIzol®. Next, 150µl of chloroform were added and the whole 
sample was vortexed for 15sec followed by 3min incubation at RT. Subsequently, the 
samples were centrifuged at 16000 x g for 15min at 4°C. The aqueous phase containing 
RNA was collected to new eppendorf tubes containing 375µl of isopropanol and 
incubated for 10min at RT. Next, samples were centrifuged at 16000 x g for 15min at 
4°C. After removing the supernatant, the pellet was washed with 750µl of 75% ethanol 
and resuspended in 50µl of HPLC water. The concentration and purity of RNA was 
measured using a NanoDrop spectrophotometer.  
B.8.2 Synthesis of cDNA  
B.8.2.1 First strand cDNA synthesis 
Complementary DNA (cDNA) was synthetized form messenger RNA (mRNA) with 
reverse transcriptase- polymerase chain reaction (RT-PCR), using the RevertAid First 
Strand cDNA Synthesis Kit, according to the manufacturer’s instructions. First, one µg of 
total RNA from each sample (obtained from RMG, see B.8.1) was mixed with one µl of 
oligo (dT) 18 primer and filled up with HPLC water to 12µl. Second, 4µl of reaction 
buffer, 1µl of RiboLock RNase Inhibitor (20U/µl), 2µl of 10mM dNTP Mix and 1µl of 
RevertAid M-MuLV reverse transcriptase (200U/µl) were added, so the total volume of 
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reaction for each sample was equal to 20µl (see Table 1). The reaction mixtures were then 
incubated for 60min at 42°C. The reaction was terminated by 5min heating to 70°C. The 
samples were then evaluated for the amount of DNA with a NanoDrop 
spectrofluorometer. Samples were stored at -80°C. 
Table 1. PCR reaction mix for the first strand cDNA amplification. 
Reagents Final concentration Amount 
cDNA (1:1000) 100ng 1µl 
Taq buffer 10x 1x 2µl 
MgCl2 (25mM) 1.5mM 1.2µl 
primer forward (10µM) 0.5µM 1µl 
primer reverse (10µM) 0.5µM 1µl 
dNTPs (10mM) 250µM 0.5µl 
Taq (5U/µl) 25mU/µl 0.1µl 
HPLC H2O Up to 20µl 13.6µl 
 
B.8.3 Quantitative real-time PCR reaction 
Quantitative changes in mRNA for selected proteins were performed applying the qPCR 
method. Reaction mixtures were prepared in the special 4titued® 96 well plates, according 
to the Table 2. Next, the plates were sealed with appropriate foil supplied by the 
manufacturer and spin at 1500 x g for 3min. Then, the plates were placed in the 
LightCycler© 480 and processed according to the program in Table 3. For loading control, 
reaction mixture of GAPDH for each analysed gene was placed on the same plate. 
Table 2. qPCR reaction mix. 
Reagents Amount 
cDNA (1:20) 2.5µl 
KAPA SYBR© FAST QPCR MasterMix 5µl 
Forward Primer* 10µM 0.2µl 
Reverse Primer* 10µM 0.2µl 
HPLC water 2.1µl 
Total volume 10µl 
*Primers were designed with NCBI Blast tool. For list of used primers see A.4 Oligonucleotides 
Using LightCycler© 480 software after each qPCR reaction, analysis of melting curve for 
each well in 96-well plate was performed, to confirm correct PCR conditions. Obtained 
data from the PCR run was calculated into crossing point (Cp) values (with LightCycler© 
480 software) and imported into Excel where all further analyses of relative changes in 
genes expression were performed. Each gene was quantified in four repetitions on the 96-
well plate. 
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B.8.4 Quantitative analysis of relative changes in gene expression 
The quantitative analysis were done using the delta-delta-CP' (∆∆CP) method (Pfaffl 
2001). The statistical quantifications were made using the Mann Whitney U test and 
GraphPad software. Levels of significance were included accordingly: *p < 0.05, **p < 
0.01, ***p <0.001 
Table 3. Program for qPCR. 
Step Temperature Time Number of 
Cycles 
Initial denaturation 94°C 3 minutes 1 
Denaturation 94°C 30 seconds 25 
Annealing *°C 30 seconds 
Extension 72°C 45 seconds 
Final extension 72°C 10 minutes 1 
*The annealing temperature was set according to calculated Tm for primers used in the reaction (see A.4) 
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III. RESULTS  
Retinitis pigmentosa is a group of retinal degenerations in which inherited mutations 
disturb the proper function of PR or RPE, leading to progressive visual loss. The affected 
genes are responsible for a variety of functions within the retina, which includes 
components of the visual transduction cascade, visual cycle and retinol metabolism as 
well as renewal and shedding of the rod outer segments (van Soest et al. 1999). Gene 
therapy of RP can prevent vision loss, but the high heterogeneity in gene mutations 
causing RP, restricts one gene therapy only to a subset of patients. In contrast, trophic 
factor delivery cannot be curative for RP, but protects PR irrespective of the underlying 
gene defect leading to significant delay in photoreceptors death and preserving residual 
vision for a longer time. 
In a first set of experiments (Part one), primary mouse RMG (mRMG) cells were 
stimulated with the neuroprotective factor GDNF and a list of seven highly upregulated 
proteins was established. Subsequently, Cyr61 was chosen for validation as the molecule 
with the greatest potential for neuroprotective activity. Ex vivo experiments on short term 
and long term rd1 mouse retinal explants showed increased PR survival and proved 
Cyr61’s neurotrophic activity.  
In a second set of experiments (Part two), emphasis was put on describing the spectrum 
of action of Cyr61 within the retinal cells as well as induction of the molecular pathways 
leading to the observed neuroprotection. Stimulation of the whole retinal tissue revealed 
activation of mitogen-activated protein kinase (MAPK)/Erk and janus kinase (JAK)/Stat 
pathways, but not phosphoinositide 3-kinase (PI3K)/Akt. Stimulation of very pure PR 
preparations with Cyr61 showed no activation of any of mentioned pathways thus 
suggesting no direct prosurvival effect of Cyr61 on PR. Further analysis of primary 
porcine RMG cells showed an increase in phosphorylation of all investigated proteins: 
Erk1/2, Stat3 and Akt, revealing a positive feedback loop of Cyr61 action on RMG and 
implying its indirect neuroprotection through RMG. Treatment of primary porcine RPE 
cells with Cyr61 uncovered very strong activation of MAPK/Erk and PI3K/Akt but not 
JAK/Stat3, suggesting indirect protection of PR through RPE stimulation. Treatment of 
MIO-M1 and ARPE19 (human RMG and RPE cell lines, respectively) with Cyr61, led 
robust activation of MAPK/Erk and its nuclear translocation as well as weaker activation 
of PI3K/Akt. On the other hand, MIO-M1 cells did not show activation of the JAK/Stat 
pathway, indicating changes and limits of this cell line model in comparison to porcine 
primary cell cultures.  
The indirect manner of the neuroprotective effect led to the question if an RMG secreted 
factor may be the link between RMG/RPE stimulation and neuroprotection. This question 
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was addressed in Part three, where the influence of Cyr61 on protein secretion in primary 
porcine RMG cells was analysed. Quantification of secretome changes using LC-MS/MS 
based quantitative proteomics for primary RMG cell cultures revealed an increase in the 
secretion of a few proteins involved in extracellular matrix organization. Additional 
qPCR quantifications for three of the proteins chose from the secretome data or literature, 
showed mRNA increase in collagen, type III alpha 1 (COL3A1) and family with 
sequence similarity 3, member C (FAM3C), but not in VEGF. 
In the last section (Part four), preliminary data of an in vivo application of Cyr61 was 
investigated in a study on S334ter-3 rats. Cyr61, injected two times with two day 
intervals into the vitreous body of seven day old rats, caused high changes in 
vascularization of the retina and did not decrease the number of TUNEL positive cells in 
ONL. Furthermore, injections of Cyr61 significantly increased the percentage of TUNEL 
positive cells in INL, possibly due to vasculature disorganization. The obtained data 
implies a too high dosage of the applied Cyr61 in this first in vivo experiment, causing 
vasculature impairment, which might have diminished neuroprotective potential of 
Cyr61. 
Taken together, these results introduce Cyr61 as a novel neuroprotective agent that 
prolongs PR survival in an indirect way through stimulation of RMG and RPE cells. 
Attempts to elucidate the mechanism through which RMG and RPE mediate 
neuroprotection of PR are ongoing. In parallel, the adaptation of the promising Cyr61 
treatment of retinitis pigmentosa in the S334ter rat model will be investigated thoroughly 
in the future. 
Part one: Cyr61 is secreted by RMG and prolongs PR survival in the 
rd1 mouse model of retinitis pigmentosa 
1.1 GDNF induces changes in the secretome of primary mouse RMG  
The following results are based on the experimental work of Patricia del Rio (Research 
Unit Protein Science, Helmholtz Zentrum München, Germany), who kindly provided the 
raw data for subsequent analyses. 
Injection of GDNF into the subretinal space of rd1 mice delayed PR cell death (Frasson et 
al. 1999a). The fact that RMG cells, but not PR, posses GDNF receptors on their 
membrane (Harada et al. 2003, Hauck et al. 2006b) suggests that the prosurvival effect of 
GDNF on PR is indirect, mediated by RMG (Hauck et al. 2006b). However, it remained 
unclear which factors released by GDNF stimulated RMG, directly influenced PR and led 
to their prolonged survival.  
In order to identify which factors are synthesized and secreted by RMG upon GDNF 
stimulation, protein expression profile changes were investigated in primary mRMG cells  
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Figure 14. Cyr61 is secreted by GDNF stimulated Müller glial cells. 
Mouse retinal Müller glial cells (RMG) cells were stimulated with 0,1µg/ml GDNF. The changes in 
secreted proteins between stimulated (A) and control (B) arrays were quantified and proteins with 
significantly increased abundance are presented showing fold changes (C) as well as normalized signal 
intensity (D). Normalized signal intensity for Cyr61 in all experiments are shown on panel E. Intracellular 
changes in protein content between stimulated mRMG (F) and control (G) membranes were quantified 
confirming increase in synthesis of all seven proteins selected based on supernatant data. Induction of each 
individual protein is shown as the ratio of stimulated cells to control (H) or as normalized signal intensity 
(I). Additionally, normalized signal intensity differences of Cyr61 for both experiments are shown on panel 
J. Error bars indicate standard error of measurements (SEM). 
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with antibody-based arrays (Fig. 14). Pure RMG cell preparations were prepared from the 
retinas of GFAP-eGFP/C57BL6 mice, which express eGFP under the control of the 
GFAP promoter. Consequently, their RMG and astrocyte cells are labelled with green 
fluorescence, making it possible to confirm RMG enrichment in the obtained cultures 
after isolation from the retinal tissue. The medium with secreted proteins (Fig. 14A) and 
whole cell lysates (Fig. 14F) of mRMG treated with 0,1µg/ml GDNF were compared to 
conditioned media and cells lysate of untreated controls (Fig. 14B, G). First, mRMG 
supernatants were analysed, as secretome changes were the most likely mechanism of 
GDNF mediated neuroprotection. When defining a threshold of at least two-fold 
expression change in all three repetitions of the experiment, seven proteins were found to 
be significantly induced: tissue factor (TF), Cyr61, endostatin, fibroblast growth factor 1 
(FGF-1), fractalkine (CX3CL1), insulin-like growth factor-binding protein 3 (IGFBP-3) 
and placental growth factor 2 (PGF-2) (for details see Table 4 and Fig. 14C). 
Additionally, increases in abundance of these seven proteins were plotted as a comparison 
of normalized signal intensities for one representative experiment (Fig. 14D). Ratio 
changes for intracellular level of the proteins were calculated, using the same criteria of 
regulation through GDNF as for the supernatants. In the mRMG total cell lysates, twenty-
two proteins displayed a greater than two-fold change in abundance relative to controls in 
response to GDNF treatment (see Table 4). 
Finally, differential protein expression in lysates and supernatants were compared. All 
seven proteins induced in the supernatant were also highly increased on the intracellular 
level, confirming the validity of the identified secretome changes (Table 4 and Fig. 14H). 
Changes in quantity for these seven proteins are additionally presented as normalized 
signal intensities for one representative experiment (Fig. 14I). From the pool of secreted 
proteins significantly increased after GDNF treatment, Cyr61 appeared to be the most 
promising candidate to be a neuroprotective factor. This extracellular matrix protein is 
well known for its prosurvival effect in oral squamous cell carcinoma (Kok et al. 2010), 
breast cancer cells (Menendez et al. 2005), osteosarcoma (Sabile et al. 2012) and many 
other malignant tumour cells (Babic et al. 1998, Tang et al. 2011). Additionally, 
downregulation of Cyr61 expression has been reported in infantile Batten disease where 
one of the first symptoms is lost of vision leading to blindness (Haltia 2006, Qiao et al. 
2007). 
Based on these studies pointing to a potential pro-survival activity of neuronal cells and 
due to the robust induction of Cyr61 in mRMG supernatants (Table 4 and Fig. 14C - E) as 
well as in cell lysates (Table 4 and Fig. 14H – J), this protein was selected for further 
functional studies.  
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Table 4. Changes in mouse retinal Müller glial cells secretome and cell lysates after 
stimulation with 0,1µg/ml GDNF. 	  





Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 
1 tissue factor, 
coagulation factor III 
TF 3.3 5.5 2.3 4.4 11.0 




2.5 2.2 20.4 9.4 19.6 
3 endostatin, 
colagen XVIII 
 2.3 2.2 3.8 14.0 39.6 
4 fibroblast growth 
factor 1 
FGF-1 2.0 7.3 4.1 6.2 3.0 
5 fractalkine CX3CL1 13.4 2.0 13.3 12.4 19.6 
6 insuline-like growth 
factor binding 
protein 3 
IGFBP-3 3.9 14.9 10.8 39.4 34.0 
7 placenta growth 
factor 2 
PGF-2 7.0 5.3 82.2 16.1 12.2 
8 amphiregulin AR 3.0 1.8 1.4 3.3 3.3 
9 angiogenin ANG 1.9 1.4 0.6 7.8 6.1 
10 endoglin CD105 8.1 1.0 1.4 11.4 7.6 




HB-EGF 1.9 2.0 0.5 13.5 4.8 
13 insulin-like growth 
factor binding 
protein 1 
IGFBP-1 3.8 3.1 0.6 2.7 3.2 
14 insulin-like growth 
factor binding 
protein 2 







1.4 6.8 0.8 2.5 2.8 
16 leptin OB 1.9 2.2 0.3 2.5 2.7 
17 chemokine (C-C 
motif) receptor 2 
MCP-1, 
CCL2/JE 
2.1 22.0 1.2 21.4 12.1 
18 matrix 
metallopeptidase 3 
MMP-3 6.1 4.4 1.9 2.5 3.4 
19 matrix 
metallopeptidase 8 
MMP-8 6.7 1.0 2.0 4.2 6.2 
20 platelet-derived 




1.3 2.3 0.4 6.7 4.2 
21 platelet-derived 




2.0 3.1 0.4 63.5 12.7 
1 Index of the protein on the membrane array (Fig. 14) 
2Name of proteins according to the mouse cytokine membrane array protocol 
3Ratio treated/untreated for supernatant for three independent experiments 
4Ratio treated/untreated for lysate from two independent experiments 
1.2 Cyr61 reduces cell death in Pde6brd1 retinal explant cultures 
The observed upregulation of Cyr61 synthesis and secretion by GDNF stimulated mRMG 
implied its participation in the prolonged survival of PR, observed in the eyes of rd1 mice 
injected with GDNF (Frasson et al. 1999a). In order to validate this hypothesis, the effect 
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of Cyr61 application on PR survival rates was examined in explanted retinal cultures (for 
details see Materials and Methods B.3). The main advantage of this organotypic system is 
the possibility of study in in vivo-like complex behaviour of a tissue under simple in vitro 
settings (Oh et al. 2013). On the other hand, the retinal explanted tissue is studied without 
the other parts of the eye like vitreous body or the choroid layer, which may also 
contribute to an overall answer to the factor.  
	  
Figure 15. Experimental setup of Cyr61 stimulation of retinal explants. 
Retinal explants were prepared from postnatal day (PN)5 rd1 mice. The applied treatment regimen 
consisted of medium changes every second day. Cyr61 was added to the fresh medium at a final 
concentration of 0.5 or 1µg/ml (for short- or long-term retinal explants, respectively) for treatment samples 
(green) but omitted for control sample retinas. PR survival was analysed using a TUNEL assay at either 
PN11 or PN17 (violet). 
Short-term and long-term retinal cultures were prepared by Patricia del Rio (Research 
Unit Protein Science, Helmholtz Zentrum München, Germany) and Blanca Arango-
Gonzalez (Institute of Ophthalmic Research, at University of Tübingen, Germany), 
respectively. They kindly provided the data on which following paragraph is based on. 
Retinal explant cultures were prepared from rd1 mice, which possess a mutation in the 
gene coding for the PDE6β-subunit, what causes a rapid PR degeneration starting at PN8 
and leading to complete loss of rods within the central retina within the next three weeks 
(PN36) (Bowes et al. 1990, Pennesi et al. 2012). As a result, their retinas are an expedient 
system to study neuroprotective effects, as they exhibit a basal level of PR apoptosis in ex 
vivo culture. 
To prepare an organotypic culture, PN5 rd1 mice were scarified, eyes were enucleated 
and retinas were explanted on polycarbonate membranes, which separate explants from 
the medium (Fig. 13). The tissue was cultured in R-16 supplemented medium (see 
Materials and Methods A.7.1) that was exchanged every second day for control as well as 
for experimental samples. As Cyr61 was added to the fresh medium for all treatment 
samples, the first Cyr61 application took place at the second day of retinal explant 
culturing. All retinal explants were cultured for six days (short term retinal explants) with 
R-16 supplemented medium (control samples) or with R-16 supplemented medium with 
addition of 0.5 µg/ml Cyr61 (four days of Cyr61 treatment) (Fig. 15). After six days of 
culture all retinas were fixed and TUNEL analysis was performed (Fig. 16). Cyr61 did 
indeed reduce the number of apoptotic cells in short term explants, based on the TUNEL 
analysis. Specifically, photoreceptor death rates in explants treated with Cyr61 (mean 
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2,3%; ±0,42 of TUNEL positive cells in the ONL; Fig. 16C) were reduced to almost half 
that of untreated controls (mean 5,1%; ±0,94 of TUNEL positive cells in the ONL; Fig. 
16C). In order to further confirm this outcome, long term retinal explants were prepared 
in the same way as described above, but the tissue was cultured for 12 days (10 days of 
Cyr61 stimulation) and the medium of Cyr61 treated retinas was supplemented with 
1µg/ml Cyr61 (Fig. 16A) as opposed to untreated explants (Fig. 16B). After long term 
Cyr61 treatment of the tissue, reduced rate of TUNEL positive cells was  
	  	  	  	  	  	   	  
Figure 16. Cyr61 prolongs photoreceptor survival in rd1 mouse retinal explants. 
Retinal tissue was explanted and cultured for a short period of time (postnatal (PN)5 days in vitro (DIV)6) 
with 0.5µg/ml Cyr61 or for a long period of time (PN5 DIV12) with 1µg/ml Cyr61. After the experiment, 
retinas were fixed and stained according to the TUNEL protocol (see Materials and Methods B.5). 
Quantifications of photoreceptor cell death were performed for short term (C) as well as for long-term (D) 
retinal explants. Moreover, in the long-term retinal explants the number of photoreceptors (PR) was 
quantified and compared to the control values (E). Graphs show data from at least three independent 
experiments. TUNEL positive cells (red), DAPI stained nuclei (blue). Error bars indicate standard error of 
measurements (SEM); levels of significance: *p < 0.05, Scale bars - 50µm. 
still evident (mean 4,7%; ±0,9 of TUNEL positive cells in the ONL; Fig. 16D) in 
comparison to controls (mean 10,3%; ±1.14 of TUNEL positive cells in the ONL). 
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Moreover, in the long term retinal explants this decreased death rate translated into a 
significantly higher numbers of residual PR (mean 682; ±66) in comparison to control 
samples (403; ±19) (Fig. 16E). 
In conclusion, Cyr61 is a molecule secreted by RMG and with neuroprotective activity on 
retinal PR cells. 
Part two: Molecular pathway and mechanism of Cyr61 action within 
the retina 
Screening the secretome of GDNF stimulated RMG cells led to a list of seven 
upregulated proteins, out of which only Cyr61 was chosen for validation of its 
neuroprotective potential. The ex vivo experiments shown in the previous section revealed 
its prosurvival action on PR of the retinitis pigmentosa rd1 mouse model. Nevertheless, 
these experiments could by their nature give no information about the responsiveness of 
particular cell types within the retina. However, a variety of different primary cell culture 
systems were used to determine which retinal cell types are primarily responsive to Cyr61 
and which prosurvival signalling pathways are activated. 
Given the fact that Cyr61 binds to integrins or heparan sulfate proteoglycans (HSPG) on 
the cell surface (Kular et al. 2011) thus influencing cell processes, four hypothesis were 
formulated: 
1. Cyr61 protects PR directly through integrins (Brem et al. 1994) and/or HSPG 
expressed on PR (Tawara & Inomata 1987, Tawara et al. 1989, Landers et al. 1994). 
2. Cyr61 protects PR indirectly through stimulation of RMG by binding to integrins and 
HSPG, whose presence on RMG plasma membranes has previously been published 
(Hering et al. 2000, Aricescu et al. 2002). 
3. Cyr61 protects PR indirectly through stimulation of RPE cells by binding to integrins 
and HSPG, both of which are known to be present on RPE plasma membranes (Clegg et 
al. 2000, Geraldes et al. 2007). 
4. Combinations of any of the previous hypotheses.  
In order to test these hypotheses, we analysed three types of retinal cells separately: PR, 
RMG cells and RPE cells. Primary porcine cells of all three types were used along with 
two human cell lines – MIO-M1 and ARPE19. In these, three main signalling pathways 
related to survival were investigated: PI3K/Akt, MAPK/Erk and JAK/Stat, to determine 
the effect of Cyr61 on retinal cell function. The rationale for focussing on the PI3K/Akt 
and MAPK/Erk prosurvival pathways lies in their known activation by Cyr61 in different 
cancer cells (Menendez et al. 2005, Yoshida et al. 2007, Sabile et al. 2012, Zhang et al. 
2012c). In contrast, there have been no reports showing Cyr61 activation of JAK/Stat 
signalling, but Cyr61 was shown to be activated via JAK/Stat pathway (Klein et al. 2012) 
and activation of this cascade has been found in many studies on retinal neuroprotection 
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(Adamus et al. 2003, Maier et al. 2004, Joly et al. 2008, Chollangi et al. 2009, 
Schallenberg et al. 2012). 
2.1 Cyr61 activates the MAPK/Erk and JAK/Stat pathways in an ex vivo 
organotypic stimulation model 
In a first step, the response of the selected signalling pathways to Cyr61 was investigated 
on whole retinal tissue. To this end, very short-term organotypic tissue cultures were 
established, which gave the opportunity to monitor molecular changes in the conditions 
very similar to the in vivo situation, without the necessity to perform an experiment on a 
living animal. 
	  
Figure 17. Cyr61 induce MAPK/Erk and JAK/Stat activity in rd1 mouse retinal explants. 
Retinas of rd1 mice were explanted, mounted onto polycarbonate membranes and allowed to recover for six 
hours in serum free medium. Following this recovery and starvation period, retinas were treated with 
1µg/ml Cyr61 for the indicated durations. Stimulated retinas were lysed, and phosphorylation of Stat3, Akt 
and Erk was assessed by western blot, using antibodies against the unmodified proteins as well as against 
Tyr705 of Stat3, Ser473 of Akt and Thr202/Tyr204 of Erk1/2 (A). pErk1/2 and pStat3 band intensities from 
two replicates were quantified and normalized to the band intensity of Erk1/2 and Stat3, B and C 
respectively. Error bars indicate standard error of measurements (SEM). 
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Retinas from rd1 mice were dissected and prepared as for the short term and long-term 
retinal explants, described above. After dissection, the polycarbonate membranes with 
retinas were placed in basal medium and retinas were kept in an incubator for six hours, 
to allow the stressed tissue to recover after the preparation procedure. Subsequently, 
mouse retinal explants were treated with 1µg/ml Cyr61, lysed and analysed using the 
western blot technique, detecting critical components of the JAK/Stat, PI3K/Akt and 
MAPK/Erk pathways (Fig. 17). Phosphorylation of Tyr705 in Stat3 is crucial for its 
activation, followed by its dimerization, nuclear translocation and binding to DNA (Ihle 
1995, Bromberg et al. 1999). Phosphorylation of Akt at Ser473 is the critical step to fully 
activate Akt Ser/Thr kinase (Sarbassov et al. 2005). Activation of the MAPK/Erk 
pathway was followed by the observation of parallel Erk1 and Erk2 phosphorylation at 
Thr202 and Tyr204, respectively, which is essential for the enzyme activation (Roskoski 
2012). 
Cyr61 stimulation resulted in an increase of phosphorylated Erk1/2, indicative of 
increased MAPK activity, which peaked at 20 minutes (ratio 3.3), slowly declining to a 
ratio of 1.8 after two hours (Fig. 17A, B). Likewise, Cyr61 treatment induced 
phosphorylation of Stat3, one of the main transcriptional activator downstream of JAK, 
which was evident after 20 minutes (ratio 1.7) persisted until 60min (ratio 1.8) but had 
returned to baseline levels by 120 minutes. Contrary to activation of Erk1/2, induction of 
Stat3 decreased to control levels after two hours (Fig. 17A, C). In contrast, no difference 
in Akt phosphorylation though Cyr61 was found in stimulated explants (Fig. 18A). 
Taken together, analysis of Cyr61’s effect on the whole retinal tissue revealed significant 
phosphorylation of key signalling components of the JAK/Stat and MAPK/Erk but not 
PI3K/Akt pathways. 
2.2 Cyr61 does not stimulate PR in primary cell culture 
In order to test the hypothesis that Cyr61 stimulates PR survival through a direct 
mechanism, we prepared primary PR from porcine eyes. Porcine retina has two main 
advantages for the study: One is that this retina is very similar to the human one and can 
serve as a good substitute for human studies. The second one is that the bigger size of a 
pig eye in comparison to a mouse eye, allows obtaining ample numbers of cells 
translating to a much higher yield in terms of protein amounts in comparison to mouse 
eyes, thus facilitating subsequent western blot analyses considerably. 
Primary PR, prepared from porcine eyes, were the next day serum starved for two hours 
the day after preparation and treated with 1µg/ml Cyr61 for 10, 20 or 120 minutes. The 
comparably short starvation time was chosen to conserve PR cell viability (24h starvation 
lead to PR death, data not shown) and has been used successfully for stimulation of other 
cells during this study.  
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Figure 18. Cyr61 does not stimulate photoreceptors directly. 
Cultured photoreceptors (PR) were stimulated with 1µg/ml Cyr61 for the indicated periods of time. 
Afterwards, the cells were lysed and analyzed by western blotting using antibodies against pStat3, pAkt and 
pErk1/2 as well as their unmodified form to control the loading. 
PR cell lysates were analysed using western blot in the same way as whole retinal lysates 
(see 2.1). PR cells displayed basal levels of phosphorylated Akt, Erk and Stat3 at all 
analysed time points, but no significant changes in the phosphorylation state of either of 
those three proteins was observed following Cyr61 stimulation at any time point (Fig. 
18).  
In order to exclude the possibility that the failure of PR cells to respond to Cyr61 was 
caused by low cell viability, control dishes were stained with the dead cell marker 
propidium iodide (PI) or the live cell marker calcein (Fig 19). The majority of cells were 
still viable at the time of the experiment (Fig. 19A), while a certain portion of cells were 
dead, as shown by their failure to exclude PI (Fig. 19B). Based on these results the 
possibility that PR did not react to Cyr61 because of low vitality can be excluded.  
In summary, the lack of Cyr61 mediated activation on the three neuroprotective signalling 
pathways in PR, led to the rejection of the hypothesis of a direct mechanism of 
neuroprotection through Cyr61.  
2.3 Cyr61 activates the JAK/Stat, PI3K/Akt and MAPK/Erk pathways in primary 
RMG cells 
Since PR did not answer directly to Cyr61 treatment, the second hypothesis, stating that 
Cyr61 prolongs PR survival indirectly through RMG stimulation, was pursued further. 
To this end, primary RMG cells were isolated from porcine eyes and cultivated for up to 
11 days (Fig. 20A) to achieve >75% confluence (for details see Materials and Methods 
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B.1.2.2). At the day of experiment cells were serum starved for two hours in followed by 
treatment with 1µg/ml Cyr61 for different periods of time. Stimulation of signal 
transduction pathways was monitored by western blot analogous to the previous 
experiments. 
	  
Figure 19. Porcine photoreceptor cells were prepared with sufficient viability. 
At the day of experiment photoreceptor (PR) cells were fixed and their viability was assessed with two 
different fluorescent probes. Living cells were visualized with calcein, (green, A). Dead cells were stained 
with PI (red, B). Overlay of A and B is shown on panel C while phase contrast picture of PR is presented on 
panel D. Scale bars 200µm. 
Cyr61 did indeed induce the phosphorylation of all three monitored proteins in RMG 
cells (Fig. 20). Interestingly, the activation of each of the three proteins showed a 
different kinetic. Activation of Stat3 was evident from the beginning of the experiment 
but relatively short lived, dropping to values lower than in control samples after 120 
minutes stimulation. Increase in Stat3 phosphorylation (Fig. 20B) reached its peak after 
10 minutes of Cyr61 stimulation, (ratio 4.4), after which the signal decreased to a ratio 
2.2 after 20 minutes. After 60 minutes, phosphorylation of Stat3 dropped below control 
level to ratio 0.6 and did not recover even after 120 minutes (ratio 0.6). 
Similarly, the peak in phosphorylation of Akt occurred at 10 minutes (ratio 2.6, Fig. 20C) 
although the stimulation was much weaker compared to Stat3 activation. After 20 
minutes the effect on Akt was slowly diminishing (ratio 1.8) and, like for Stat3, decreased 
below control level after 60 minutes (ratio 0.4) and stayed low till the last observed time 
point - 120 minutes (ratio 0.5). In contrast, the activation pattern of Erk1/2 was 
characterised by a robust and sustained activation with ratios staying significantly 
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elevated till the end of the stimulation. Specifically, phosphorylation of Erk1/2 (Fig. 20D) 
was significantly increased after 30 minutes (ratio 2.1) and decreased very slowly, 
reaching a ratio of 1.9 and 1.8, after 60 and 120 minutes, respectively (Fig. 20D). 
	  	  	   	  
Figure 20. Cyr61 induces the JAK/Stat, PI3K/Akt and MAPK/Erk pathways in primary 
retinal Müller glial cells. 
Primary porcine retinal Müller glial (RMG) cells (A) were stimulated with 1µg/ml Cyr61 for the indicated 
periods of time. Next, the cells were lysed and analysed by western blot. Membranes were probed with 
antibodies against phosphorylated Stat3 (B), Akt (C) and Erk1/2 (D). Graphs show data from three 
independent experiments. Error bars indicate standard error of measurements (SEM). Scale Bar - 200 µm. 
Taken together, the responsiveness of primary RMGs to Cyr61 treatment is in line with 
the second hypothesis, postulating an indirect PR protection through RMG stimulation. 
Moreover, while PI3K/Akt and MAPK/Erk are often activated by the same receptor, here 
most notably by integrins, Stat3 is associated with a different set of receptors – cytokine 
receptors. It is therefore tempting to speculate that Cyr61 may bind to more than one 
cognate receptor on the RMG cell surface. 
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2.4 RMG cell contamination of PR cultures can be a dominant confounding factor 
for functional assays 
In light of the findings that RMG but not PR are responsive to Cyr61, an important 
technical point concerning isolation of primary retinal cells is worth highlighting. 
Contamination of PR cultures with a small number of RMG can skew the results 
drastically and may even lead to incorrect conclusions. Initially, PR cell cultures were 
prepared according to the previously published protocol I, where a first fraction of PR is 
isolated form retinas and combined with a second fraction, prepared by repeated and 
more vigorous dissociation of the retina to increase the efficiency of isolation (for details 
see Materials and Methods B.1.2.1). Many experiments were performed according to the 
described protocol I, but results were not reproducible and misleading, showing 
stimulation of different proteins in some instances but not in others (Fig. 21). 
	  
Figure 21. Contamination of photoreceptor cultures with retinal Müller glial cells is a major 
confounding factor in assessing the functional outcome of Cyr61 stimulation. 
Both fractions of the photoreceptor (PR) isolation, contaminated with retinal Müller glial (RMG) cells, 
were mixed and plated onto culture dishes (see Materials and Methods B.1.2.1). Three repplicates, each 
showing different stimulation pattern are presented. Conflicting results indicated three different activation 
patterns with increases in pAkt and pErk1/2 but not pStat3 (A), increase in pStat3 but not pAkt and pErk1/2 
(B) or no stimulation at all (C).  
To find the reason for this inconsistency, the first and second fractions were collected 
separately and representative aliquots were stained for PR and RMG marker proteins to 
evaluate the purity of each fraction. The first fraction showed almost exclusively 
recoverin stained PR cells (Fig. 22A). Here, RMG cells were almost absent as shown by 
the extremely low number of GS positive cells (Fig. 22B). In contrast, the second fraction  
	  	  72 
	  
Figure 22. The first photoreceptor fraction has extremely high purity while the second PR 
fraction is contaminated with retinal Müller glial cells. 
First and second photoreceptor (PR) fractions were isolated from porcine retina as described in Materials 
and Methods B.1.2.1. Aliquots of the fractions were plated separately onto 6cm dish for the following 
immunocytochemistry analysis. The next day the cells were fixed and stained with recoverin to visualise 
photoreceptors (green; A, E), glutamine synthetase to visualise retinal Müller glial (RMG) cells (red; B, F) 
and with Hoechst 33342 to visualise nuclei (blue; C, G). Panels D and H present merged channels for the 
first and second fractions respectively. Scale bar - 200µm. 
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contained many GS positive RMG cells (Fig.22F) interspersed with recoverin positive PR 
cells (Fig. 22E), as well as other not identified cells (for both fractions compare nuclei 
with PR and RGM staining, Fig. 22). 
For this reason only the first fraction of the PR isolations, with highest purity, was used 
for testing the effect of Cyr61 on PR presented in section 2.2. To ensure highest purity, 
PR culture purity was monitored by two different methods: western blotting and ICC (for 
details see Materials and methods B.1.2.1). Given the outcome of Cyr61 stimulation on 
pure and viable PR cultures presented in 2.2 and on RMG cultures presented in 2.3, it 
appears very likely that varying degrees of RMG contamination account for the 
inconsistently observed stimulation of the different signalling pathways shown in Fig 21. 
Strikingly, even a minor contamination of PR culture with RMG (Fig. 22) can have a 
major impact on the outcome of biological assays, in this instance implying a false 
positive PR responsiveness to Cyr61.  
2.5 Cyr61 activates the PI3K/Akt and MAPK/Erk pathway in MIO-M1 cell cultures 
In addition to primary porcine RMG, the responsiveness of the human RMG cell line 
MIO-M1 to Cyr61 was investigated. MIO-M1 in culture preserve the same morphological 
features and express, except for GFAP, characteristic for primary RMG markers: cellular 
retinaldehyde binding protein (CRALBP), epidermal growth factor receptor (EGF-R), 
GS, and alpha smooth muscle actin (α-SMA) (Limb et al. 2002).  
As descibred for primary cultures, cells were starved for two hours and treated for 
different time points with 1µg/ml Cyr61. Next, obtained lysates form the cells were 
analysed with regard to activation of the three signal transduction pathways by western 
blots. Similar to primary RMG cells increased phosphorylation of Akt after 10 minutes 
was found in MIO-M1 cells, but the induction was much weaker (ratio 1.6) and no 
stimulation of Akt was visible after 20 minutes and later time-point (Fig. 23A, B). 
Analysis of MAPK/Erk pathway activation revealed an increase in pErk1/2 already after 
10 minutes (ratio 1.9), staying at the same level at 20 minutes (ratio 1.9) and 60 minutes 
(ratio 1.8) but dropping to a ratio of 1.3 after two hours of stimulation (Fig. 23A, C). 
Similar to primary RMG cells, Erk1/2 phosphorylation in MIO-M1 was strong and 
sustained, contrasting it to the activation of Akt. On the other hand, the observed cell line 
response with both proteins was always weaker and shorter than the answer of primary 
RMG. 
Western blot analysis of activation of Stat3 did not reveal any activation of the protein, 
which is at odds with the results from primary porcine RMGs. 
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Figure 23. Cyr61 activates the PI3K/Akt and MAPK/Erk pathways in the human retinal 
Müller glial cell line MIO-M1. 
MIO-M1 cells were stimulated with 1µg/ml Cyr61, and changes in phosphorylation of Akt (A, B), Erk1/2 
(A, C) and Stat3 (A) were investigated using the western blotting technique. Additionally, analyses of 
nuclear and cytosolic fractions were conducted to show pErk1/2 nuclear translocation (D, E) and changes of 
pErk1/2 in cytosolic fractions (D, F). Nuclear fractions were additionally blotted with total cell fractions 
(total, D) and tested for PARP to show the efficiency of nuclear fraction isolation as well to with α-tubulin 
to control for cytoplasmic contaminations. Graphs show data from at least three independent experiments. 
Error bars indicate standard error of measurements (SEM). 
Nuclear translocation of pErk1/2 in astrocytes increases genes transcription and secretion 
of prosurvival factors (Dhandapani et al. 2007). To investigate nuclear movement of 
pErk1/2 in MIO-M1, cells were stimulated with Cyr61 as described above but then 
separated intonuclear and cytoplasmic fractions and analysed using western blotting. To 
control purity of nuclear fractions, additional detection of α-tubulin was performed (Fig. 
23D). In Cyr61 stimulated MIO-M1 cells, phosphorylated Erk1/2 was abundant in 
nuclear fractions already after 20 minutes of Cyr61 stimulation (ratio 1.7; Fig. 23D, E) 
which corresponded to the presence of activated Erk1/2 in the cytosolic fractions (ratio 
1.8; Fig. 23D, F). Nevertheless, after two hours the effect of stimulation was diminished 
in both fractions (Fig. 23D, E, F).  
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Taken together, these results show that the human RMG cell line can also be used to 
study Cyr61’s action within the retina, but with some limitations. MIO-M1 cells answer 
to Cyr61 treatment similarly to primary RMG cells with activation of Akt and Erk1/2. On 
the other hand, MIO-M1 cells treated with Cyr61 do not respond with Stat3 activation, 
contrasting their response to that of primary RMG cells. In addition, nuclear movement of 
pErk1/2 upon Cyr61 treatment could be shown in MIO-M1 cells, suggesting changes in 
transcriptome and secretome of RMG cells through Cyr61 as a possible mechanism of its 
indirect neuroprotective effect on PR cells. 
2.6 Cyr61 activates the PI3K/Akt and MAPK/Erk pathways in primary RPE cells  
Eventually, the third hypothesis, stating that Cyr61 protects PR survival indirectly 
through RPE stimulation, was tested. To investigate the responsiveness of RPE to Cyr61, 
primary porcine RPE cell cultures were prepared (Fig. 24A) (for details see Materials and 
Methods B.1.2.3). RPE cells were cultured for up to eight days to achieve >95% 
confluence (Fig. 24A). Subsequently, primary RPE were stimulated in the same way as 
primary PR and RMG (see above). 
Cyr61 stimulation increased phosphorylation of two of the studied signalling molecules: 
Akt and Erk1/2, but not Stat3 (Fig. 24). Activation of Akt was characterised by a strong 
and long answer, still clearly visible till the end of stimulation. Robust phosphorylation of 
Akt was visible already 10 minutes after Cyr61 activation (ratio 2.7) with a peak after 20 
minutes (ratio 3.5) and decreasing to a ratio of 2.6 after two hours (Fig. 24B). 
Phosphorylation of Erk1/2 was distinctly visible at all time points (Fig. 24C) with a 
strong increase in pErk1/2 already after 10 minutes (ratio 4.5) reaching its maximum after 
20 minutes (ratio 4.8) and then dropping to a ratio of 3.1 after 120 minutes (Fig. 24C).  
In summary, Cyr61 stimulates primary porcine RPE cells leading to activation of the 
PI3K/Akt and MAPK/Erk signalling pathways. Thus, the hypothesis, that Cyr61 protects 
PR through stimulation of RPE cells cannot be excluded. 
2.7 Cyr61 activates the PI3K/Akt and MAPK/Erk pathway in the ARPE19 cells 
To analyse the response of a human RPE cell line to Cyr61 the commercially available 
ARPE19 cell line was used. ARPE19 is a spontaneously evolved human cell line which 
express markers specific for RPE cells: CRALBP and RPE65. Furthermore, when plated 
on laminin-coated Transwell-COL filters they exhibit morphological polarization and 
form tight-junctions (Dunn et al. 1996), indicating that they retain characteristics of RPE 
cells. ARPE19 cells were serum starved for two hours and analysed with the western blot 
technique (Fig. 25), as described for the MIO-M1 cell line.  
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Figure 24. Cyr61 induces the PI3K/Akt and MAPK/Erk pathways in primary porcine 
retinal pigment epithelium cells. 
Primary porcine retinal pigment epithelium (RPE) cells (A) were stimulated with 1µg/ml Cyr61 for 
indicated periods of time. Cells were lysed and analysed by western blotting. Membranes were incubated 
with antibodies against phosphorylated Akt (B), Erk1/2 (C) and Stat3 (D) signalling molecules to show 
changes in activation of the proteins. Graphs show data from three biologically independent experiments. 
Error bars indicate standard error of measurements (SEM). Scale Bar - 200µm. 
Activation of Akt started from the beginning of the experiment (10 minutes, ratio 2.2) and 
stayed high until the end of the stimulation (Fig. 25A, B). Analysis of Erk1/2 
phosphorylation revealed a kinetic similar to pAkt but with a higher peak of fold 
activation at 20 minutes (ratio 5), after which the stimulation declined to a ratio of 2.45 at 
60 minutes, but rebounded to a ratio of 3.6 at 120 minutes (Fig. 25A, C). 
Similarly to primary porcine RPE cells, analysis of the whole cell lysate towards 
phosphorylation of Stat3 showed no influence of Cyr61 on JAK/Stat3 pathway activation. 
To investigate whether activation of Erk1/2 may lead to changes on the transcriptional 
level, analysis of the nuclear movement of pErk1/2 was conducted in the same way as for 
MIO-M1 cells (see above). Purity of the nuclear fraction was controlled with additional 
α-tubulin staining (Fig. 25D). Similarly as observed for MIO-M1 cells, after 20 minutes 
phosphorylated Erk1/2 was significantly enriched in the nuclear fraction (ratio 2.7; Fig. 
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25D, E) and even to a higher extend in the cytosolic fraction (ratio 3.6; Fig. 25D, F). Two 
hours after Cy61 treatment, the level of Erk1/2 phosphorylation started to decrease 
slowly, but in contrast to MIO-M1 cells, stayed high until the end of the experiment 
(ratios 2.5 and 2.3, for nuclear and cytoplasmic factions, respectively) (compare Fig. 23D, 
E, F and 25D, E, F). 
	  
Figure 25. Cyr61 activates the PI3K/Akt and MAPK/Erk pathways in the human retinal 
pigment epithelium cell line ARPE19. 
Cells were incubated with 1µg/ml Cyr61 and the changes in activation of the observed pathways were 
determined applying the western blotting method. Membranes with separated proteins from the lysates were 
incubated with antibodies against phosphorylated Akt (A, B), Erk1/2 (A, C) and Stat3 (A). Moreover, cell 
lysate was separated into two fractions and analysed for changes in pErk1/2 in nuclear (D, E) as well as 
cytosolic fraction (D, F). To confirm the purity of isolation, nuclear fractions were blotted with total cell 
fraction (total, D) and controlled for α-tubulin content. Additionally, staining with PARP presents the 
efficiency of nuclear fraction isolation. Graphs show data from at least three independent experiments. 
Error bars indicate standard error of measurements (SEM). 
The presented data shows that ARPE19 cells are a good substitute for primary porcine 
RPE cells in regard to Cyr61. Cyr61 activated the same two signalling pathways in 
APRE19 as in primary RPE cells, with comparable kinetic and magnitude. Additionally, 
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the nuclear translocation of pErk1/2 in Cyr61 stimulated ARPE19 cells could be shown, 
implying its influence on transcriptome and secretome changes.  
Part three: Investigation of the influence of Cyr61 on the RMG 
secretome 
Results pertaining to Cyr61’s influence on intracellular signalling pathways activity 
provided new insights into its influence on retinal cells. However, the experiments up to 
this point did not give any information concerning putative protein expression and 
secretome changes following Cyr61 stimulation.  
Two methods were applied, quantitative proteomics and quantitative PCR (qPCR) to 
investigate Cyr61’s influence on transcriptome and secretome of primary porcine RMG 
cells. Due to time constraints of the presented thesis, the results are based on four 
(proteomics) or on two (qPCR data) replicates. These results provide first clues about the 
influence of Cyr61 on RMG transcriptome and secretome changes. Further improvement 
of the experimental design will be necessary to obtain comprehensive results and confirm 
these preliminary data. 
3.1 Proteomic analysis of protein secretion after Cyr61 stimulation of primary RMG 
cells  
The samples were analysed in cooperation with the Helmholtz Core Facility Proteomics 
and Alexander Schäfer. 
To investigate secretome changes, RMG cells were starved for two hours in serum-free 
medium followed by 0.5µg/ml Cyr61 medium supplementation for 24 hours. The next 
day, medium enriched in proteins secreted by the cells was collected and the secretomes 
were compared using quantitative LC-MS/MS based proteomics. To this end, secreted 
proteins were digested with trypsin using the filter aided sample preparation (FASP) 
digestion protocol (for details see Materials and Methods B.9.4). The resulting tryptic 
peptides were analysed by LC-MS/MS (four biological replicates for both control and 
Cyr61 stimulation) on an Orbitrap XL LC-MS system. 
Following data acquisition, proteins were identified using the Mascot search engine and 
quantified using a label-free approach implemented in the Progenesis LC-MS software 
(described in detail in Materials and Methods B.9.4). In this way, a list of 1754 quantified 
proteins was generated out of which only a few showed differences in abundance in 
Cyr61 treated samples. It should be noted however, that many of these proteins represent 
cytoplasmatic protein like actin, and are most likely contaminations originating from cells 
dying during the stimulation period of the experiment. This heavy contamination of 
conditioned medium with cytoplasmic proteins is a well-known problem of non-targeted 
proteomic analysis of secretomes (Dupont et al. 2004, Zwickl et al. 2005). As the current 
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working hypothesis stated that Cyr61 causes changes in proteins secreted by RMG to 
protect PR, only proteins with significantly altered abundance which are known to be 
secreted (soluble factors or extracellular matrix constituents) are reported in this thesis. In 
total, only seven proteins fulfilled these criteria (Table 5).  
Table 5. List of secreted proteins significantly increased in supernatants of primary porcine 
retinal Müller glial cells after stimulation with 0,5µg/ml Cyr61. 	  












collagen, type III, 
alpha 1  
COL3A1 24 7 0,000 4,9 
insulin-like 
growth factor 
binding protein 5 
IGFBP-5 13 1 0,023 1,6 




member C  
FAM3C 13 3 0,042 1,4 
retinaldehyde 
binding protein 1 
RLBP1 11 4 0,026 1,3 
matrilin 4 MATN4 20 10 0,044 1,3 
chondroadherin CHAD 15 2 0,043 0,6 
 
Collagen type III, alpha 1 showed the highest upregulation with a ratio of 4.9, while most 
other regulated proteins had much smaller increases: insulin-like growth factor binding 
protein 5 (IGFBP-5, ratio 1.6), cystatin E/M (CYTM; ratio 1.5), FAM3C (ratio 1.4), 
retinaldehyde binding protein 1 (RLBP1, ratio 1.3), matrilin 4 (MATN4, ratio 1.3), On 
the other hand, one extracellular matrix protein – chondroadherin (CHAD), was found to 
be downregulated after Cyr61 treatment, dropping to the ratio 0.6.  
In summary, Cyr61 caused distinct changes in the secretion of several proteins by RMG 
cells. 
3.2 Changes in mRNA of stimulated primary RMG after Cyr61 stimulation  
In order to confirm changes in protein secretion after Cyr61 stimulation, three proteins 
were analysed with qPCR to show their induction at the transcriptional level. The 
extracellular matrix protein COL3A1 was chosen, taking into account its significant 4.9 
fold increased secretion after Cyr61 stimulation of RMG (Table 5). Additionally, the 
secreted factor FAM3C was monitored, considering its increase in secretion by 
stimulation of RMG (Table 5). Transcriptional changes in VEGF expression were also 
investigated. Although VEGF showed no significant increase in the RMG secretome 
(data not shown), its potential regulation by Cyr61 is very important considering Cyr61’s 
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possible proangiogenic activity (Zhou et al. 2005, Yu et al. 2008), which may give rise to 
detrimental side effects for its prospective use in treatment. 
Transcriptional induction of COL3A1 and FAM3C, but not VEGF, after 48 hours of 
0.5µg/ml Cyr61 medium supplementation was found, confirming results obtained by 
secretome analysis (Fig. 26A, B, C).  
	  
Figure 26. Cyr61 influences transcription of secreted proteins in porcine retinal Müller glial 
cells. 
Primary retinal Müller glial (RMG) cells were stimulated with 0.5µg/ml Cyr61 and mRNA levels of 
collagen, type III, alpha 1 (COL3A1; A), family with sequence similarity 3, member C (FAM3C; B) and 
vascular endothelial growth factor (VEGF; C) were compared using qPCR. Relative expression levels were 
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Markers for each group correspond to 
two independent experiments with four technical replicates each. Bars indicate mean ratios for each group. 
Taken together, the presented data show that Cyr61 causes changes in the secretion of a 
distinct group of proteins comprised of soluble factors and extracellular matrix proteins in 
RMG. It appears very likely that this influence of Cyr61 on the RMG secretome is 
mediated by modulation at the transcript as shown for two examples of both types of 
proteins: COL3A1 and FAM3C. The seven identified Cyr61 induced proteins are 
candidates for mediation of the indirect neuroprotective effect. However, the 
comparatively low grade induction (30-60% change in abundance for six of seven 
proteins) of most of these proteins warrants more detailed investigation of Cyr61’s effect 
on the RMG secretome in future experiments. Particularly, Cyr61 treatment duration and 
dose will need to be optimized and the contamination with cytoplasmatic proteins 
reduced in order to obtain clearer results. 
Part four: In vivo application of Cyr61 in the S334ter line 3 rat model of 
RP  
Results up to this point showed that Cyr61 is a prosurvival factor for PR employing an 
indirect mechanism of neuroprotection through stimulation of surrounding retinal cells. 
One plausible model may be activation of RMG and probably RPE cells leading to 
changes in their gene expression followed by alterations in factor secretion and/or 
modification of the extracellular matrix. However, all described experiments were 
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performed in vitro, dissecting retina or retinal cells from the intact eye. They therefore do 
not give direct answers how application of Cyr61 will influence the development of RP in 
a living organism. In the last part of the thesis, preliminary data from the first in vivo 
application of Cyr61 to eyes of S334ter-3 rats is presented. The S334ter-3 rat is an RP 
rodent model, similar to rd1 mice. In both models rapid PR degeneration as well as 
increased activation of PARP combined with calpastatin down-regulation, increased 
oxidative DNA damage and accumulation of PAR polymers can be observed (Kaur et al. 
2011). The rationale for switching models lies in the feasibility of intravitreal injection 
into PN7 rat eye in contrast to mouse eye. Following injection of Cyr61, the cell death 
ratio after Cyr61 was monitored in two retinal layers: ONL and INL. In addition, the 
number of ganglion cells in the ganglion cell layer was compared. Finally, changes in 
vasculature organization after Cyr61 injections were monitored using confocal scanning 
laser ophthalmoscopy.  
4.1 Application of Cyr61 to S334ter-3 rat eye did not prolong PR survival in vivo. 
The in vivo validation of Cyr61 was conducted in cooperation with Blanca Arango-
Gonzalez (Institute of Ophthalmic Research, at University of Tübingen, Germany), who 
injected rat eyes as well as prepared cryostock from the eyes. 
In order to test the neuroprotective activity of Cyr61 in intact eyes, ten S334ter-3 rats 
were injected with 0.25µg Cyr61 at PN7 and PN10 in their right eyes, while the left eyes 
were injected with PBS to serve as controls. At PN12, after five days of Cyr61 treatment, 
rats were sacrificed, the retinas were prepared and the level of PR cell death in two 
nuclear layers (ONL and INL) was evaluated using the TUNEL method (Fig. 27). Next, 
changes in the number of ganglion cells in GCL between control and Cyr61 treated eyes 
were evaluated. To get a more comprehensive picture, two areas of each retina were 
evaluated microscopically: one next to the optic nerve and the other from the peripheral 
retina. 
The statistical analyses of the optic nerve region in the ONL showed no difference in the 
level of percentage of TUNEL positive cells between Cyr61 treated (18.6 ± 2.62) and 
control (19.44 ± 2.02) retinas (Fig. 28A). Similarly, no difference was found in the ONL 
in the peripheral retina (14.01 ± 2.00 versus 13.68 ± 1.30, for Cyr61 treated and control, 
respectively; Fig. 28B). On the other hand, quantification of changes in cell vitality in the 
INL revealed a statistically significant increase in cell death in the region of optical nerve 
area after Cyr61 treatment (3.08 ± 0.43) versus control (1.71 ± 0.11, Fig. 27 and 28C). 
Similarly, the average number of TUNEL positive cells in the INL of the peripheral retina 
was higher between Cyr61 stimulated (2.2 ± 0.47) and DPBS treated retinas (1.66 ± 
0.17), although this difference was not significant (Fig. 28D). Analysis of the GC layer 
showed that there was no difference in the number of ganglion cells in the optic nerve 
area (22 ±1.55 versus 23.30  ± 2.57, for Cyr61 treated and control, respectively; Fig. 28E) 
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or the peripheral retina (31.88 ± 2.49 versus 29.70 ± 2.57, for Cyr61 treated and control, 
respectively; Fig. 28F).  
 
	  
Figure 27. Cyr61 does not decrease cellular death within the outer nuclear layer in S334-ter-
3 rats. 
Representative TUNEL staining from the optic nerve region of retinas from eyes treated with Cyr61 or 
Dulbecco's phosphate-buffered saline (DPBS). S334ter-3 rat were injected twice with 0.25µg Cyr61 in the 
right eye (A) or with DPBS in the left eye (B). After four days the animals were sacrificed and retinas were 
analysed with the TUNEL method. TUNEL positive cells are marked by green fluorescence; nuclei were 
counterstained with Hoechst 33342 (blue). Outer nuclear layer (ONL), inner nuclear layer (INL), ganglion 
cell layer (GCL); Scale bar 50µm. 
4.2 Cyr61 can cause pathological retinal vascularization in S334ter-3 rats 
Retinal vasculature analyses were made in Tübingen by Vinícius Monteiro de Castro 
(University of São Paulo, São Paulo, Brazil) and Blanca Arango-Gonzalez (Institute of 
Ophthalmic Research, at University of Tübingen, Germany). 
In light of Cyr61’s potential angiogenic activity (Brigstock 2002, Harris et al. 2012) and 
the detrimental effect that initiation of angiogenesis can have in the retina (Lopez & 
Green 1992, McVicar et al. 2011), the effect of Cyr61 on the developing vasculature of 
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S334ter-3 rats was also evaluated in the present experiment. Evaluation of the vessels was 
performed with cSLO, a technique that allows observing vasculature within retinal tissue  
	  
Figure 28. Cyr61 increases cell death in inner nuclear layer of S334ter-3 rats. 
Quantification of the percentage of TUNEL positive cells between five days Cyr61 treated eyes and control 
eyes injected with Dulbecco's phosphate-buffered saline (DPBS). TUNEL stained retinas from 0.25µg 
Cyr61 treated S334ter-3 rats were analysed using the Defensis 2 software to determine the total cell number 
as well as the number of TUNEL positive nuclei for outer nuclear layer (ONL) and inner nuclear layer 
(INL) from eight Cyr61 and ten control eyes. The percentage of TUNEL positive cell was compared in the 
ONL near the optic nerve (A) and the peripheral retina (B) as well as in the INL near the optic nerve (C) 
and in the peripheral retina (D). Additionally, the number of ganglion cells (GC) in ganglion cell layer 
(GCL) was compared in the optic nerve region  (E) and from the peripheral retina  (F). Bars show mean 
values, error bars indicate standard error of measurements (SEM), levels of significance: **p < 0.01 (Mann 
Whitney U test).  
(deep and superficial capillary plexus), but without detailed distinction between deep and 
superficial layers (Bartsch & Freeman 1994, Elsner et al. 1996). At the end of the 
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experiment (PN12), rats were scarified and their eyes were evaluated for vasculature 
changes using cSLO infrared reflectance imaging (excitation laser 815nm, Fig. 29) and 
red-free reflectance imaging (excitation laser 488nm) immediately afterwards. In the 
Cyr61 injected eyes, we could observe sprouting of smaller capillaries from the larger 
vessels of the retinal layers (Fig. 29, left panel) in comparison to control eyes (Fig. 29, 
right panel).  
 
	  
Figure 29. Cyr61 increases sprouting of new capillaries from existing vessels in the rat 
retina. 
Retinas of Cyr61 treated (left panel) and control eyes treated with Dulbecco's phosphate-buffered saline 
(DPBS) (right panel) of S334ter-3 rats were analysed right after the animals were sacrificed on postnatal 
day (PN)12, using  infrared reflectance imaging (excitation laser 815nm) confocal scanning laser 
ophthalmoscopy.  
In summary, Cyr61 did not protect PR from degeneration in S334ter-3 rats in this first 
attempt at in vivo validation of neuroprotective potential. In fact, apoptosis rates in the 
INL appeared significantly higher in Cyr61 treated animals. Additionally, 
ophthalmoscopy scans of the superficial and deep vascular plexus of the retina showed a 
strong disturbance in the vasculature development of the Cyr61 treated eyes. Future test 
of Cyr61’s neuroprotective capabilities in the intact eyes should explore the issue of 
finding the right dosage and duration of application of the factor as a first step. 
Nevertheless, caution concerning the proangiogenic properties of Cyr61 is warranted and 
changes within the vasculature of the eye, if confirmed in future studies, are likely to 
prohibit further in vivo applications. 
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IV. DISCUSSION 
1. Neuroprotective potential of GDNF induces changes in RMG secretome 
Our research was aimed at identifying a novel neuroprotective factor, which in the future 
could be applied as a therapy for patients with retinitis pigmentosa and possibly with 
other retinal degenerations. We focused on Müller cells, which are the main retinal glial 
cells guarding metabolic and ion homeostasis within the retinal tissue, responding to 
internal as well as external stimuli (Reichenbach & Bringmann 2013). In case of retinal 
disease, RMG react with cytoprotective activity, which involve a wide range of different 
mechanisms including synthesis and secretion of cytokines as well as neurotrophic and 
growth factors (Limb et al. 2002, Joly et al. 2008, Bringmann et al. 2009). It must be 
mentioned though, that if the pathologic condition is recurrent or chronic, RMG can 
answer with gliosis, leading to further degeneration of the retina (Reichenbach & 
Bringmann 2013). Since GDNF, one of the RMG secreted factors, has already well 
documented prosurvival activity for the retinal neurons (Frasson et al. 1999a), we started 
our study from a closer examination of its neuroprotective action. Although some 
publications claim the presence of GDNF receptors on PR membranes (Jomary et al. 
2004, Rothermel et al. 2004) the neuroprotective effect of GDNF has rather been 
attributed to an indirect mechanism through RMG stimulation (Harada et al. 2003, Hauck 
et al. 2006b). Similarly, indirect prosurvival effects on PR through RMG stimulation were 
found for other growth factors, like CNTF, BDNF (Adamus et al. 2003, Wen et al. 2006, 
Wen et al. 2008, Saito et al. 2009) as well as for a member of IL-6 family - oncostatin M 
(Xia et al. 2011). Therefore, we focused on GDNF induced changes in the RMG 
secretome, which yielded a list of seven significantly upregulated candidate proteins. Out 
of this list, and based on the available literature, we selected the extracellular matrix 
protein - Cyr61 (mean upregulation through GDNF 8.4) for further analysis. This protein 
already has well documented prosurvival effects in the context of cancer (Dunn et al. 
1996, Kok et al. 2010, Tang et al. 2011, Sabile et al. 2012), but has not been studied yet 
in a context of neuroprotective action within retinal tissue. We refrained from 
investigating the remaining six proteins from the list, for various reasons discussed in 
detail below. Some of these factors have therapeutic potential, similar to Cyr61, while 
others are unlikely to be useful for this purpose. 
Considering the mean value out of the three conducted experiments the highest increase 
in secretion was found for PGF-2 (mean ratio 31.5). PGF-2 is an angiogenic factor (Park 
et al. 1994, Luttun et al. 2002), whose biology as well as action within retinal tissue has 
already been broadly investigated. It is a member of the VEGF family and secreted, 
among others, by endothelial (Zhao et al. 2004, Yao et al. 2005) and RPE cells (Hollborn 
et al. 2006). It stimulates cells via binding to VEGF receptor 1 (VEGF-R1) (Park et al. 
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1994) or HSPG (Hauser & Weich 1993). Since VEGF-R1 is present on pericytes and 
endothelial cells, while only VEGF-R2 has been found on PR and GC (Cao et al. 2010), it 
is likely that PGF-2 does not have direct neurotrophic action on retinal neurons. PGF-2 
expression can be stimulated by VEGF (Zhao et al. 2004, Yao et al. 2005) and amplify 
VEGF action on endothelial cells (Yao et al. 2005). PGF-2 is expressed during neonatal 
retinal development, but its neutralization caused only a marked persistence of the 
hyaloid vessels without affecting development of retinal vasculature (Feeney et al. 2003). 
In the adult retina, PGF-2 is absent and its expression is associated with pathologic 
neovascularization in proliferative retinopathy (Khaliq et al. 1998), but it does not disrupt 
permeability of the retinal-endothelial cell barrier (Deissler et al. 2013). PGF-2 
expression is increased in GC under hyperoxic conditions, but not under hypoxic 
conditions (Simpson et al. 1999). Furthermore, in a mouse model of retinopathy of 
prematurity, therapeutic intravitreal injections of PGF-2 remarkably decreased hyperoxia-
induced vaso-obliteration without stimulation of vascular proliferation or 
neovascularization (Shih et al. 2003). In summary, PGF-2 has well documented 
angiogenic activity within the retinal tissue but there is currently no evidence for a potent 
neuroprotective action. 
The second upregulated protein, with mean ratio of 9.9, was IGFBP-3. Increase in 
expression of this protein by RPE cells can be induced by stimulation with IGF-1 
(Slomiany & Rosenzweig 2004) or in neovascular tufts by hypoxic conditions (Lofqvist 
et al. 2009). Functionally, IGFBP-3 forms heterotrimeric complexes with approximately 
75% of serum IGF-1 and IGF-2 (Chang et al. 2007). IGFBP-3 is increased in hypoxic 
conditions and can enhance neovascularization (Chang et al. 2007). Moreover, it induces 
CD34+ endothelial precursor cell differentiation into endothelial cells, increases their 
migration and capillary tube formation (Chang et al. 2007), but it has no 
mitogenic/proliferative effect on porcine RMG (King & Guidry 2012). IGFBP-3 has 
already been widely studied in the context of retinal degenerations. Elevated protein 
levels of IGFBP-3 were found in the vitreous bodies in proliferative diabetic retinopathy 
as well as in diabetic ischemic eyes (Pfeiffer et al. 1997). Similarly, IGFBP-3 mRNA was 
increased in retinas of a mouse model of oxygen induced retinopathy (Ishikawa et al. 
2010). These upregulation appear to be compensatory mechanisms rather than noxious 
influences, as intravitreal injections of IGFBP-3 prevent VEGF caused loss of junction 
integrity by retinal endothelial cells forming blood retinal barrier (Jarajapu et al. 2012). 
The IGFBP-3 injections could also reduce vascular leakage in VEGF-induced retinal 
vascular permeability in mice (Kielczewski et al. 2011b). Therefore, IGFBP-3 has been 
suggested as a novel protective therapy in ocular diseases like diabetic retinopathy 
(Jarajapu et al. 2012). Additionally, IGFBP-3 was successfully validated as a protective 
factor under hypoxic conditions. Overexpression of IGFBP-3 by endothelial cells in 
mouse pups that underwent oxygen-induced retinopathy resulted in decreased apoptosis 
of neurons of INL as well as pericyte and increased pericyte ensheathment and microglia 
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apoptosis (Kielczewski et al. 2011a). Moreover, administration of IGFBP3 to eyes of a 
mouse model of oxygen-induced retinopathy resulted in protection from hyperoxia-
induced vasculature regression (Chang et al. 2007). In diabetic retina, pharmacological 
elevation of IGFBP-3 prevented retinal endothelial cell apoptosis under hyperglycemic 
conditions (Zhang et al. 2012b, Zhang et al. 2013). Furthermore, IGFBP-3 may have a 
role in regulating inflammation in diabetic retinopathy (Zhang et al. 2013a). IGFBP-3 
knockout mice showed decreased b-wave as well as oscillatory potential amplitudes in 
ERG, which was accompanied by increased apoptosis in the GCL (Zhang et al. 2013a). 
These ERG alterations point to a loss of electric activity and by extension excitability in 
the retina. By the same token, repression of IGFBP-3 expression through 21 days 
propranolol treatment of rats resulted in a decrease of the b-wave amplitude (Jiang & 
Steinle 2010). On the other hand, in studies on cancer cells, IGFBP-3 was successfully 
applied as a therapeutic, activating apoptosis, and was successfully applied as an anti-
cancer therapeutic for prostate cancer cells, where it increased activation of caspase-3 and 
-7 (Liu et al. 2005). Similarly, through activation of caspase-7 and -8, IGFBP-3 induced 
apoptotic death in MCF-7 breast cancer cells (Kim et al. 2004). In summary, IGFBP-3 is 
a molecule regulating retinal vasculature development as well as neuronal cells function, 
but without indication for prosurvival action within retinal tissue. 
The third upregulated protein, fractalkine (mean ratio 9.6), is a proangiogenic chemokine 
highly expressed in developing healthy as well as rd1 mouse retina (Zeng et al. 2005), 
although it is not required in the first postnatal week for normal vascular and neuronal 
development of this tissue (Zhao et al. 2009). Within the eye, fractalkine is expressed by 
endothelial, RMG, GC and RPE cells as well as by the choroid (Silverman et al. 2003). 
Many investigations addressing fractalkine’s activity within the retina have already been 
conducted. In the light-injury rat model of retinal degeneration, fractalkine expression 
increased mainly in PR cells, enhancing their survival but also inducing microglia 
migration and release of inflammatory cytokines like IL-1β or TNF-α (Zhang et al. 
2012a). Since fractalkine modulates microglia migration in response to tissue injury 
(Liang et al. 2009), it has also been suggested to play an important role in regulating 
leukocyte efflux in inflammatory eye diseases, like anterior uveitis, retinochoroiditis 
(Silverman et al. 2003), endotoxin-induced uveitis (Chu et al. 2009) or in oxidative and 
ischemia reperfusion conditions (Juel et al. 2012). Fractalkine knockout led to 
uncontrolled retinal inflammation and increased retinal degeneration as well as increased 
PR death, underscoring its important function in modulating microglia function (Juel et 
al. 2012). In contrast, in age-related retinal degeneration, fractalkine deficiency in mice 
impaired microglial and macrophage trafficking, but did not influence loss of PR 
(Luhmann et al. 2013). Similarly, in experiments on oxygen-induced retinopathy, mice 
lacking fractalkine did not show any difference in INL neuronal cells survival as well as 
in retinal vascular repair or neovascularization following ischemia (Zhao et al. 2009). To 
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sum up, fractalkine activity within retina has already been broadly investigated and its 
influence on the cells depends on the pathologic conditions the tissue is challenged with.  
The fourth factor, FGF-1 with a mean ratio 4.5, has already been shown to play a 
prosurvival role for PR (Bugra & Hicks 1997). FGF-1 is present in GCL, within INL, in 
photoreceptor ROS and in the RPE cells (Mascarelli et al. 1989, Guillonneau et al. 1998). 
Its expression in the rat retina increases during development achieves the highest level in 
adults (Bugra & Hicks 1997). Receptors for FGF-1 are present in OPL, photoreceptor IS 
and RPE, but not in INL or on GC, and its transcription increases in light-induced retinal 
degeneration (Mascarelli et al. 1989). FGF-1 was partially protective in retinal 
degeneration induced by N-methyl-N-nitrosourea in rats by induction of the antiapoptotic 
protein Bcl-2 and repression of the proapoptotic protein Bax (Xu et al. 2008). 
Furthermore, in NaIO3 induced retinal degeneration in rats, intravitreal application of 
FGF-1 not only improved ERG amplitudes of a- and b-waves but also preserved the 
structure of photoreceptor OS and increased the integrity of the RPE monolayer. 
Additionally, the thickness of the FGF-1 treated retinal tissue was similar to the normal 
eyes, showing FGF-1 prosurvival effect on PR (Chen et al. 2009). On the other hand, 
neither the levels of FGF-1 transcript in whole retinal tissue (Bugra & Hicks 1997) nor 
the protein expression in RPE cells (Malecaze et al. 1993) was altered in the RCS rat 
model of retinitis pigmentosa. In summary, FGF-1 is an established prosurvival factor 
confirming the validity of our approach. 
Tissue factor, the fifth factor with a mean 3.7 fold induction through GDNF, is a cell 
surface protein, initiating mammalian blood coagulation and is expressed constitutively 
by vascular subendothelial cells (Drake et al. 1989). Considering retinal tissue, TF is 
expressed in IPL, OPL and the nerve fiber layers (Cho et al. 2011). It can promote 
inflammation (Chu 2005) and angiogenesis (Belting et al. 2004). TF is highly upregulated 
on the transcript as well as protein level in human age-related macula degeneration 
(AMD) maculae as well as in retinal lesions, neuroretinal tissue and cultured RPE cells of 
the DKO mouse model of age-related macular degeneration (Cho et al. 2011). Processes 
that accompany AMD - inflammation and oxidative stress - increase TF expression. 
Moreover, increasing TF mRNA level as a function of age suggests that TF expression 
may play a role in the pathogenesis of AMD (Cho et al. 2011). Given TF’s association 
with angiogenesis, inflammation and AMD it did not appear to be a promising candidate 
for neuroprotection. 
The last GDNF induced factor, endostatin, with a mean induction of 2.8 fold, is a 20-kDa 
proteolytic product of collagen XVIII that is crucial for proper eye vasculature 
development. A loss of function mutation in endostatin, present in Knobloch syndrome, 
causes vitreoretinal degeneration, retinal detachment and myopia (Fukai et al. 2002). In 
fact, lack of endostatin leads to RPE and PR abnormalities as well as increased GFAP 
expression in the retina, which causes a progressive age-dependent visual loss (Marneros 
	  	   89 
et al. 2004). Additionally, endostatin can inhibit angiogenesis (O'Reilly et al. 1997, 
Bhutto et al. 2008) as well as decrease endothelial cell migration and proliferation 
(O'Reilly et al. 1997) and its level is increased in patients with neovascular AMD 
(Muether et al. 2013). In studies on a mouse model of retinopathy of prematurity, AAV 
vector mediated delivery of endostatin to mice eyes inhibited ischemia-induced 
neovascularization (Auricchio et al. 2002). Moreover, after photodynamic therapy in 
neurovascular AMD, an increase in endostatin levels, rather than a decrease in VEGF, 
was suggested to reduce neovascularization (Tatar et al. 2007, Tatar et al. 2008). 
Considering its inhibitory effect on choroidal neurovascular growth and vascular leakage, 
endostatin was already proposed as a new therapeutic for treatment of neurovascular 
AMD (Balaggan et al. 2006, Tatar et al. 2006, Marneros et al. 2007) and proliferative 
diabetic retinopathy (Orosz et al. 2004). 
2. Cyr61’s neuroprotective effect in the context of the rd1 mouse model of retinitis 
pigmentosa 
To validate Cyr61’s neuroprotective activity on degenerating PR, we prepared retinal 
explants from rd1 mouse model of retinitis pigmentosa. The timing chosen for our short-
term explants, PN7 and PN11, coincides with a critical phase for PR survival in rd1 mice. 
At PN8 swollen mitochondria – one of the first visible sights of molecular disturbances, 
can be observed in the inner segments of the cells (Farber & Lolley 1974). This is 
accompanied by increased uptake of oxygen, higher glucose utilization and production of 
lactic acid (Bowes et al. 1990). Moreover, at PN10, nuclei become pyknotic (Carter-
Dawson et al. 1978) and despite cellular integrity and thickness of ONL in mutant retina 
compared to healthy tissue, OS of PR already show signs of disruption (Carter-Dawson et 
al. 1978). According to the experimental schedule, the explanted tissue was collected at 
PN11, when the level of rod death rapidly increases, but the general number of PR is still 
equal to wild type retina (Portera-Cailliau et al. 1994). In our investigations, Cyr61 
applied to medium of rd1 retinal explants for only four days resulted in a decreased 
percentage of PR death. This encouraged us to challenge Cyr61’s neuroprotective 
potential and study its effect after the peak of PR degeneration, which falls between PN12 
and PN14 in rd1 mice (Sanyal & Bal 1973, Carter-Dawson et al. 1978). In this 
experiment with long term retinal explants, the tissue was stimulated with the factor 
between PN7 and PN18, covering the first symptoms and cases of rods death as well as 
the peak of degeneration and even a few of the following days. In this type of experiment 
we could show the sustained neurotrophic activity of Cyr61 on PR, resulting in 
significantly higher numbers of preserved PR in ONL versus control explants. This 
positive result motivated us to follow Cyr61 neuroprotective action and describe its 
mechanism. 
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3. Elucidation of the neuroprotective pathways, stimulated by Cyr61 within the 
retinal tissue 
Studies on prolonged PR survival indicate the PI3K/Akt (Kayama et al. 2011) and 
MAPK/Erk (German et al. 2006) pathways to be one of the most important for PR 
survival in retinal degenerations. We decided to monitor changes in activation of these 
pathways, considering the prosurvival effect of Cyr61 on different cancer cells through 
phosphorylation of Akt and Erk1/2 (Menendez et al. 2005, Yoshida et al. 2007, Sabile et 
al. 2012, Zhang et al. 2012c). Furthermore, we decided to monitor the JAK/Stat pathway, 
which has already been linked with PR survival in different models of retinal 
degeneration (Adamus et al. 2003, Maier et al. 2004, Joly et al. 2008, Chollangi et al. 
2009, Schallenberg et al. 2012) and implicated in the regulation of Cyr61 expression 
(Klein et al. 2012), although it has not yet been shown to be induced after Cyr61 
stimulation.  
The first step to find the molecular mechanism of Cyr61’s prosurvival action was 
stimulation of the whole explanted retinal tissue. For this experiment, retina at the age of 
PN6 was chosen, before any visible signs of PR degeneration. We found phosphorylation 
of Stat3 and Erk1/2, but not Akt. Activation of Stat3 was already found to be protective 
for PR in light induced retinal degeneration after treatment with LIF (Burgi et al. 2009) as 
well as in the RCS rat model of inherited retinal degeneration treated with GM-CSF 
(Schallenberg et al. 2012). Moreover, in experimental antibody-induced retinal 
degeneration, injections of AAV-CNTF viruses into Lewis rats resulted in an increase in 
pStat3 in the whole retinal tissue (Adamus et al. 2003). Furthermore, therapies leading to 
protection of PR from light-induced degeneration, like 24h to 48h of subtoxic levels of 
continuous illumination or administration of agonists for α2-adrenergic receptors, 
increased pStat3 in the whole retinal tissue (Peterson et al. 2000). On the other hand, 
docosahexaenoic acid protected PR survival during development and upon oxidative 
stress via stimulation of the MAPK/Erk signalling pathway (German et al. 2006). 
Furthermore, preconditioning of the rat retina with bright light, before applying light of 
the intensity necessary to induce degeneration, resulted in increased survival of PR, 
accompanied by Erk1/2 activation (Liu et al. 1998). Similarly, induced upregulation of 
GDNF and BDNF after optic nerve injury and activation of Erk1/2 increased GC survival 
(Nakatani et al. 2011). Moreover, CNTF intravitreal injections into rat eyes from a 
multiple sclerosis model protected GC through activation of Erk1/2 and Stat3 (Maier et 
al. 2004). Additionally, in experiments on axotomized GC, treatment with IL2 or FGF-2 
resulted in increased neuronal survival mediated by activation of the MAPK/Erk together 
with the JAK/Stat3 pathway or only the MAPK/Erk pathway, respectively (Rios-Munoz 
et al. 2005, Marra et al. 2011). Interestingly, the PI3K/Akt pathway was not activated in 
these studies. 
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Thus, a variety of neuroprotective factors activate MAPK/Erk and JAK/Stat, but not 
necessarily PI3K/Akt, showing these two signalling pathways to be the main mediators of 
neuronal survival in retinal degenerations. 
4. Dissection of retinal cell type responsiveness to Cyr61 prosurvival action 
4.1 Photoreceptors 
Cyr61 can stimulate cells through integrins and via binding to HSPG (Kular et al. 2011, 
Lau 2011). To reveal the mechanism of Cyr61 neurotrophic activity within rd1 retinal 
tissue, we first tested whether Cyr61 may stimulate PR directly via binding to integrins 
present at PR (Brem et al. 1994) and/or through HSPG (Tawara & Inomata 1987, Tawara 
et al. 1989, Landers et al. 1994). Pig retina was shown to be similar to human retina, 
which made it an attractive model to use in our study (Chandler et al. 1999, Hendrickson 
& Hicks 2002, Hendrickson et al. 2008). We prepared primary porcine PR cells of very 
high cell-type purity and vitality, and monitored changes in phosphorylation of Stat3, Akt 
and Erk1/2 upon Cyr61 stimulation. Although PRs showed basic level of phosphorylation 
of all three signalling molecules, we could not observe any influence of Cyr61 on them at 
any of the investigated time points. This result implies that direct stimulation of PR by 
Cyr61 is very likely not the mechanism behind prolonged PR survival. Although there are 
integrins present on PR (α2, α4, α5, and β2) none of these integrins have been shown to 
bind Cyr61 (except for α2 but only when coupled to β1 (Lin et al. 2007)). This led us to 
investigate other PR supporting cells, potentially responding to Cyr61. It should be noted 
though, that Cyr61 might stimulate PR cells by activating other prosurvival pathways not 
investigated in this study.  
4.2 Retinal Müller glial cells 
RMG cells secrete a variety of neurotrophic factors to protect PR from external injury 
(Bringmann et al. 2009). In order to test an indirect neuroprotective action of Cyr61 
through binding to integrins (Guidry et al. 2003) and/or HSPG (Aricescu et al. 2002) on 
RMG cell membranes, we used primary porcine RMG cell cultures as well as cultures of 
MIO-M1 – a human RMG cell line. After Cyr61 stimulation of primary porcine RMG, 
we could observe activation of all three investigated pathways – JAK/Stat, PI3K/Akt and 
MAPK/Erk. In contrast, Cyr61 stimulation of MIO-M1 increased phosphorylation of Akt 
as well as Erk1/2, but not Stat3. The fact that Cyr61 treatment of MIO-M1 did not 
stimulate the JAK/Stat pathway may rather suggest changes in cellular membrane 
receptor content, although differences between species cannot be excluded. 
Increase in phosphorylation of Stat3, Akt and Erk1/2 suggests a marked induction of 
RMG intracellular signalling pathways leading to complex transcriptome and secretome 
changes. It has already been described that activation of Stat3 in RMG cells, but not in 
PR, in S334ter-3 rats by intravitreal injection of oncostatin M, a member of IL-6 family 
of cytokines, promoted regeneration of cone OS in an indirect way in the early stages of 
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their degeneration (Xia et al. 2011). By the same token, CNTF was shown to protect PR 
survival indirectly through RMG and this effect was dependent on Stat3 activation 
(LaVail et al. 1998, Rhee et al. 2013). Similarly, phosphorylation of Stat3 is also 
increased in RMG in developing retina and stimulation of progenitor cells with CNTF 
enhances genesis of RMG through pStat3 (Goureau et al. 2004). In fact, increase in Stat3 
activity is required for maximal RMG proliferation during regeneration of the light-
damaged zebrafish retina (Kassen et al. 2009, Nelson et al. 2012). All these examples 
support the hypothesis that Cyr61 stimulated RMG can protect PR from preliminary 
death via activation of the JAK/Stat signalling pathway. 
In our studies, Cyr61 treatment of RMG resulted also in a strong and persistent 
phosphorylation of Erk1/2. As has already been documented, RMG cells answer to 
endotoxin-induced uveitis (Takeda et al. 2002) or to mechanical stress (Lindqvist et al. 
2010) with increased phosphorylation of Erk1/2, most probably to protect the retina from 
ensuing damage. Moreover, we could show nuclear movement of pErk1/2 in MIO-M1 
cells. Considering that activated Erk1/2 was shown to phosphorylate c-Fos (Chen et al. 
1996), Elk-1 (Gille et al. 1995) or Sap-1 (Janknecht et al. 1995) influencing 
transcriptome and proteome changes (Roberts & Der 2007) this observation strongly 
suggests that Cyr61 protects PR survival indirectly, through modulation of RMG and/or 
RPE protein expression or secretion patterns. It has already been shown, in experiment on 
rats, that preconditioning of the retina with bright light increased pErk1/2 in RMG, which 
was accompanied by increased expression of FGF-2 and CNTF in the whole retinal tissue 
(Liu et al. 1998). Furthermore, GNDF induced activation of the MAPK/Erk signalling 
pathway in RMG led to increased secretion of neuroprotective FGF-2 (Hauck et al. 
2006b). Additionally, in zebrafish light-damaged retina, CNTF indirectly protected PR 
through increase pErk1/2 but not the pStat3 or pAkt signalling molecules in RMG 
(Kassen et al. 2009). In accordance with these results, inhibition of Erk1/2 activation in 
RMG resulted in increased death of GC in a rat model of ischemia and reperfusion 
(Akiyama et al. 2002).  
Activation of PI3K/Akt has been observed in RMG cells in response to GDNF (Hauck et 
al. 2006b), but no available data imply this pathway to be crucial in upregulated secretion 
of neuroprotective factors. Nevertheless, Akt activation was shown to be a prosurvival 
mechanism of RMG rather than PR (Kuser-Abali et al. 2013) and can be protective for 
RMG from a cytotoxic environment within the retina, caused by massively degenerating 
PR.  
Activation of three different signalling pathways suggests activation of two different 
receptors on RMG cell membrane, as MAPK/Erk and PI3K/Akt are often activated by the 
same receptors, e.g. receptor tyrosine kinases (McCubrey et al. 2012), while Stat is 
activated by cytokine receptors (Stepkowski et al. 2008). Integrins like α1, α2, α3, and β1 
are expressed on the RMG cell membrane (Guidry et al. 2003). In cardiac myocytes cells, 
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Cyr61 increased phosphorylation of Akt as well as Erk1/2 through interaction with 
integrin β1, but the observed antiapoptotic effect was mainly due to the PI3K/Akt induced 
signalling cascade (Gille et al. 1995). In this study we show for the first time that Cyr61 
stimulates Stat3 phosphorylation. While the most likely suspect would be a cytokine 
receptor, it is interesting to note that binding of fibronectin to β1 integrin on breast cancer 
cells was also shown to induced the JAK/Stat signalling pathway (Balanis et al. 2013). 
To sum up, our data shows that Cyr61 secreted by RMG in turn activates an autocrine-
signalling loop involving at least three different cellular signalling pathways, which may 
mediate a sustained prosurvival action within the retinal tissue (Fig. 30).  
4.3 Retinal pigment epithelium cells 
Similar to RMG, retinal RPE cells support PR through releasing a variety of neurotrophic 
factors (Li et al. 2011) and participating in the PR visual cycle (Wright et al. 2010). 
Unlike the former they are also responsible for phagocytosis of PR outer segments 
(Kandel et al. 2000). After excluding the possibility that Cyr61 directly prolonged 
survival of PR and confirming its autocrine stimulation of RMG, we additionally focused 
on Cyr61’s influence on RPE cells. 
After Cyr61 stimulation of primary porcine RPE cells we observed increases in the 
activation of the MAPK/Erk and PI3K/Akt, but not the JAK/Stat signalling pathways. 
Furthermore, experiments conducted on the human ARPE19 cell line confirmed this 
result and showed that nuclear translocation of Erk1/2 happened analogous to MIO-M1 
cells. Activation of the two pathways in RPE cells may lead to the secretion of 
prosurvival factors similar to RMG, but it is also conceivable in the context of the rd1 
model that it is part of a defence mechanism against oxidative stress. 
Severe mitochondrial oxidative stress is noticeable already after one week of rd1 mouse 
life (Farber & Lolley 1974, Vlachantoni et al. 2011), which may be caused by calcium 
overload, shown in neuronal cells to results in mitochondrial depolarization and 
subsequent reactive oxygen species production (Lipton & Nicotera 1998). This led to the 
conclusion that mitochondrial oxidative stress can be one of the reasons leading to the 
massive RPE atrophy following PR degeneration that is observed in some patients with 
RP (Mitamura et al. 2012) as well as in rodent models of this disease - rd1 (Pennesi et al. 
2012) and the rd10 mice (Pennesi et al. 2012, Samardzija et al. 2012). Along these lines, 
activation of Akt and Erk1/2, observed in RPE, may protect the cells from harmful 
substances released by degenerating PR, allowing for their sustained supporting activity. 
Phosphorylation of Erk1/2 after PEDF treatment was shown to protect ARPE19 cells 
from oxidative stress (Tsao et al. 2006). By the same token, stimulation of the PI3K/Akt 
signalling pathway with NDP1 as well as with clusterin increased RPE survival during 
oxidative-stress induced apoptosis (Faghiri & Bazan 2010, Halapin & Bazan 2010, Kim 
et al. 2010). Similarly, an autocrine loop involving VEGF secretion and stimulation exists 
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in ARPE19 cells, which enhances their survival under induction of oxidative stress via 
the PI3K/Akt signalling pathway (Byeon et al. 2010). Additionally, activation of Akt was 
involved in protection of ARPE19 from H2O2 through the carotenoid Astaxanthin, which 
reduced apoptosis and intracellular reactive oxygen species production (Li et al. 2013). 
Cyr61 stimulation of PI3K/Akt and MAPK/Erk signalling pathways suggests it’s binding 
to integrins on the RPE cell membrane, like αvβ5 integrins (Nandrot et al. 2004) or αvβ3 
(Finnemann & Rodriguez-Boulan 1999). There are examples for activation of MAPK/Erk 
and PI3K/Akt through binding of Cyr61 to these specific integrin heterodimers in diverse 
cell types. In synoviocytes, Cyr61 could activate Akt by binding to αvβ5 integrins (Lin et 
al. 2012) and Erk1/2 in osteosarcoma cells through binding to αvβ3 integrins (Tan et al. 
2009). Similarly, the induction of VEGF in decidual natural killer cells through Cyr61 
was mediated through αvβ3 integrin and Akt, but not Erk1/2 (Zhang et al. 2012c). In this 
regard, it is also noteworthy that thrombospondin 1 employs the same receptors as Cyr61, 
α5β1 and αvβ5 integrins, to dramatically induce secretion of FGF-2 and VEGF from RPE 
cells (Mousa et al. 1999). 
To sum up, RMG secreted Cyr61 increases PR survival through stimulation of RMG in 
an autocrine way and RPE cells in a paracrine way, probably by binding to their integrin 
receptors (Fig. 30). Stimulation of RPE cells may induce secretion of prosurvival factors 
from RPE but it may also improve their adaptation to oxidative stress. 
5. Cyr61 induces transcriptome and secretome changes in RMG cells 
In order to test the hypothesis that Cyr61 triggers transcriptome and secretome changes in 
RMG, we performed quantitative proteomic analysis of Cyr61 stimulated RMG 
secretomes. In this way, we found six proteins, whose abundance in RMG supernatants 
increases significantly after Cyr61 treatment and one, whose amount decreased. The 
available information on these proteins in the context of the eye and retinal degeneration 
is discussed below. 
The highest increase was found for COL3A1. The upregulation of this protein was also 
confirmed at the mRNA level. Upregulation of COL3A1 mRNA expression after Cyr61 
was already shown in a fibroblast cell line stimulated with TGF-β. Selective blockage of 
this effect in vivo decreased choroidal neovascular lesion size and fibrosis (Caballero et 
al. 2011). COL3A1 belongs to the fibrillar collagen family and is a late marker of fibrosis 
(Zou et al. 2012). It can be upregulated by low levels of mechanical stress (Chen et al. 
2013) and downregulated by oxidative stress (Luna et al. 2009). COL3A1 increase 
extracellular matrix stability (Chen et al. 2013), decrease cell motility (Yun et al. 2014) 
and takes part in scar formation in wound healing (Moura et al. 2014). It is essential for 
proper fibrillogenesis of all organs in the body. Consequently, heterogeneous mutations in 
the COL3A1 gene cause Ehlers-Danlos syndrome, where reduction of collagen synthesis 
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results in general fragility of tissue organs and in some cases can also lead to retinal 
detachment (Omori et al. 2011, Beridze & Frishman 2012).  
The second highest Cyr61 induced protein was IGFBP-5. During eye development 
IGFBP-5 is expressed in neuroepithelium, INL, GCL and it probably influences cell 
differentiation into neuron and glial cells (de la Rosa et al. 1994). It can bind with high-
affinity to neuroprotective insulin-like growth factors (IGF-1, IGF-2), which were already 
shown to promote PR survival (Savchenko et al. 2001, Englund-Johansson et al. 2010), or 
to other extracellular matrix proteins like osteopontin or thrombospondin-1 which are 
known to enhance cellular prosurvival responses to IGF-1 (Jones et al. 1993, Nam et al. 
2000). IGFBP-5 induces human breast cancer cell adhesion and increases cell survival but 
inhibits cell migration (Sureshbabu et al. 2012) and angiogenesis (Hung et al. 2008). 
IGFBP-5 was also shown to mediate RPE endocytosis (Ainscough et al. 2009), which 
may support RPE cells during retinal degeneration in RP. 
Cystatin E/M is a secreted glycoprotein belonging to the human family 2 cystatins and a 
protease inhibitor (Ni et al. 1997), and its expression is developmentally regulated (Hong 
et al. 2002). Differentiation of hippocampal neuronal cells induced by FGF-2 treatment is 
accompanied by increased expression of cystatin E/M, its glycosylation and secretion into 
the medium (Hong et al. 2002). Although cystatin E/M is a classically secreted protein, its 
activity is not restricted to the extracellular matrix. It can localize to the nuclei of cells 
and regulate the intra- and extracellular activity of other proteins (Smith et al. 2012). 
Cystatin E/M has mainly been investigated in the context of cancer. It was found 
upregulated in human squamous cell carcinomas (Haider et al. 2006), but downregulated 
in cervical cancer cells (Veena et al. 2008), malignant glioma cancer cells (Qiu et al. 
2008), prostate tumor tissues (Pulukuri et al. 2009) melanoma cells (Briggs et al. 2010), 
and breast cancer cells (Jin et al. 2012). Cystatin E/M medium supplementation for either 
of these cells inhibited growth, motility, proliferation or invasion.  
The next candidate protein is FAM3C, which was also confirmed to be upregulated on the 
transcriptional level. FAM3C is a secreted protein expressed in retina, brain and many 
other tissues (Zhu et al. 2002, Katahira et al. 2010). FAM3C is probably involved in 
regulation of energy metabolism (Yang & Guan 2013) as well as retinal laminar 
formation and a loss of function mutations of FAM3C has been reported to cause PR 
dislocation (Katahira et al. 2010). Moreover, the FAM3C protein level is increased in 
aqueous humor in patients suffering from Fuchs endothelial corneal dystrophy, where 
corneal endothelial decompensation leads to corneal edema, and vision impairment 
(Richardson et al. 2010). Interestingly, FAM3C is among a group of proteins containing a 
GG domain, which has been implicated in human muscle-eye-brain disease and non-
syndromic hearing loss (Guo et al. 2006).  
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RLBP1, the fifth protein selected from our proteomics data, is a member of the family of 
retinoid-binding proteins found in RPE and RMG cells (Anderson et al. 1986) as well as 
in oligodendrocytes in the optic nerve (Saari et al. 1997). Its known ligands are 11-cis-
retinaldehyde as well as 9- and 11-cis-retinol (Saari et al. 1982, Helbling et al. 2013). 
RLBP1 is involved in visual pigment regeneration, retinol metabolism (Saari et al. 2001) 
and contributes to trafficking and apical localization of retinoids within RPE cells 
(Nawrot et al. 2004). Some data implies, that there are more functions of RLBP1, which 
till now remain undiscovered (Saari et al. 1997). Alterations in molecular structure of the 
RLBP1 protein lead to serious retinal pathologies. Mutations disrupting the retinol 
binding activity of RLBP1 have been identified in autosomal recessive RP (Maw et al. 
1997) and autosomal recessive RP of Bothnia type (Burstedt et al. 2001, Burstedt et al. 
2008). Furthermore, a mutation in the RLBP1 gene was found in a patient with retinitis 
punctata albescens, a retinal degeneration characterised by delayed rod desensitization, 
white deposits and retinal pigmentary abnormalities (Morimura et al. 1999, Katsanis et al. 
2001, Fishman et al. 2004). RLBP1 increases after prolonged light exposure of the retina 
(Zhang et al. 2010) but it does not change in neovascular age-related macular 
degeneration (Frank et al. 1999). Moreover, observed increase of RLBP1 in induced 
proliferative vitreoretinopathy (McGillem & Dacheux 1999) can be a defence 
mechanism, since laser injury of the RPE layer in rat retina resulted in decreased RLBP1 
in these cells followed by their intense proliferation and subretinal neovascularization 
(Zhang et al. 1993). These findings are also supported by a study where induction of 
ARPE19 proliferation inhibited RLBP1 gene expression (Steindl-Kuscher et al. 2011). 
Although found in both RPE and RMG, RLBP1’s transcriptional regulation is probably 
different in both cell types (Kennedy et al. 2003). Patients with a group of inherited 
macular dystrophies, fundus flavimaculatus, present with RPE cells filled with lipofuscin 
and with reduced RLBP1 expression, changes not observed in RMG (Birnbach et al. 
1994). On the other hand, RLBP1 expression decreases in RMG cells together with 
progression of PR degeneration and retinal dystrophy in RCS rats and rd1 mouse 
(Sheedlo et al. 1995) as well as after experimental retinal detachment (Lewis et al. 1989). 
Furthermore, histopathological examination of RPE from RP patients revealed no 
immunoreactivity for RLBP1 nor for lipofuscin (Li et al. 1995).  
The next Cyr61 upregulated protein in RMG, matrilin-4, belongs to the matrilin family of 
extracellular matrix proteins (Wagener et al. 1998). It is expressed in nervous, skeletal, 
epithelial, muscle and connective tissue as well as on the joint surface during their 
development (Klatt et al. 2002). In the eye, matrilin-4 is present in the stroma and 
epithelial basement membrane of the cornea. Its abundance is increased in granular and 
lattice type I dystrophies, which suggests its involvement in reorganization and 
regeneration of the corneal matrix (Szalai et al. 2012).  
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Figure 30. Model of Cyr61's neuroprotective action on photoreceptors within retinal tissue. 
Cyr61 stimulates retinal Müller glial cells (RMG) as well as retinal pigment epithelium cells (RPE), which 
leads to phosphorylation of the Stat3, Akt and Erk1/2 signalling molecules. The activated cascades lead to 
transcriptional and secretome changes of prosurvival factors and extracellular matrix proteins, which in the 
end leads to prolonged photoreceptor (PR) survival. 
Chondroadherin is the only protein we found suppressed in RMG cell supernatants after 
Cyr61 stimulation. At this point, information about the function of chondroadherin in an 
eye is sparse. It is expressed in the cornea, lens and retina (Tasheva et al. 2004). 
Decreased mRNA levels of chondroadherin have been found during Candida albicans 
infection of the cornea, which has been suggested to contribute to the acute inflammatory 
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response to the fungus (Yuan et al. 2010). The best-researched functions of 
chondroadherin pertain to its role in cartilage. It binds to collagen, mediating adhesion of 
osteoblasts and chondrocytes (Mizuno et al. 1996, Mansson et al. 2001). In light of the 
importance of integrins for Cyr61, it is interesting to note that binding of chondroadherin 
to α2β1 integrins or HSPG on chondrocytes increased intracellular signalling (Haglund et 
al. 2011, Haglund et al. 2013). Moreover, chondroadherin inhibits osteoclast and bone 
resorption through integrin binding (Capulli et al. 2014).  
Taken together, Cyr61 induced RMG transcriptome changes, which led to alterations in a 
pattern of the RMG secretome. Considering that the proteins found to be upregulated are 
extracellular matrix proteins as well as secreted factors, the results suggest that 
neuroprotective action through RMG may include extracellular matrix remodelling as 
well as secretion of a factor directly influencing PR survival (Fig. 30). 
6. Cyr61 in vivo application in the S334ter-3 rat retina 
After showing the neuroprotective efficiency of Cyr61 in retinal mouse explants and 
dissecting the response of prosurvival pathways of three different retinal cell types, we 
conducted a first in vivo examination of Cyr61 prosurvival potential in the S334ter-3 rat 
model of retinal degeneration.  
Delivery of the neurotrophic factor was achieved by local injection into the eye, since 
most of factors are either too big to cross the blood-retinal barrier (Kastin et al. 2003) or 
can elicit unacceptable systemic side effects. Therefore, local administration directly into 
the eye is regarded as the only practical way of factor delivery. For long term 
experiments, when injection of the factor would have to be applied repetitively, several 
delivery methods have been developed, including transduction of retinal cells using adeno 
associated viruses to secrete neuroprotection factors (McGee Sanftner et al. 2001) or cell 
based delivery of factors (MacDonald et al. 2007). Nevertheless, as a proof of concept 
experiment we decided to use two simple injections of recombinant human Cyr61. In 
some studies neurotrophic factors were tested by injection into the subretinal space 
(Frasson et al. 1999a) despite the accompanying retinal detachment and gliosis. We chose 
intravitreal injections over this method, since it causes less retinal trauma and pathologic 
gliosis (Dalkara et al. 2011).  
In this first experiment, Cyr61 failed to reduce the number of TUNEL positive cell in the 
ONL and even led to an increase of apoptosis in the INL. There are several possible 
explanations for the failure of this experiment. The dose of Cyr61 may have been too 
high and will need to be titrated carefully in future projects. The amount of applied Cyr61 
was 0.25µg in 1µl, which is 500 and 250 times more than used during short term and long 
term retinal explants, respectively. Alternatively, human Cyr61 may not work for the 
treatment of the S334ter-3 rat, although it was effective for rd1 mice. In this regard, other 
models of retinal degeneration may be explored, but it is impractical to perform 
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intravitreal injections on a mouse eye. However, the S334ter-3 rat model of retinitis 
pigmentosa may be substituted for a different model with a less rapidly proceeding PR 
degeneration. Although S334ter-3 rats were used in many studies on retinal degeneration, 
their PR never reach normal morphology and their rapid degeneration introduce changes 
in the retina, including fewer horizontal processes and bipolar cells dendrites than, for 
example, in the S334ter-5 rat (Martinez-Navarrete et al. 2011).  
The influence of Cyr61 on the retinal vasculature also seems to have been a major 
confounding factor. In S334-ter-3 rats, degeneration of photoreceptors negatively 
influences development of the deep capillary plexus. By PN15, only 6-7% of the number 
observed in the wild type retinas is left and the capillary plexus vasculature atrophies 
(Pennesi et al. 2008). With the method we applied to visualise retinal vasculature we 
cannot distinguish deep capillary plexus from superficial capillary plexus. This could be 
achieved via injections of sodium fluorescein (Paques et al. 2006). Nevertheless, given 
that the experiment was conducted with the timeframe of the development of the deep 
capillary plexus and that Cyr61 is responsible for proper retinal vasculature development 
(Hasan et al. 2011), we would expect that Cyr61 would most prominently affect the 
development of the deep capillary plexus. In line with this hypothesis are our 
observations: Cyr61 increased cell death within INL, the layer penetrated by the deep 
capillary plexus. Moreover, Cyr61 did not influence the number of GC within the 
ganglion cell layer, which is supplied by the superficial capillary plexus. Therefore, the 
observed lack of neuroprotective action within PR cells could have been caused by severe 
changes in the inner plexiform vasculature leading to an increasing cell death rate within 
the INL. In this way the neurotrophic potential of Cyr61 may have been masked by its 
angiogenic property.  
In the context of neovascularization, Cyr61 has already been associated with vascular 
alterations in diabetic retinopathy (You et al. 2009, You et al. 2012). On the other hand, it 
was also successfully validated as a therapeutic strategy in an animal model of 
retinopathy of prematurity (Hasan et al. 2011). Furthermore, Cyr61 was positively tested 
as a potential therapeutic factor in models of peripheral ischemic diseases (Fataccioli et 
al. 2002, Rayssac et al. 2009).  
Two solutions for future in vivo experiments can be considered. First would be to titrate 
the dosage of Cyr61 to find the proper concentration that would promote PR survival, 
without introducing vascular disturbances. The second option would be to use a mutant of 
Cyr61 that does not bind to the endothelial αvβ3 receptor leading to their increased 
migration, adhesion, mitogenesis and tube formation (Leu et al. 2002). However, this 
mutant Cyr61 would have to be tested for neuroprotective activity first. 
In summary, our first in vivo experiment failed to show Cyr61 neuroprotective action on 
PR in S334ter-3 rat model of retinitis pigmentosa. However, refinement of the 
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experimental approach and addressing the issue of Cyr61’s angiogenic properties may yet 
lead to success in the future. The presented research up to this point demonstrates that 
Cyr61 is a potent neuroprotective factor within the retina and encourages further 
investigation of Cyr61’s action with the goal of harnessing the therapeutic potential of 
this protein.  
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